GlaxoSmithKline_NN
180_CD
Glossary_NN
of_PIN
terms_NN
Terms_NN
used_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
US_FPP1
equivalent_JJ
or_CC
brief_JJ
description_NOMZ
Accelerated_VBN
capital_NN
allowances_NN
Tax_NN
allowance_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
arising_VBG [WZPRES]
from_PIN
the_DT
purchase_NN
of_PIN
fixed_JJ
assets_NN
that_TSUB
delay_VPRT
the_DT
charging_VBG
and_CC
payment_NOMZ
of_PIN
tax_NN
._.
The_DT
US_FPP1
equivalent_NN
of_PIN
tax_NN
depreciation_NOMZ
._.
Advance_NN
Corporation_NOMZ
Tax_NN
ACT_NN
An_DT
advance_NN
payment_NOMZ
of_PIN
UK_NN
tax_NN
that_TSUB
was_VBD [PASS]
made_VBN
when_RB
dividends_NN
are_VPRT [PASS]
paid_VBN
._.
American_JJ
Depositary_NN
Receipt_NN
ADR_NN
Receipt_NN
evidencing_VBG [WZPRES]
title_NN
to_PIN
an_DT
ADS_NN
._.
Each_QUAN
GlaxoSmithKline_NN
ADR_NN
represents_VPRT
two_CD
ordinary_JJ
shares_NN
._.
American_JJ
Depositary_NN
Shares_NN
ADSs_NN
Ordinary_NN
Shares_NN
registered_VBD
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
Called-up_JJ
share_NN
capital_NN
Ordinary_NN
Shares_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
._.
CER_NN
growth_NN
Growth_NN
at_PIN
constant_JJ
exchange_NN
rates_NN
._.
Combined_NN
Code_NN
Guidelines_NN
required_VBN [SUAV] [WZPAST]
by_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
to_TO
address_VB
the_DT
principal_JJ
aspects_NN
of_PIN
Corporate_JJ
Governance_NN
._.
Currency_NN
swap_NN
An_DT
exchange_NN
of_PIN
two_CD
currencies_NN
,_,
coupled_VBN [PASTP]
with_PIN
a_DT
subsequent_JJ
re-exchange_NN
of_PIN
those_DEMO
currencies_NN
,_,
at_PIN
agreed_VBN [SUAV] [PUBV]
exchange_NN
rates_NN
and_PHC
dates_NN
._.
Defined_VBN
benefit_NN
plan_NN
Pension_NN
plan_NN
with_PIN
specific_JJ
employee_NN
benefits_NN
,_,
often_RB
called_VBN
final_JJ
salary_NN
scheme_NN
._.
Defined_VBN
contribution_NOMZ
plan_NN
Pension_NN
plan_NN
with_PIN
specific_JJ
contributions_NOMZ
and_CC
a_DT
level_NN
of_PIN
pension_NN
dependent_JJ
upon_PIN
the_DT
growth_NN
of_PIN
the_DT
pension_NN
fund_NN
._.
Derivative_JJ
financial_JJ
instrument_NOMZ
A_DT
financial_JJ
instrument_NOMZ
that_TSUB
derives_VPRT
its_PIT
value_NN
from_PIN
the_DT
price_NN
or_CC
rate_NN
of_PIN
some_QUAN
underlying_VBG
item_NN
._.
Diluted_JJ
earnings_GER
per_PIN
share_NN
Diluted_JJ
income_NN
per_PIN
share_NN
._.
Earnings_GER
per_PIN
share_NN
Basic_JJ
income_NN
per_PIN
share_NN
._.
Employee_NN
Share_NN
Ownership_NN
Plan_NN
Trusts_VPRT
Trusts_NN
established_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Group_NN
to_TO
satisfy_VB
share_NN
based_VBN
employee_NN
incentive_NN
plans_NN
._.
Equity_NOMZ
shareholders_NN
funds_NN
The_DT
aggregation_NOMZ
of_PIN
shares_NN
and_PHC
reserves_NN
owned_VBN [WZPAST]
by_PIN
shareholders_NN
._.
The_DT
US_FPP1
equivalent_NN
is_VPRT
shareholders_NN
equity_NOMZ
._.
Freehold_NN
Ownership_NN
with_PIN
absolute_JJ
rights_NN
in_PIN
perpetuity_NOMZ
._.
Gearing_VBG
ratio_NN
Net_JJ
debt_NN
as_IN
a_DT
percentage_NN
of_PIN
shareholders_NN
funds_NN
net_JJ
debt_NN
and_PHC
minority_NOMZ
interests_NN
._.
The_DT
Group_NN
GlaxoSmithKline_NN
plc_NN
and_CC
its_PIT
subsidiary_NN
undertakings_GER
._.
Hedging_VBG [PRESP]
The_DT
reduction_NOMZ
of_PIN
risk_NN
,_,
normally_RB
in_PIN
relation_NOMZ
to_PIN
foreign_JJ
currency_NN
or_CC
interest_NN
rate_NN
movements_NOMZ
,_,
by_PIN
making_VBG
off-setting_JJ
commitments_NOMZ
._.
Intangible_JJ
fixed_JJ
assets_NN
Assets_NN
without_PIN
physical_JJ
substance_NN
,_,
such_JJ
as_IN
brands_NN
,_,
licences_NN
,_,
patents_NN
,_,
know-how_NN
and_PHC
marketing_GER
rights_NN
purchased_VBN [WZPAST]
from_PIN
outside_PLACE
parties_NN
._.
Interest_NN
cover_NN
The_DT
number_NN
of_PIN
times_NN
profit_NN
before_IN
interest_NN
exceeds_VPRT
net_JJ
interest_NN
payable_JJ
._.
Non-equity_JJ
minority_NOMZ
interest_NN
Preference_NN
shares_NN
issued_VBN [WZPAST]
by_PIN
a_DT
subsidiary_NN
to_PIN
outside_PLACE
parties_NN
._.
Preference_NN
shares_NN
Shares_NN
issued_VBD
at_PIN
varying_VBG
dividend_NN
rates_NN
that_TSUB
are_VPRT [PASS]
treated_VBN
as_IN
outside_PLACE
interests_NN
._.
Profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
Retained_VBN
earnings_GER
._.
Profit_NN
attributable_JJ
to_PIN
shareholders_NN
Net_JJ
income_NN
._.
Share_NN
capital_NN
Ordinary_NN
Shares_NN
,_,
capital_NN
stock_NN
or_CC
common_JJ
stock_NN
issued_VBN
and_CC
fully_AMP
paid_VBN
._.
Share_NN
premium_NN
account_NN
Additional_JJ
paid-up_JJ
capital_NN
or_CC
paid-in_PIN
surplus_NN
not_XX0
distributable_JJ
._.
Shares_NN
in_PIN
issue_NN
Shares_NN
outstanding_JJ
._.
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Statement_NOMZ
of_PIN
comprehensive_JJ
income_NN
._.
Subsidiary_JJ
undertaking_GER
An_DT
affiliate_NN
in_PIN
which_WDT [PIRE]
GlaxoSmithKline_NN
holds_VPRT [PRIV]
a_DT
majority_NOMZ
shareholding_GER
and_CC
or_CC
exercises_VPRT
control_NN
._.
Tangible_JJ
fixed_JJ
assets_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
._.
Contact_NN
details_NN
INTERNET_NN
Information_NOMZ
for_PIN
investors_NN
and_CC
about_IN
the_DT
company_NN
is_VPRT [BEMA]
available_PRED
on_PIN
GlaxoSmithKlines_NN
corporate_JJ
website_NN
at_PIN
www_NN
._.
com_NN
HEAD_NN
OFFICE_NN
AND_PHC
REGISTERED_NN
OFFICE_NN
GlaxoSmithKline_NN
plc_NN
980_CD
Great_NN
West_NN
Road_NN
Brentford_NN
Middlesex_NN
TW8_NN
9GS_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5000_CD
UNITED_NN
KINGDOM_NN
UNITED_NN
STATES_NN
OF_PIN
AMERICA_NN
Investor_NN
relations_NOMZ
Investor_NN
relations_NOMZ
980_CD
Great_NN
West_NN
Road_NN
One_CD
Franklin_NN
Plaza_NN
Brentford_NN
PO_NN
Box_NN
7929_CD
Middlesex_NN
TW8_NN
9GS_NN
Philadelphia_NN
PA_NN
19101_CD
Tel_NN
:_:
44_CD
0_CD
20 8047 5557 5558_CD
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Fax_NN
:_:
44_CD
0_CD
20 8047 7807_CD
Tel_NN
:_:
1_CD
215 751 7003_CD
outside_PLACE
the_DT
USA_NN
Fax_NN
:_:
1_CD
215 751 3233_CD
Registrar_NN
Lloyds_NN
TSB_NN
Registrars_NN
ADR_NN
program_NN
administrator_NN
The_DT
Causeway_NN
The_NN
Bank_NN
of_PIN
New_NN
York_NN
Worthing_GER
Shareholder_NN
Relations_NOMZ
West_NN
Sussex_NN
BN99_NN
6DA_NN
PO_NN
Box_NN
11258_CD
www_NN
._.
co._FW
uk_FW
Church_NN
Street_NN
Station_NOMZ
New_NN
York_NN
NY_NN
10286-1258_CD
General_NN
enquiries_NN
,_,
Annual_JJ
Report_NN
orderline_NN
and_PHC
www_NN
._.
com_NN
Corporate_JJ
Nominee_NN
service_NN
Tel_NN
:_:
1_CD
877 353 1154_CD
toll_NN
free_JJ
Tel_NN
:_:
0870 600 3991_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
1_CD
610 382 7836_CD
outside_PLACE
the_DT
USA_NN
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
outside_PLACE
the_DT
UK_NN
Customer_NN
response_NN
center_NN
Shareholder_NN
Investment_NOMZ
Plans_NN
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Dividend_NN
re-investment_NOMZ
enquiries_NN
Tel_NN
:_:
0870 241 3018_CD
inside_PLACE
the_DT
UK_NN
Corporate_NN
Share_NN
dealing_VBG [WZPRES]
facility_NOMZ
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
outside_PLACE
the_DT
UK_NN
-_:
Ordinary_NN
holders_NN
Smith_NN
Barney_NN
Tel_NN
:_:
44_CD
0_CD
121 415 7146_CD
outside_PLACE
the_DT
UK_NN
-_:
Employees_NN
Attn_NN
:_:
GSK_NN
Services_NN
53_CD
State_NN
Street_NN
Monthly_JJ
Savings_GER
Plan_NN
enquiries_VPRT
39th_JJ
Floor_NN
Tel_NN
:_:
0870 606 0268_CD
inside_PLACE
the_DT
UK_NN
Boston_NN
,_,
MA_NN
02109_CD
Tel_NN
:_:
44_CD
0_CD
131 527 3746_CD
outside_PLACE
the_DT
UK_NN
Tel_NN
:_:
1_CD
800 347 6179_CD
toll_NN
free_JJ
ISA_NN
enquiries_NN
Tel_NN
:_:
1_CD
617 589 3341_CD
outside_PLACE
the_DT
USA_NN
Tel_NN
:_:
0870 242 4244_CD
inside_PLACE
the_DT
UK_NN
Fax_NN
:_:
1_CD
617 589 3474_CD
Tel_NN
:_:
44_CD
0_CD
1903 854 062_CD
outside_PLACE
the_DT
UK_NN
TheTaylorGroup@SmithBarney_NN
._.
com_NN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
corporate_JJ
PEPs_NN
The_DT
Share_NN
Centre_NN
Limited_NN
Oxford_NN
House_NN
Oxford_NN
Road_NN
Aylesbury_NN
Bucks_NN
HP21_NN
8SZ_NN
Tel_NN
:_:
44_CD
0_CD
1296 414 144_CD
Corporate_JJ
Share_NN
dealing_VBG [WZPRES]
facility_NOMZ
Smith_NN
Barney_NN
Attn_NN
:_:
GSK_NN
Services_NN
Citigroup_NN
Centre_NN
,_,
Level_NN
20_CD
Canada_NN
Square_NN
,_,
Canary_NN
Wharf_NN
London_NN
E14_NN
5LB_NN
Tel_NN
:_:
44_CD
0_CD
20 7508 1795_CD
Fax_NN
:_:
44_CD
0_CD
20 7890 7281_CD
TheBalaesGroup@Citigroup_NN
._.
com_NN
Printed_NN
by_PIN
The_DT
Midas_NN
Press_NN
in_PIN
the_DT
UK_NN
._.
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
the_DT
production_NOMZ
of_PIN
this_DEMO
document_NOMZ
is_VPRT [PASS]
made_VBN
from_PIN
pulp_NN
harvested_VBN [WZPAST]
from_PIN
sustainable_JJ
forests_NN
,_,
also_RB
using_VBG
sawmill_NN
residues_NN
and_PHC
forest_NN
thinnings_GER
._.
GlaxoSmithKline_NN
Annual_JJ
Report_NN
2004_CD
Annual_JJ
Report_NN
2004_CD
New_NN
challenges_NN
New_NN
thinking_VBG [PRIV] [WZPRES]
www_NN
._.
com_NN
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_JJ
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
New_NN
thinking_VBG [PRIV] [WZPRES]
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
The_DT
world_NN
is_VPRT
changing_VBG
..._:
Todays_NN
global_JJ
healthcare_NN
challenges_NN
mean_VPRT [PRIV]
that_THVC
new_JJ
thinking_GER
is_VPRT [PASS]
called_VBN
for_PIN
by_PIN
the_DT
pharmaceutical_JJ
industry_NN
R&D_NN
productivity_NOMZ
Healthcare_NN
funding_GER
crisis_NN
It_PIT
is_VPRT
getting_VBG
more_EMPH
difficult_JJ
and_CC
taking_VBG
longer_RB
currently_RB
an_DT
average_JJ
The_DT
demand_NN
for_PIN
quality_NOMZ
healthcare_NN
is_VPRT
growing_VBG
faster_RB
than_PIN
of_PIN
12_CD
years_NN
to_TO
develop_VB
new_JJ
medicines_NN
._.
Despite_PIN
a_DT
substantial_JJ
governments_NOMZ
and_PHC
healthcare_NN
purchasers_NN
ability_NOMZ
to_TO
support_VB
it_PIT
._.
GSKs_NN
increase_NN
in_PIN
global_JJ
R&D_NN
expenditure_NN
,_,
fewer_JJ
novel_NN
medicines_NN
were_VBD
challenge_NN
is_VPRT
to_TO
deliver_VB
innovative_JJ
and_PHC
affordable_JJ
medicines_NN
that_TSUB
meet_VPRT
launched_VBN
in_PIN
2003_CD
than_PIN
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
last_JJ
20_CD
years_NN
._.
the_DT
real_JJ
and_PHC
unmet_JJ
needs_NN
of_PIN
people_NN
burdened_VBN [WZPAST]
by_PIN
disease_NN
._.
By_PIN
working_VBG
GSKs_NN
challenge_NN
is_VPRT
to_TO
discover_VB [PRIV]
new_JJ
medicines_NN
faster_RB
and_PHC
more_EMPH
closely_RB
with_PIN
patient_JJ
groups_NN
,_,
we_FPP1
are_VPRT [BEMA]
able_PRED
to_TO
tailor_VB
our_FPP1
development_NOMZ
economically_RB
._.
In_PIN
recent_JJ
years_NN
,_,
we_FPP1
have_VPRT [PEAS]
transformed_VBN
our_FPP1
R&D_NN
process_NN
to_PIN
better_JJ
meet_VB
patient_JJ
needs_NN
and_CC
maximize_VB
the_DT
effectiveness_NOMZ
function_NOMZ
._.
The_DT
result_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
nearly_DWNT
80_CD
%_NN
increase_NN
in_PIN
the_DT
of_PIN
our_FPP1
R&D_NN
expenditure_NN
._.
number_NN
of_PIN
New_NN
Chemical_NN
Entities_NOMZ
in_PIN
our_FPP1
pipeline_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
now_TIME
one_CD
of_PIN
the_DT
largest_JJ
in_PIN
our_FPP1
industry_NN
._.
Access_NN
to_PIN
medicines_NN
Transparency_NN
In_PIN
the_DT
developing_VBG
world_NN
,_,
where_RB
infectious_JJ
diseases_NN
present_VPRT
an_DT
Today_TIME
,_,
physicians_NN
,_,
patients_NN
,_,
stakeholders_NN
and_PHC
investors_NN
quite_RB
rightly_RB
enormous_JJ
burden_NN
,_,
there_EX
is_VPRT
an_DT
urgent_JJ
need_NN
for_PIN
medicines_NN
but_CC
a_DT
lack_NN
demand_NN
greater_JJ
levels_NN
of_PIN
transparency_NN
about_IN
the_DT
safety_NN
and_CC
of_PIN
resources_NN
to_TO
pay_VB
for_PIN
them_TPP3
._.
GSK_NN
is_VPRT [BEMA]
the_DT
only_DWNT
company_NN
that_DEMP
is_VPRT
efcacy_NN
of_PIN
medicines_NN
._.
In_PIN
2004_CD
,_,
GSK_NN
started_VBD
publishing_VBG
its_PIT
clinical_JJ
developing_VBG
medicines_NN
and_PHC
vaccines_NN
to_TO
treat_VB
all_QUAN
three_CD
of_PIN
the_DT
World_NN
trial_NN
data_NN
on_PIN
the_DT
internet_NN
for_PIN
anyone_QUPR
to_PIN
access_NN
._.
We_FPP1
are_VPRT [BEMA]
the_DT
first_JJ
Health_NN
Organizations_NOMZ
top_JJ
priority_NOMZ
diseases_NN
:_:
malaria_NN
,_,
tuberculosis_NN
pharmaceutical_JJ
company_NN
to_TO
offer_VB
this_DEMO
level_NN
of_PIN
transparency_NN
._.
In_PIN
2004_CD
,_,
GSK_NN
shipped_VBD
33_CD
million_CD
tablets_NN
of_PIN
have_VPRT [SPAU] [PEAS]
also_RB
increased_VBN
the_DT
information_NOMZ
made_VBN
available_JJ
through_PIN
our_FPP1
Combivir_NN
GSKs_NN
HIV_NN
treatment_NOMZ
to_PIN
Africa_NN
._.
reporting_VBG [PUBV]
and_CC
on_PIN
our_FPP1
corporate_JJ
website_JJ
www_NN
._.
And_ANDC
were_VBD
changing_VBG
too_RB
..._:
GSK_NN
recognizes_VPRT [PRIV]
the_DT
implications_NOMZ
of_PIN
todays_NN
changing_VBG [WZPRES]
world_NN
._.
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
embracing_VBG
change_NN
,_,
turning_VBG
challenges_NN
into_PIN
opportunities_NOMZ
and_CC
new_JJ
thinking_GER
into_PIN
new_JJ
ways_NN
of_PIN
working_VBG
In_PIN
the_DT
past_JJ
four_CD
years_NN
,_,
we_FPP1
have_VPRT [PEAS]
transformed_VBN
our_FPP1
R&D_NN
function_NOMZ
,_,
introducing_VBG
innovative_JJ
ways_NN
of_PIN
working_VBG
,_,
and_ANDC
advanced_VBD
technology_NN
and_PHC
automation_NOMZ
to_TO
help_VB
us_FPP1
discover_VB [PRIV]
and_PHC
develop_VB
medicines_NN
and_PHC
vaccines_NN
more_EMPH
efficiently_RB
and_PHC
effectively_RB
._.
We_FPP1
have_VPRT [PEAS]
sharpened_VBN
our_FPP1
operations_NOMZ
,_,
introducing_VBG
operational_JJ
excellence_NN
programs_NN
,_,
streamlining_VBG [PRESP]
our_FPP1
processes_NN
,_,
building_VBG
partnerships_NN
with_PIN
our_FPP1
stakeholders_NN
,_,
and_ANDC
focusing_VBG
on_PIN
the_DT
unmet_JJ
needs_NN
of_PIN
patients_NN
._.
And_ANDC
we_FPP1
have_VPRT [PEAS]
invested_VBN
in_PIN
the_DT
communities_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
,_,
developing_VBG
medicines_NN
for_PIN
the_DT
developing_VBG
world_NN
,_,
supporting_VBG
community_NOMZ
health_NN
education_NOMZ
programs_NN
,_,
donating_VBG
medicines_NN
,_,
and_ANDC
introducing_VBG
preferential_JJ
pricing_GER
for_PIN
those_DEMO
in_PIN
need_NN
._.
This_DEMP
is_VPRT [BEMA]
an_DT
ongoing_JJ
challenge_NN
,_,
and_ANDC
much_QUAN
remains_VPRT
to_TO
be_VB [PASS]
done_VBN
._.
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
participating_VBG
in_PIN
the_DT
debate_NN
on_PIN
healthcare_NN
reform_NN
and_CC
playing_VBG
our_FPP1
part_NN
in_PIN
addressing_VBG
the_DT
key_JJ
issues_NN
._.
This_DEMO
Annual_JJ
Review_NN
explains_VPRT [PUBV]
how_RB [WHCL]
GSK_NN
is_VPRT
embracing_VBG
change_NN
and_ANDC
how_RB
our_FPP1
efforts_NN
are_VPRT
delivering_VBG
results_NN
._.
Front_NN
cover_NN
We_FPP1
have_VPRT [PEAS]
chosen_VBN
the_DT
image_NN
of_PIN
a_DT
pill_NN
Contents_VPRT
Annual_JJ
Review_NN
2004_CD
for_PIN
our_FPP1
front_JJ
cover_NN
because_CAUS
it_PIT
is_VPRT [BEMA]
the_DT
essence_NN
of_PIN
what_WP
New_NN
challenges_NN
14_CD
Business_NOMZ
operating_GER
review_NN
02_CD
Chairmans_NN
and_PHC
CEOs_NN
statement_NOMZ
New_NN
thinking_VBG [PRIV] [THATD] [WZPRES]
we_FPP1
do_VPRT
:_:
discovering_VBG [PRIV]
,_,
developing_VBG
,_,
manufacturing_VBG
and_CC
18_CD
The_DT
Board_NN
03_CD
Highlights_NN
of_PIN
the_DT
year_NN
delivering_VBG [WZPRES]
medicines_NN
to_PIN
the_DT
people_NN
who_WP [WHSUB]
need_VPRT
them_TPP3
._.
19_CD
The_DT
Corporate_JJ
Executive_NN
Team_NN
04_CD
So_IN
what_WP
is_VPRT [BEMA]
the_DT
big_JJ
challenge_NN
?_.
It_PIT
also_RB
represents_VPRT
the_DT
20_CD
Summary_NN
remuneration_NOMZ
report_NN
06_CD
Transforming_VBG
R&D_NN
global_JJ
nature_NN
of_PIN
our_FPP1
business_NOMZ
and_CC
our_FPP1
global_JJ
23_CD
Corporate_JJ
governance_NN
08_CD
Delivering_VBG
the_DT
pipeline_NN
responsibility_NOMZ
to_TO
provide_VB
access_NN
to_PIN
medicines_NN
for_PIN
both_DT
25_CD
Summary_NN
financial_JJ
statements_NOMZ
10_CD
Sharpening_VBG
our_FPP1
operations_NOMZ
the_DT
developed_VBN
and_PHC
developing_VBG
world_NN
._.
27_CD
Shareholder_NN
information_NOMZ
12_CD
Contributing_VBG
to_PIN
society_NN
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
New_JJ
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
1_CD
Chairmans_NN
and_PHC
CEOs_NN
Statement_NOMZ
We_FPP1
knew_VBD [PRIV]
2004_CD
would_PRMD
be_VB [BEMA]
a_DT
challenging_JJ
year_NN
for_PIN
GSK_NN
and_CC
we_FPP1
are_VPRT [BEMA]
pleased_PRED
to_TO
report_VB [PUBV]
that_THVC
we_FPP1
have_VPRT [PEAS]
achieved_VBN
our_FPP1
financial_JJ
and_CC
business_NOMZ
objectives_NN
In_PIN
our_FPP1
last_JJ
Annual_JJ
Review_NN
,_,
we_FPP1
predicted_VBD [PUBV]
that_THVC
Our_FPP1
pipeline_NN
is_VPRT [PASS]
focused_VBN
on_PIN
developing_VBG
new_JJ
2004_CD
would_PRMD
be_VB [BEMA]
a_DT
challenging_JJ
year_NN
as_IN
we_FPP1
felt_VBD [PRIV]
medicines_NN
and_PHC
vaccines_NN
to_TO
treat_VB
diseases_NN
of_PIN
the_DT
full_JJ
impact_NN
of_PIN
generic_JJ
competition_NOMZ
to_PIN
Paxil_NN
unmet_JJ
medical_JJ
need_NN
,_,
such_JJ
as_IN
cancer_NN
and_CC
and_CC
the_DT
introduction_NOMZ
of_PIN
generic_JJ
Wellbutrin_NN
._.
Many_QUAN
of_PIN
these_DEMP
have_VPRT
the_DT
GSK_NN
managed_VBD
this_DEMO
year_NN
well_RB
,_,
thanks_NN
to_PIN
the_DT
potential_NN
to_TO
be_VB [BEMA]
important_JJ
new_JJ
products_NN
._.
underlying_VBG
strength_NN
of_PIN
the_DT
business_NOMZ
._.
In_PIN
fact_NN
,_,
For_CONJ
example_NULL
,_,
we_FPP1
believe_VPRT [PRIV]
that_THVC
Cervarix_NN
,_,
our_FPP1
GSK_NN
is_VPRT [BEMA]
a_DT
much_QUAN
stronger_JJ
company_NN
today_TIME
than_PIN
promising_JJ
vaccine_NN
candidate_NN
against_PIN
cervical_JJ
it_PIT
was_VBD [BEMA]
a_DT
year_NN
ago_RB
._.
cancer_NN
,_,
has_VPRT
the_DT
potential_JJ
to_TO
make_VB
a_DT
major_JJ
contribution_NOMZ
to_PIN
healthcare_NN
globally_RB
and_CC
to_PIN
Our_FPP1
broad-based_JJ
portfolio_NN
of_PIN
fast-growing_JJ
become_VBN
our_FPP1
best-selling_JJ
vaccine_NN
._.
We_FPP1
expect_VPRT [PRIV]
Sir_NN
Christopher_NN
Gent_NN
,_,
Non-Executive_NN
Chairman_NN
products_NN
and_CC
continued_VBD
focus_NN
on_PIN
controlling_VBG
to_TO
le_FW
Cervarix_NN
in_PIN
the_DT
European_NN
Union_NN
and_PHC
costs_NN
enabled_VBD
us_FPP1
to_TO
absorb_VB
the_DT
loss_NN
of_PIN
more_EMPH
international_JJ
markets_NN
in_PIN
2006_CD
._.
than_PIN
1.5_CD
billion_CD
of_PIN
business_NOMZ
to_PIN
generics_NN
and_CC
still_RB
achieve_VB
a_DT
1_CD
%_NN
increase_NN
in_PIN
global_JJ
Great_JJ
opportunities_NOMZ
lie_VPRT
ahead_PLACE
of_PIN
us_FPP1
._.
Turnover_NN
of_PIN
20_CD
billion_CD
This_DEMO
year_NN
,_,
we_FPP1
will_PRMD
work_VB
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
greater_JJ
grew_VBD
1_CD
%_NN
at_PIN
constant_JJ
exchange_NN
rates_NN
CER_NN
,_,
understanding_GER
by_PIN
key_JJ
stakeholders_NN
of_PIN
the_DT
and_CC
we_FPP1
achieved_VBD
our_FPP1
guidance_NN
of_PIN
earnings_GER
value_NN
of_PIN
innovative_JJ
medicines_NN
._.
We_FPP1
will_PRMD
per_PIN
share_NN
EPS_NN
at_PIN
least_JJ
in_PIN
line_NN
with_PIN
business_NOMZ
continue_VPRT
our_FPP1
contribution_NOMZ
to_TO
nding_VBG
a_DT
performance_NN
EPS_NN
in_PIN
2003_CD
at_PIN
CER_NN
._.
Our_FPP1
EPS_NN
solution_NOMZ
to_PIN
the_DT
healthcare_NN
funding_GER
crisis_NN
,_,
and_ANDC
grew_VBD
2_CD
%_NN
to_TO
75p_VB
in_PIN
2004_CD
._.
we_FPP1
will_PRMD
seek_VB
new_JJ
ways_NN
of_PIN
improving_VBG
access_NN
to_PIN
our_FPP1
medicines_NN
for_PIN
the_DT
people_NN
who_WP [WHSUB]
need_VPRT
them_TPP3
In_PIN
2005_CD
,_,
we_FPP1
expect_VPRT [PRIV]
to_TO
see_VB [PRIV]
faster_JJ
growth_NN
most_EMPH
but_CC
are_VPRT [BEMA]
least_RB
able_PRED
to_TO
pay_VB
for_PIN
them_TPP3
._.
Our_FPP1
with_PIN
an_DT
EPS_NN
percentage_NN
CER_NN
growth_NN
in_PIN
the_DT
Corporate_JJ
Responsibility_NOMZ
Principles_NN
continue_VPRT
low_JJ
double-digit_JJ
range_NN
on_PIN
an_DT
International_NN
to_TO
guide_VB
the_DT
way_NN
we_FPP1
do_VPRT [PROD]
business_NOMZ
._.
A_DT
separate_JJ
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
basis_NN
._.
2004_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
This_DEMP
is_VPRT
being_VBG [BYPA]
driven_VBN
by_PIN
the_DT
strong_JJ
growth_NN
of_PIN
available_JJ
from_PIN
the_DT
GSK_NN
website_NN
explains_VPRT [PUBV]
Jean-Pierre_NN
Garnier_NN
,_,
Chief_NN
Executive_NN
officer_NN
key_NN
products_NN
and_CC
continuing_VBG
efficiencies_NN
in_PIN
progress_NN
against_PIN
these_DEMO
Principles_NN
during_PIN
our_FPP1
operations_NOMZ
._.
Our_FPP1
most_EMPH
exciting_JJ
phase_NN
of_PIN
the_DT
year_NN
._.
growth_NN
will_PRMD
come_VB
when_RB
the_DT
new_JJ
compounds_NN
and_PHC
vaccines_NN
currently_RB
in_PIN
development_NOMZ
start_NN
Acknowledgements_NOMZ
contributing_VBG [WZPRES]
to_PIN
our_FPP1
performance_NN
over_IN
the_DT
next_JJ
We_FPP1
acknowledge_VPRT [PUBV]
with_PIN
gratitude_NN
the_DT
few_QUAN
years_NN
._.
contribution_NOMZ
of_PIN
Sir_NN
Christopher_NN
Hogg_NN
and_PHC
Sir_NN
Peter_NN
Job_NN
,_,
who_WP
retired_VBD
from_PIN
the_DT
Board_NN
at_PIN
GSK_NN
has_VPRT
one_CD
of_PIN
the_DT
largest_JJ
and_CC
most_EMPH
the_DT
end_NN
of_PIN
2004_CD
._.
Sir_NN
Christopher_NN
chaired_VBD
promising_JJ
pipelines_NN
in_PIN
the_DT
industry_NN
,_,
with_PIN
GSK_NN
through_PIN
a_DT
period_NN
that_TSUB
saw_VBD [PRIV]
the_DT
Company_NN
140_CD
projects_NN
in_PIN
clinical_JJ
development_NOMZ
as_IN
at_PIN
the_DT
derive_NN
the_DT
full_JJ
benets_NN
of_PIN
the_DT
merger_NN
and_PHC
end_NN
of_PIN
February_NN
2005_CD
,_,
including_VBG [PRESP]
88_CD
New_NN
meet_VB
the_DT
challenges_NN
caused_VBN [WZPAST]
by_PIN
the_DT
loss_NN
of_PIN
Chemical_NN
Entities_NOMZ
NCEs_NN
,_,
32_CD
Product_NN
Line_NN
patent_NN
protection_NOMZ
on_PIN
major_JJ
products_NN
._.
Of_PIN
these_DEMO
compounds_NN
,_,
43_CD
NCEs_NN
have_VPRT [PEAS]
moved_VBN [SUAV]
into_PIN
Phase_NN
John_NN
Coombe_NN
,_,
Chief_NN
Financial_NN
officer_NN
,_,
will_PRMD
II_NN
trials_NN
,_,
including_VBG
compounds_NN
to_TO
treat_VB
HIV_NN
,_,
retire_VPRT
from_PIN
the_DT
Board_NN
of_PIN
GSK_NN
on_PIN
31_CD
March_NN
diabetes_NN
,_,
blood_NN
disorders_NN
and_CC
multiple_JJ
2005_CD
._.
John_NN
has_VPRT [PEAS]
served_VBN
GSK_NN
and_CC
its_PIT
sclerosis_NN
,_,
and_ANDC
data_NN
on_PIN
at_PIN
least_JJ
15_CD
of_PIN
these_DEMO
predecessor_NN
companies_NN
in_PIN
an_DT
exemplary_JJ
are_VPRT [PASS]
expected_VBN [PRIV]
during_PIN
2005_CD
._.
In_PIN
2005_CD
,_,
we_FPP1
also_RB
manner_NN
for_PIN
more_EMPH
than_PIN
18_CD
years_NN
,_,
playing_VBG [PRESP]
a_DT
anticipate_VPRT [PRIV]
the_DT
launch_NN
of_PIN
six_CD
new_JJ
products_NN
,_,
major_JJ
role_NN
in_PIN
guiding_VBG
the_DT
Company_NN
through_PIN
including_VBG
Rotarix_NN
for_PIN
rotavirus_NN
,_,
Vesicare_NN
for_PIN
the_DT
post-merger_JJ
period_NN
and_CC
establishing_VBG [PRIV]
overactive_JJ
bladder_NN
,_,
Boniva_NN
for_PIN
osteoporosis_NN
,_,
GSK_NN
as_IN
a_DT
leader_NN
within_PIN
the_DT
global_JJ
Avandaryl_NN
for_PIN
diabetes_NN
,_,
Requip_NN
for_PIN
restless_JJ
pharmaceutical_JJ
industry_NN
._.
legs_NN
syndrome_NN
and_PHC
Entereg_NN
for_PIN
post-operative_JJ
bowel_NN
disorders_NN
._.
We_FPP1
thank_VPRT
all_QUAN
three_CD
departing_VBG
directors_NN
for_PIN
All_QUAN
percentage_NN
growth_NN
rates_NN
are_VPRT [BEMA]
at_PIN
constant_JJ
their_TPP3
substantial_JJ
contributions_NOMZ
to_PIN
GSK_NN
and_PHC
exchange_NN
rates_NN
CER_NN
,_,
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
See_NN
Business_NOMZ
operating_VBG [WZPRES]
review_NN
page_NN
15_CD
wish_NN
them_TPP3
well_RB
for_PIN
the_DT
future_NN
._.
2_CD
2_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
HIGHLIGHTS_NN
OF_PIN
THE_DT
YEAR_NN
FINANCIAL_NN
PERFORMANCE_NN
PRODUCT_NN
PIPELINE_NN
GSKS_NN
BUSINESS_NOMZ
STRATEGY_NN
GSKs_NN
business_NOMZ
strategy_NN
developed_VBD
projects_NN
in_PIN
2001_CD
at_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
in_PIN
clinical_JJ
is_VPRT
delivering_VBG
results_NN
:_:
development_NOMZ
20bn_JJ
140_CD
Total_JJ
turnover_NN
grew_VBD
1_CD
%_NN
despite_PIN
a_DT
Our_FPP1
promising_JJ
product_NN
pipeline_NN
is_VPRT [BEMA]
one_CD
To_TO
build_VB
the_DT
best_JJ
product_NN
pipeline_NN
1.5_CD
billion_CD
loss_NN
of_PIN
sales_NN
to_PIN
generics_NN
of_PIN
the_DT
largest_JJ
in_PIN
the_DT
industry_NN
in_PIN
the_DT
industry_NN
To_TO
achieve_VB
commercial_JJ
and_CC
spent_VBD
each_QUAN
operational_JJ
excellence_NN
day_NN
on_PIN
R&D_NN
8m_CD
To_TO
improve_VB
access_NN
to_PIN
medicines_NN
GSK_NN
spends_VPRT
more_EMPH
on_PIN
R&D_NN
than_PIN
any_QUAN
for_PIN
those_DEMP
who_WP
can_POMD
not_XX0
afford_VB
them_TPP3
6bn_VB
other_JJ
UK_NN
company_NN
profit_NN
before_IN
tax_NN
grew_VBD
2_CD
%_NN
To_TO
make_VB
GSK_NN
the_DT
best_JJ
place_NN
for_PIN
the_DT
best_JJ
people_NN
to_TO
do_VB [PROD]
their_TPP3
best_JJ
work_NN
To_TO
contribute_VB
to_PIN
investment_NOMZ
in_PIN
04_CD
X._NN
Xbn_NN
Nearly80_CD
%_NN
communities_NOMZ
around_PLACE
the_DT
world_NN
increase_NN
in_PIN
New_NN
Chemical_NN
Entities_NOMZ
To_TO
ensure_VB [SUAV] [PRIV]
our_FPP1
business_NOMZ
decisions_NN
take_VPRT
NCEs_NN
in_PIN
pipeline_NN
since_OSUB
merger_NN
into_PIN
consideration_NOMZ
ethical_JJ
,_,
social_JJ
and_PHC
75p_JJ
environmental_JJ
concerns_NN
Earnings_GER
per_PIN
share_NN
grew_VBD
2_CD
%_NN
in_PIN
2004_CD
,_,
in_PIN
line_NN
with_PIN
our_FPP1
BEST_NN
PEOPLE_NN
earnings_GER
guidance_NN
82_CD
%_NN
CARING_NN
FOR_PIN
THE_DT
ENVIRONMENT_NOMZ
of_PIN
managers_NN
surveyed_VBN
believe_VPRT [PRIV]
that_THVC
GSK_NN
employees_NN
are_VPRT [PASS]
committed_VBN
and_PHC
enabled_VBN
to_TO
make_VB
meaningful_JJ
contributions_NOMZ
2nd_RB
largest_JJ
7_CD
%_NN
83_CD
%_NN
pharmaceutical_NN
of_PIN
managers_NN
surveyed_VBN [WZPAST]
are_VPRT [BEMA]
proud_PRED
to_TO
be_VB
part_NN
decrease_NN
in_PIN
greenhouse_NN
gas_NN
company_NN
in_PIN
of_PIN
GSK_NN
and_CC
77_CD
%_NN
would_PRMD [SPAU]
gladly_RB
refer_VB
a_DT
emissions_NN
per_PIN
unit_NN
sales_NN
the_DT
world_NN
friend_NN
or_CC
family_NN
member_NN
to_TO
work_VB
for_PIN
GSK_NN
ACCESS_NN
TO_PIN
MEDICINES_NN
COMMERCIAL_NN
&_CC
OPERATIONAL_NN
EXCELLENCE_NN
More_EMPH
than_PIN
475,000_CD
500m_JJ
patients_NN
have_VPRT
access_NN
to_PIN
GSKs_NN
medicines_NN
12_CD
GSK_NN
products_NN
achieved_VBD
sales_NN
of_PIN
more_EMPH
mostly_RB
free_JJ
of_PIN
charge_NN
,_,
through_PIN
the_DT
US_FPP1
Patient_NN
than_PIN
500_CD
million_CD
in_PIN
2004_CD
Assistance_NN
Program_NN
More_EMPH
than_PIN
2.5_CD
bn_NN
85m_NN
sales_NN
of_PIN
Seretide_NN
Advair_NN
up_RB
19_CD
%_NN
people_NN
protected_VBN [WZPAST]
from_PIN
lymphatic_JJ
lariasis_NN
GSKs_NN
largest_JJ
product_NN
and_CC
the_DT
worlds_NN
with_PIN
GSK-donated_JJ
albendazole_NN
sixth_RB
largest_JJ
pharmaceutical_JJ
product_NN
50m_JJ
value_NN
of_PIN
donated_VBN
INVESTMENT_NOMZ
IN_PIN
COMMUNITIES_NOMZ
medicines_NN
Method_NN
of_PIN
giving_VBG
Value_NN
of_PIN
global_JJ
community_NOMZ
including_VBG [WZPRES]
US_FPP1
Patient_NN
Assistance_NN
Program_NN
investment_NOMZ
activities_NOMZ
33m_VPRT
5_CD
%_NN
Management_NOMZ
328m_NN
costs_NN
15_CD
%_NN
Combivir_NN
tablets_NN
5.4_CD
%_NN
of_PIN
profit_NN
before_IN
tax_NN
Cash_NN
HIV_NN
treatment_NOMZ
1_CD
%_NN
In_PIN
kind_NN
shipped_VBN [WZPAST]
to_PIN
Africa_NN
21m_CD
Health_NN
programs_NN
and_PHC
activities_NOMZ
79_CD
%_NN
Product_NN
18m_CD
Education_NOMZ
programs_NN
and_PHC
activities_NOMZ
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
3_CD
3_CD
3_CD
So_IN
what_WP
is_VPRT [BEMA]
the_DT
big_JJ
challenge_NN
?_.
An_DT
interview_NN
with_PIN
JP_NN
Garnier_NN
,_,
Chief_NN
Executive_NN
officer_NN
Ultimately_RB
,_,
it_PIT
is_VPRT [BEMA]
the_DT
crisis_NN
of_PIN
healthcare_NN
nancing_GER
and_PHC
pricing_GER
pressures_NN
largely_RB
due_JJ
to_TO
ageing_VBG
populations_NOMZ
in_PIN
the_DT
developed_JJ
world_NN
What_WP
is_VPRT [BEMA]
the_DT
main_JJ
challenge_NN
facing_VBG [WZPRES]
the_DT
How_RB
healthy_JJ
is_VPRT [BEMA]
GSKs_JJ
pipeline_NN
of_PIN
In_PIN
September_NN
2004_CD
,_,
GSK_NN
was_VBD [PASS]
ranked_VBN
first_RB
in_PIN
pharmaceutical_JJ
industry_NN
and_ANDC
how_RB
is_VPRT [BEMA]
potential_JJ
new_JJ
medicines_NN
?_.
terms_NN
of_PIN
market_NN
share_NN
in_PIN
10_CD
of_PIN
the_DT
21_CD
therapy_NN
GSK_NN
responding_VBG [WZPRES]
to_PIN
it_PIT
?_.
We_FPP1
currently_RB
have_VPRT
54_CD
New_NN
Chemical_NN
areas_NN
in_PIN
which_WDT [PIRE]
GSK_NN
has_VPRT [PEAS]
launched_VBN
products_NN
._.
Ultimately_RB
,_,
it_PIT
is_VPRT [BEMA]
the_DT
crisis_NN
of_PIN
healthcare_NN
Entities_NOMZ
NCEs_NN
in_PIN
Phases_NN
II_NN
and_PHC
III_NN
late_TIME
stage_NN
nancing_GER
and_PHC
pricing_GER
pressures_NN
largely_RB
due_JJ
to_PIN
clinical_JJ
trials_NN
,_,
and_ANDC
have_VPRT [PEAS]
achieved_VBN
good_JJ
results_NN
In_PIN
2004_CD
,_,
our_FPP1
turnover_NN
grew_VBD
1_CD
%_NN
despite_PIN
the_DT
ageing_JJ
populations_NOMZ
in_PIN
the_DT
developed_JJ
world_NN
._.
over_IN
the_DT
last_JJ
few_QUAN
months_NN
from_PIN
studies_NN
of_PIN
some_QUAN
significant_JJ
loss_NN
of_PIN
more_EMPH
than_PIN
1.5_CD
billion_CD
of_PIN
our_FPP1
An_DT
increasing_VBG
ageing_JJ
population_NOMZ
means_VPRT [PRIV]
that_THVC
of_PIN
our_FPP1
key_JJ
compounds_NN
,_,
including_VBG
Lapatinib_NN
for_PIN
business_NOMZ
to_PIN
generics_NN
during_PIN
the_DT
year_NN
._.
We_FPP1
also_RB
there_EX
is_VPRT
an_DT
increasing_VBG
demand_NN
for_PIN
new_JJ
cancer_NN
and_PHC
Cervarix_NN
,_,
a_DT
vaccine_NN
against_PIN
cervical_JJ
continued_VBN
to_TO
focus_VB
on_PIN
managing_VBG
our_FPP1
costs_NN
medicines_NN
to_TO
treat_VB
chronic_NN
and_CC
degenerative_JJ
cancer_NN
._.
A_EMPH
lot_NULL
remains_VPRT
to_TO
be_VB [PASS]
done_VBN [PROD]
,_,
of_PIN
course_NN
,_,
through_PIN
our_FPP1
operational_JJ
excellence_NN
diseases_NN
._.
and_ANDC
there_EX
will_PRMD [SPAU]
always_RB
be_VB [BEMA]
some_QUAN
pipeline_NN
programs_NN
see_VPRT [PRIV]
Sharpening_VBG
our_FPP1
operations_NOMZ
,_,
attrition_NOMZ
,_,
but_CC
we_FPP1
are_VPRT
making_VBG
good_JJ
progress_NN
._.
In_PIN
2005_CD
,_,
we_FPP1
expect_VPRT [PRIV]
to_TO
see_VB [PRIV]
faster_JJ
While_OSUB
this_DEMP
presents_VPRT
an_DT
opportunity_NOMZ
for_PIN
GSK_NN
We_FPP1
believe_VPRT [PRIV] [THATD]
we_FPP1
have_VPRT
one_CD
of_PIN
the_DT
largest_JJ
and_CC
growth_NN
._.
Continued_VBN
scrutiny_NN
of_PIN
costs_NN
and_CC
new_JJ
and_PHC
other_JJ
pharmaceutical_JJ
companies_NN
,_,
it_PIT
is_VPRT
also_RB
most_EMPH
promising_JJ
pipelines_NN
in_PIN
the_DT
industry_NN
-_:
in_PIN
initiatives_NN
to_TO
streamline_VB
our_FPP1
operations_NOMZ
remains_VPRT
placing_VBG
a_DT
financial_JJ
burden_NN
on_PIN
governments_NOMZ
fact_NN
,_,
the_DT
number_NN
of_PIN
NCEs_NN
in_PIN
the_DT
pipeline_NN
has_VPRT
a_DT
key_JJ
strategic_JJ
focus_NN
for_PIN
us_FPP1
._.
and_ANDC
healthcare_NN
purchasers_NN
that_DEMP
is_VPRT
growing_VBG
increased_VBN
by_PIN
nearly_DWNT
80_CD
%_NN
since_OSUB
the_DT
merger_NN
._.
faster_JJ
than_PIN
their_TPP3
ability_NOMZ
to_TO
support_VB
it_PIT
._.
In_PIN
the_DT
Many_QUAN
patients_NN
in_PIN
both_DT
the_DT
developed_VBN
developing_VBG
world_NN
,_,
where_RB
infectious_JJ
diseases_NN
In_PIN
2005_CD
,_,
data_NN
are_VPRT [PASS]
expected_VBN [PRIV]
on_PIN
at_PIN
least_JJ
15_CD
and_CC
developing_VBG
worlds_NN
do_VPRT
not_XX0
have_VB
present_JJ
an_DT
enormous_JJ
burden_NN
,_,
there_EX
products_NN
and_PHC
vaccines_NN
in_PIN
Phase_NN
II_NN
clinical_JJ
trials_NN
,_,
access_NN
to_PIN
the_DT
medicines_NN
they_TPP3
need_VPRT
._.
is_VPRT [BEMA]
an_DT
urgent_JJ
need_NN
for_PIN
medicines_NN
but_CC
a_DT
lack_NN
of_PIN
including_VBG
compounds_NN
to_TO
treat_VB
HIV_NN
,_,
diabetes_NN
,_,
What_WP
is_VPRT
GSK_NN
doing_VBG [WZPRES]
to_TO
improve_VB
this_DEMO
resources_NN
to_TO
pay_VB
for_PIN
them_TPP3
._.
blood_NN
disorders_NN
and_CC
multiple_JJ
sclerosis_NN
._.
Our_FPP1
pipeline_NN
is_VPRT [PASS]
targeted_VBN
at_PIN
developing_VBG
Therefore_CONJ
,_,
GSKs_NN
challenge_NN
is_VPRT
to_TO
deliver_VB
In_PIN
the_DT
meantime_NN
,_,
can_POMD
GSK_NN
continue_VPRT
to_PIN
medicines_NN
that_TSUB
address_VPRT
real_JJ
and_PHC
unmet_JJ
affordable_JJ
medicines_NN
that_TSUB
meet_VPRT
the_DT
needs_NN
deliver_VPRT
strong_JJ
performance_NN
?_.
medical_JJ
needs_NN
,_,
both_DT
in_PIN
the_DT
developed_VBN
and_CC
of_PIN
people_NN
burdened_VBN [WZPAST]
by_PIN
disease_NN
._.
We_FPP1
have_VPRT [PEAS]
been_VBN [BEMA]
able_PRED
to_TO
stay_VB
on_PIN
track_NN
developing_VBG [WZPRES]
world_NN
._.
we_FPP1
must_NEMD
continue_VB
to_TO
build_VB
partnerships_NN
with_PIN
nancially_RB
because_CAUS
of_PIN
the_DT
performance_NN
governments_NOMZ
and_PHC
healthcare_NN
purchasers_NN
,_,
of_PIN
our_FPP1
key_JJ
pharmaceutical_JJ
products_NN
,_,
such_JJ
as_IN
We_FPP1
have_VPRT [PEAS]
learned_VBN [PRIV]
valuable_JJ
lessons_NN
from_PIN
being_VBG
and_CC
other_JJ
external_JJ
stakeholders_NN
._.
They_TPP3
need_VPRT
Seretide_NN
Advair_NN
and_PHC
Avandia_NN
._.
We_FPP1
have_VPRT
also_RB
proactive_JJ
and_PHC
innovative_JJ
,_,
and_ANDC
we_FPP1
arent_VPRT
afraid_JJ
to_TO
understand_VB [PRIV]
the_DT
scale_NN
,_,
complexity_NOMZ
and_PHC
cost_NN
done_VBN [WZPAST]
very_AMP
well_RB
with_PIN
products_NN
such_JJ
as_IN
Coreg_NN
to_TO
be_VB
first_RB
._.
For_CONJ
example_NULL
,_,
GSK_NN
started_VBD
the_DT
first_JJ
of_PIN
research_NN
and_PHC
development_NOMZ
,_,
and_ANDC
we_FPP1
need_VPRT
for_PIN
heart_NN
failure_NN
and_PHC
Lamictal_NN
for_PIN
epilepsy_NN
and_PHC
savings_GER
card_NN
for_PIN
prescription_NOMZ
medicines_NN
the_DT
to_TO
work_VB
with_PIN
them_TPP3
to_TO
nd_VB
new_JJ
solutions_NOMZ
bipolar_JJ
disorder_NN
,_,
Valtrex_NN
for_PIN
genital_JJ
herpes_NN
and_PHC
Orange_NN
Card_NN
,_,
for_PIN
US_FPP1
senior_JJ
citizens_NN
and_CC
we_FPP1
to_PIN
funding_GER
._.
These_DEMO
products_NN
grew_VBD
were_VBD [BEMA]
the_DT
first_JJ
company_NN
to_TO
sell_VB
our_FPP1
HIV_NN
drugs_NN
22_CD
%_NN
in_PIN
2004_CD
._.
on_PIN
a_DT
non-profit_JJ
basis_NN
in_PIN
Africa_NN
,_,
where_RB
we_FPP1
also_RB
now_TIME
have_VPRT
six_CD
voluntary_JJ
licensing_GER
agreements_NOMZ
._.
4_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV] [THATD]
We_FPP1
have_VPRT [PEAS]
learned_VBN [PRIV]
valuable_JJ
lessons_NN
from_PIN
being_VBG [BEMA]
proactive_PRED
and_PHC
innovative_PRED
,_,
and_ANDC
we_FPP1
arent_VPRT
afraid_JJ
to_TO
be_VB [BEMA]
first_PRED
I_FPP1
am_VPRT [BEMA]
proud_PRED
of_PIN
our_FPP1
commitment_NOMZ
to_TO
increasing_VBG
Our_FPP1
Corporate_JJ
Responsibility_NOMZ
Principles_NN
How_RB
do_VPRT
you_SPP2
expect_VPRT [PRIV]
GSK_NN
to_TO
look_VB
in_PIN
access_NN
to_PIN
medicines_NN
and_CC
our_FPP1
generosity_NOMZ
in_PIN
a_DT
articulate_VPRT
the_DT
standards_NN
we_FPP1
are_VPRT [BEMA]
committed_PRED
five_CD
years_NN
time_NN
?_.
wide_JJ
variety_NN
of_PIN
philanthropic_JJ
undertakings_GER
._.
to_PIN
meeting_GER
in_PIN
our_FPP1
work_NN
and_PHC
interaction_NOMZ
with_PIN
JPG_NN
._.
Our_FPP1
goal_NN
is_VPRT
to_TO
develop_VB
innovative_JJ
communities_NOMZ
._.
These_DEMP
are_VPRT [PASS]
embedded_VBN
in_PIN
the_DT
medicines_NN
of_PIN
value_NN
faster_RB
than_PIN
our_FPP1
In_PIN
2004_CD
,_,
we_FPP1
invested_VBD
328_CD
million_CD
in_PIN
way_NN
we_FPP1
do_VPRT [PROD]
business_NOMZ
,_,
and_ANDC
we_FPP1
report_VPRT [PUBV]
annually_RB
competitors_NN
,_,
and_ANDC
to_TO
sell_VB
and_PHC
market_VB
our_FPP1
community_NOMZ
programs_NN
,_,
product_NN
donations_NOMZ
on_PIN
our_FPP1
progress_NN
against_PIN
each_QUAN
of_PIN
these_DEMO
products_NN
in_PIN
new_JJ
and_PHC
innovative_JJ
ways_NN
._.
We_FPP1
will_PRMD
and_CC
charitable_JJ
contributions_NOMZ
._.
Principles_NN
see_VPRT [PRIV] [THATD]
Corporate_JJ
Responsibility_NOMZ
continue_VPRT
to_TO
collaborate_VB
with_PIN
key_JJ
stakeholders_NN
Report_NN
at_PIN
www_NN
._.
to_TO
nd_VB
new_JJ
ways_NN
to_TO
help_VB
people_NN
receive_VB
the_DT
We_FPP1
believe_VPRT [PRIV]
that_THVC
we_FPP1
have_VPRT
a_DT
key_JJ
role_NN
to_TO
play_VB
in_PIN
medicines_NN
they_TPP3
need_VPRT
._.
improving_VBG
access_NN
to_PIN
medicines_NN
,_,
and_ANDC
we_FPP1
are_VPRT
How_RB
does_VPRT
GSK_NN
keep_VB
its_PIT
employees_NN
committed_VBN
to_TO
continuing_VBG
our_FPP1
efforts_NN
._.
motivated_VBN [PASTP]
in_PIN
this_DEMO
challenging_JJ
As_IN
now_TIME
,_,
we_FPP1
will_PRMD
aim_VB
to_TO
meet_VB
the_DT
demands_NN
environment_NOMZ
?_.
of_PIN
our_FPP1
patients_NN
,_,
our_FPP1
customers_NN
and_CC
our_FPP1
The_DT
pharmaceutical_JJ
industry_NN
JPG_NN
._.
We_FPP1
are_VPRT [BEMA]
open_PRED
with_PIN
our_FPP1
people_NN
about_IN
the_DT
employees_NN
with_PIN
integrity_NOMZ
._.
And_ANDC
we_FPP1
will_PRMD [SPAU]
generally_RB
receives_VPRT
a_DT
negative_JJ
press_NN
._.
challenges_NN
we_FPP1
face_VPRT
,_,
the_DT
actions_NOMZ
we_FPP1
are_VPRT
taking_VBG
continue_VPRT
to_TO
be_VB [BEMA]
a_DT
company_NN
that_TSUB
highly_AMP
talented_VBD
How_RB
can_POMD
GSKs_NN
reputation_NOMZ
be_VB
and_CC
the_DT
progress_NN
being_VBG [WZPRES] [PASS]
made_VBN
._.
Im_NN
pleased_JJ
people_NN
want_VPRT
to_TO
join_VB
in_PIN
order_NN
to_TO
make_VB
their_TPP3
improved_VBN
?_.
to_TO
say_VB [PUBV]
that_THVC
employees_NN
are_VPRT [SPAU] [PASS]
highly_AMP
engaged_VBN
._.
contribution_NOMZ
,_,
and_ANDC
to_TO
enjoy_VB
a_DT
challenging_JJ
and_CC
JPG_NN
._.
GSK_NN
has_VPRT
a_DT
very_AMP
high_JJ
standing_GER
among_PIN
the_DT
GSK_NN
people_NN
continue_VPRT
to_TO
be_VB [BEMA]
enthusiastic_PRED
and_PHC
meaningful_PRED
career_NN
._.
The_DT
innovation_NOMZ
show_NN
enormous_JJ
passion_NN
for_PIN
their_TPP3
company_NN
._.
and_ANDC
quality_NOMZ
associated_VBN [WZPAST]
with_PIN
many_QUAN
of_PIN
our_FPP1
initiatives_NN
is_VPRT [SPAU] [PASS]
widely_RB
recognized_VBN [PRIV]
,_,
often_RB
through_PIN
We_FPP1
undertook_VBD
a_DT
management_NOMZ
survey_NN
prestigious_JJ
awards_NN
._.
However_CONJ
,_,
this_DEMP
is_VPRT [BEMA]
not_XX0
last_JJ
year_NN
._.
The_DT
results_NN
showed_VBD [PRIV]
that_THVC
people_NN
feel_VPRT [PRIV]
always_RB
visible_JJ
to_PIN
the_DT
general_JJ
public_NN
._.
better_RB
about_IN
working_VBG
at_PIN
GSK_NN
today_TIME
than_PIN
they_TPP3
did_VBD [PROD]
two_CD
years_NN
ago_RB
,_,
despite_PIN
the_DT
challenging_JJ
By_PIN
continuing_VBG
to_TO
be_VB [BEMA]
more_EMPH
open_PRED
and_CC
environment_NOMZ
._.
transparent_JJ
in_PIN
the_DT
way_NN
we_FPP1
run_VPRT
our_FPP1
business_NOMZ
,_,
we_FPP1
will_PRMD
be_VB [BEMA]
able_PRED
to_TO
increase_VB
our_FPP1
external_JJ
Employees_NN
take_VPRT
our_FPP1
companys_NN
quest_NN
to_TO
bring_VB
stakeholders_NN
understanding_VBG [PRIV] [WZPRES]
of_PIN
the_DT
industry_NN
._.
medicines_NN
of_PIN
value_NN
to_PIN
patients_NN
very_AMP
seriously_RB
Good_JJ
examples_NN
include_VPRT
making_VBG
our_FPP1
clinical_JJ
indeed_RB
._.
GSK_NN
will_PRMD
continue_VB
to_TO
engage_VB
and_CC
trial_NN
results_NN
available_JJ
to_PIN
the_DT
public_NN
by_PIN
putting_VBG
support_NN
our_FPP1
employees_NN
in_PIN
driving_VBG
changes_NN
them_TPP3
on_PIN
the_DT
internet_NN
see_VB [PRIV]
page_NN
9_CD
and_CC
the_DT
through_PIN
the_DT
organization_NOMZ
,_,
and_ANDC
to_TO
recognize_VB [PRIV]
extension_NN
of_PIN
our_FPP1
Patient_NN
Advocacy_NN
initiative_NN
and_PHC
reward_NN
exceptional_JJ
and_PHC
innovative_JJ
work_NN
._.
see_VB [PRIV]
page_NN
10_CD
throughout_PIN
the_DT
world_NN
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
5_CD
Transforming_VBG
R&D_NN
In_PIN
2004_CD
,_,
GSK_NN
invested_VBD
more_EMPH
than_PIN
2.8_CD
billion_CD
15.9_CD
%_NN
of_PIN
pharmaceutical_JJ
turnover_NN
in_PIN
Research_NN
and_PHC
Development_NOMZ
R&D_NN
Ten_CD
years_NN
ago_RB
,_,
we_FPP1
conducted_VBD
500,000_CD
screening_VBG
tests_NN
in_PIN
a_DT
year_NN
._.
In_PIN
2004_CD
,_,
we_FPP1
ran_VBD
more_EMPH
than_PIN
65_CD
million_CD
tests_NN
in_PIN
our_FPP1
screening_VBG
No._NN
._.
1_CD
facilities_NOMZ
investor_NN
in_PIN
R&D_NN
among_PIN
UK_NN
companies_NN
Bob_NN
Hertzberg_NN
,_,
Vice_NN
President_NN
,_,
Molecular_NN
Screening_GER
,_,
Discovery_NN
Research_NN
,_,
Upper_NN
Providence_NN
,_,
US_FPP1
15,037_CD
R&D_NN
employees_NN
worldwide_VPRT
GSKs_NN
continuing_VBG [WZPRES]
success_NN
depends_VPRT
on_PIN
a_DT
Each_QUAN
of_PIN
R&D_NN
s_VPRT [BEMA]
seven_CD
Centres_NN
of_PIN
Excellence_NN
can_POMD
maximize_VB
its_PIT
return_NN
on_PIN
investment_NOMZ
is_VPRT [BEMA]
vibrant_PRED
and_PHC
productive_PRED
Research_NN
and_CC
for_PIN
Drug_NN
Discovery_NN
CEDDs_NN
is_VPRT [PASS]
focused_VBN
on_PIN
a_DT
through_PIN
partnerships_NN
and_PHC
collaborations_NOMZ
with_PIN
Development_NOMZ
R&D_NN
function_NOMZ
._.
Because_CAUS
of_PIN
their_TPP3
smaller_JJ
academic_JJ
institutions_NOMZ
,_,
and_ANDC
other_JJ
scale_NN
and_PHC
focus_NN
,_,
the_DT
CEDDs_NN
are_VPRT [BEMA]
able_PRED
to_TO
make_VB
pharmaceutical_JJ
and_CC
biotechnology_NN
It_PIT
takes_VPRT
well_RB
over_IN
500_CD
million_CD
and_CC
between_PIN
rapid_JJ
and_PHC
informed_JJ
decisions_NN
about_IN
whether_IN
companies_NN
._.
These_DEMO
partnerships_NN
work_VPRT
on_PIN
the_DT
10_CD
and_CC
12_CD
years_NN
to_TO
develop_VB
a_DT
new_JJ
drug_NN
._.
to_TO
progress_VB
a_DT
compound_NN
to_TO
midand_VB
lateprinciple_NN
of_PIN
shared_VBN
risk_NN
and_PHC
reward_NN
for_PIN
the_DT
For_PIN
every_QUAN
million_CD
compounds_NN
screened_VBD
,_,
stage_NN
development_NOMZ
._.
The_DT
strength_NN
of_PIN
GSKs_NN
partners_NN
,_,
through_PIN
in-licensing_GER
and_CC
third-party_JJ
approximately_RB
250_CD
make_VPRT
it_PIT
to_PIN
pre-clinical_JJ
pipeline_NN
is_VPRT [BEMA]
an_DT
early_TIME
sign_NN
that_DEMP
this_DEMO
innovative_JJ
arrangements_NOMZ
._.
This_DEMP
allows_VPRT [SUAV]
GSK_NN
to_PIN
co-develop_JJ
testing_GER
,_,
10_CD
advance_NN
to_PIN
clinical_JJ
trials_NN
and_CC
just_EMPH
approach_NN
is_VPRT
working_VBG
._.
or_CC
co-market_JJ
compounds_NN
that_TOBJ
we_FPP1
consider_VPRT [PRIV]
one_CD
is_VPRT [PASS]
approved_VBN
for_PIN
patient_JJ
use_NN
._.
would_PRMD
enhance_VB
our_FPP1
product_NN
portfolio_NN
._.
Building_GER
on_PIN
the_DT
successful_JJ
CEDD_NN
structure_NN
,_,
in_PIN
With_PIN
these_DEMO
odds_NN
,_,
GSKs_NN
R&D_NN
must_NEMD
be_VB [BEMA]
fast_PRED
2004_CD
,_,
R&D_NN
introduced_VBD
six_CD
Medicine_NN
GSK_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
largest_JJ
collaborators_NN
in_PIN
the_DT
and_CC
accurate_JJ
in_PIN
its_PIT
screening_GER
,_,
identication_NOMZ
,_,
Development_NOMZ
Centres_NN
MDCs_NN
._.
Their_TPP3
remit_JJ
pharmaceutical_JJ
industry_NN
,_,
with_PIN
a_DT
network_NN
of_PIN
development_NOMZ
and_PHC
testing_GER
of_PIN
new_JJ
quality_NOMZ
is_VPRT
to_TO
streamline_VB
decision-making_NN
and_CC
more_EMPH
than_PIN
50_CD
collaborators_NN
partners_NN
._.
compounds_NN
if_COND
it_PIT
is_VPRT
to_TO
meet_VB
the_DT
needs_NN
of_PIN
maximize_VPRT
the_DT
worldwide_JJ
development_NOMZ
patients_NN
._.
The_DT
MDCs_NN
Pipeline_NN
momentum_NN
February_NN
2005_CD
are_VPRT [BEMA]
responsible_PRED
for_PIN
managing_VBG
compounds_NN
Focus_NN
on_PIN
patient_JJ
needs_NN
from_PIN
the_DT
proof-of-concept_JJ
stage_NN
,_,
through_PIN
160_CD
Late-Stage_NN
26_CD
%_NN
of_PIN
140_CD
R&D_NN
s_VPRT
starting_VBG
point_NN
is_VPRT [BEMA]
always_RB
the_DT
real_JJ
and_PHC
midand_JJ
late-stage_JJ
development_NOMZ
Phases_NN
II_NN
Growth_NN
pipeline_NN
11_CD
39_CD
%_NN
of_PIN
unmet_JJ
needs_NN
of_PIN
patients_NN
._.
The_DT
information_NOMZ
and_PHC
III_NN
,_,
see_VPRT [PRIV]
page_NN
9_CD
to_TO
manufacturing_VBG
and_CC
120_CD
118_CD
pipeline_NN
gleaned_VBN [WZPAST]
from_PIN
consultation_NOMZ
with_PIN
patients_NN
,_,
marketing_GER
._.
The_DT
MDCs_NN
collaborate_VPRT
at_PIN
an_DT
early_TIME
12_CD
43_CD
19_CD
their_TPP3
doctors_NN
,_,
key_JJ
opinion_NN
leaders_NN
and_PHC
experts_NN
stage_NN
with_PIN
the_DT
CEDDs_NN
._.
By_PIN
integrating_VBG
the_DT
80_CD
25_CD
in_PIN
the_DT
health_NN
sector_NN
is_VPRT [PASS]
used_VBN
to_TO
shape_VB
GSKs_NN
technical_JJ
development_NOMZ
and_PHC
manufacturing_GER
34_CD
drug_NN
development_NOMZ
program_NN
._.
functions_NOMZ
,_,
GSK_NN
can_POMD
ensure_VB [SUAV] [PRIV]
the_DT
rapid_JJ
and_CC
41_CD
40_CD
effective_JJ
launch_NN
and_PHC
delivery_NN
of_PIN
products_NN
to_PIN
32_CD
Innovative_JJ
ways_NN
of_PIN
working_VBG
the_DT
patients_NN
who_WP [WHSUB]
need_VPRT
them_TPP3
._.
21_CD
20_CD
R&D_NN
s_VPRT [BEMA]
exible_PRED
and_PHC
innovative_PRED
structure_NN
,_,
0_CD
2001_CD
2004_CD
introduced_VBN
at_PIN
the_DT
formation_NOMZ
of_PIN
GSK_NN
,_,
allows_VPRT [SUAV]
it_PIT
Partnerships_NN
and_PHC
collaborations_NOMZ
to_TO
concentrate_VB
resources_NN
where_RB
they_TPP3
will_PRMD
There_EX
will_PRMD [SPAU]
always_RB
be_VB
more_EMPH
opportunities_NOMZ
to_TO
n_VB
Vaccines_NN
n_VPRT
Product_NN
Line_NN
Extensions_NN
n_VPRT
New_NN
Chemical_NN
Entities_NOMZ
NCEs_NN
Phase_NN
I_FPP1
have_VPRT
the_DT
maximum_NN
impact_NN
and_CC
benefit_VB
the_DT
develop_VB
new_JJ
medicines_NN
and_PHC
vaccines_NN
than_PIN
n_JJ
NCEs_NN
Phase_NN
II_NN
n_FW
NCEs_NN
Phase_NN
III_NN
registration_NOMZ
most_EMPH
patients_NN
._.
One_CD
way_NN
that_TOBJ
R&D_NN
6_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
Using_VBG
the_DT
latest_JJ
in_PIN
ultra_NN
high-throughput_JJ
screening_GER
robotic_JJ
systems_NN
at_PIN
Tres_NN
Cantos_NN
in_PIN
Spain_NN
,_,
we_FPP1
will_PRMD
be_VB [BEMA]
able_PRED
to_TO
do_VB [PROD]
300,000_CD
experiments_NOMZ
a_DT
day_NN
,_,
as_RB
well_RB
as_IN
manage_VB
the_DT
large_JJ
amount_NN
of_PIN
information_NOMZ
gathered_VBN [PRIV]
Emilio_NN
Diez_NN
,_,
Director_NN
,_,
Discovery_NN
Research_NN
Automation_NOMZ
Facilities_NOMZ
Innovation_NOMZ
and_PHC
investment_NOMZ
:_:
By_PIN
introducing_VBG
innovative_JJ
new_JJ
ways_NN
of_PIN
working_VBG
and_CC
by_PIN
investing_VBG
in_PIN
advanced_JJ
technology_NN
,_,
GSK_NN
has_VPRT [PEAS]
been_VBN [BEMA]
able_PRED
to_TO
achieve_VB
three_CD
years_NN
of_PIN
sustained_VBN
increase_NN
in_PIN
R&D_NN
productivity_NOMZ
._.
In_PIN
2001_CD
,_,
we_FPP1
had_VBD
118_CD
projects_NN
in_PIN
the_DT
clinic_NN
and_CC
in_PIN
2004_CD
we_FPP1
had_VBD
140_CD
projects_NN
in_PIN
the_DT
clinic_NN
see_VB [PRIV]
Pipeline_NN
momentum_NN
opposite_PIN [STPR]
._.
Imaging_GER
techniques_NN
:_:
Imaging_GER
techniques_NN
are_VPRT
providing_VBG
increasingly_RB
accurate_JJ
predictions_NOMZ
of_PIN
the_DT
clinical_JJ
effect_NN
of_PIN
potential_JJ
medicines_NN
early_TIME
on_PIN
in_PIN
the_DT
development_NOMZ
process_NN
._.
The_DT
objective_NN
is_VPRT
to_TO
save_VB
time_NN
and_PHC
money_NN
,_,
and_ANDC
to_TO
increase_VB
the_DT
chances_NN
of_PIN
success_NN
in_PIN
the_DT
subsequent_JJ
clinical_JJ
trials_NN
._.
Automation_NOMZ
:_:
The_DT
automation_NOMZ
of_PIN
our_FPP1
chemicalsynthesis_NN
and_CC
molecule-screening_JJ
operations_NOMZ
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
take_VB
up_RP
to_PIN
two_CD
years_NN
off_PIN
the_DT
drug_NN
discovery_NN
process_NN
._.
New_NN
facilities_NOMZ
are_VPRT [BEMA]
fully_AMP
operational_PRED
in_PIN
Tres_NN
Cantos_NN
,_,
Spain_NN
and_CC
in_PIN
Harlow_NN
,_,
UK_NN
._.
In_PIN
2004_CD
,_,
GSK_NN
opened_VBD
a_DT
new_JJ
combined_VBN
facility_NOMZ
for_PIN
high-throughput_JJ
screening_GER
of_PIN
drug_NN
targets_NN
and_CC
high-throughput_JJ
chemistry_NN
in_PIN
Upper_NN
Providence_NN
,_,
US_FPP1
._.
R&D_NN
is_VPRT
using_VBG
advanced_JJ
technology_NN
in_PIN
the_DT
search_NN
for_PIN
new_JJ
drugs_NN
Pharmacogenetics_NN
:_:
Pharmacogenetics_NN
is_VPRT
being_VBG [PASS]
applied_VBN
in_PIN
early_TIME
clinical_JJ
trials_NN
to_TO
identify_VB
Electronic_JJ
data_NN
capture_NN
:_:
The_DT
greater_JJ
the_DT
types_NN
of_PIN
patients_NN
most_EMPH
likely_JJ
to_TO
benefit_VB
use_NN
of_PIN
electronic_JJ
capture_NN
of_PIN
clinical_JJ
trial_NN
from_PIN
a_DT
potential_JJ
drug_NN
._.
The_DT
goal_NN
is_VPRT
to_TO
define_VB
data_NN
is_VPRT
allowing_VBG [SUAV]
scientists_NN
to_TO
be_VB
more_EMPH
more_EMPH
precisely_RB
the_DT
populations_NOMZ
to_TO
be_VB [PASS]
enrolled_VBN
productive_JJ
throughout_PIN
the_DT
in_PIN
subsequent_JJ
,_,
larger_JJ
clinical_JJ
trials_NN
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
7_CD
Delivering_VBG
the_DT
pipeline_NN
GSKs_NN
product_NN
pipeline_NN
is_VPRT
maturing_VBG
rapidly_RB
and_CC
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
largest_JJ
in_PIN
the_DT
industry_NN
My_FPP1
son_NN
Mario_NN
was_VBD [BEMA]
14_CD
weeks_NN
old_JJ
when_RB
he_TPP3
received_VBD
his_TPP3
first_JJ
dose_NN
of_PIN
Rotarix_NN
._.
I_FPP1
am_VPRT [BEMA]
happy_PRED
I_FPP1
was_VBD [BEMA]
able_PRED
to_TO
give_VB
the_DT
vaccine_NN
195_CD
projects_NN
to_PIN
Mario_NN
and_CC
to_TO
protect_VB
him_TPP3
against_PIN
rotavirus_NN
diarrhoea_NN
in_PIN
development_NOMZ
,_,
of_PIN
which_WDT [PIRE]
140_CD
are_VPRT [BEMA]
in_PIN
the_DT
clinic_NN
Yolanda_NN
Cervantes_NN
and_PHC
Mario_NN
,_,
now_DPAR
six_CD
months_NN
old_JJ
Nearly_DWNT
80_CD
%_NN
increase_NN
in_PIN
New_NN
Chemical_NN
Entities_NOMZ
in_PIN
the_DT
pipeline_NN
since_OSUB
the_DT
merger_NN
GSKs_NN
pipeline_NN
shows_VPRT [PRIV]
considerable_JJ
strength_NN
._.
candidate_NN
against_PIN
cervical_JJ
cancer_NN
,_,
which_WDT [SERE]
type_NN
2_CD
diabetes_NN
,_,
Entereg_NN
for_PIN
post-operative_JJ
At_PIN
the_DT
end_NN
of_PIN
February_NN
2005_CD
,_,
there_EX
were_VBD
140_CD
turned_VBD
out_PIN
to_TO
be_VB [BEMA]
even_RB
better_PRED
than_PIN
we_FPP1
had_VBD
bowel_NN
problems_NN
and_PHC
Requip_NN
for_PIN
restless_JJ
legs_NN
projects_NN
in_PIN
clinical_JJ
development_NOMZ
,_,
including_VBG
hoped_VBN [PRIV]
for_PIN [STPR]
._.
Cervarix_NN
showed_VBD [PRIV]
a_DT
100_CD
%_NN
efcacy_NN
in_PIN
syndrome_NN
._.
88_CD
New_NN
Chemical_NN
Entities_NOMZ
NCEs_NN
,_,
32_CD
Product_NN
Phase_NN
II_NN
trials_NN
against_PIN
the_DT
most_EMPH
common_JJ
strains_NN
Line_NN
Extensions_NN
PLEs_NN
and_CC
20_CD
vaccines_NN
._.
of_PIN
the_DT
human_JJ
papilloma_NN
virus_NN
HPV_NN
,_,
which_WDT [SERE]
Meeting_VBG
unmet_JJ
medical_JJ
needs_NN
cause_VPRT
more_EMPH
than_PIN
70_CD
%_NN
of_PIN
cervical_JJ
cancers_NN
._.
GSK_NN
is_VPRT
making_VBG
significant_JJ
progress_NN
with_PIN
Since_OSUB
the_DT
merger_NN
,_,
the_DT
number_NN
of_PIN
NCEs_NN
in_PIN
Major_JJ
resources_NN
are_VPRT
being_VBG [PASS]
allocated_VBN
to_PIN
this_DEMO
potential_JJ
new_JJ
medicines_NN
to_TO
treat_VB
depression_NN
,_,
clinical_JJ
development_NOMZ
has_VPRT [PEAS]
increased_VBN
by_PIN
nearly_DWNT
project_NN
in_PIN
2005_CD
in_PIN
order_NN
to_TO
complete_VB
Phase_NN
III_NN
schizophrenia_NN
,_,
multiple_JJ
sclerosis_NN
,_,
Alzheimer_NN
's_POS
80_CD
%_NN
and_CC
our_FPP1
pipeline_NN
has_VPRT [PEAS]
matured_VBN
._.
In_PIN
2001_CD
,_,
trials_NN
and_CC
to_TO
apply_VB
for_PIN
a_DT
licence_NN
in_PIN
early_TIME
2006_CD
._.
disease_NN
and_PHC
migraine_NN
._.
more_EMPH
than_PIN
half_PDT
our_FPP1
NCEs_NN
were_VBD [BEMA]
in_PIN
Phase_NN
I_FPP1
:_:
by_PIN
the_DT
end_NN
of_PIN
February_NN
2005_CD
,_,
almost_DWNT
two-thirds_NN
New_JJ
product_NN
launches_NN
in_PIN
2005_CD
In_PIN
2004_CD
,_,
we_FPP1
announced_VBD [PUBV]
the_DT
establishment_NOMZ
of_PIN
a_DT
of_PIN
our_FPP1
NCEs_NN
were_VBD [BEMA]
in_PIN
Phases_NN
II_NN
and_PHC
III_NN
._.
GSK_NN
plans_VPRT
to_TO
launch_VB
six_CD
new_JJ
products_NN
in_PIN
2005_CD
._.
pre-clinical_JJ
research_NN
facility_NOMZ
in_PIN
Singapore_NN
,_,
which_WDT [SERE]
Two_CD
of_PIN
these_DEMP
,_,
Rotarix_NN
and_PHC
Vesicare_NN
,_,
have_VPRT
will_PRMD
employ_VB
a_DT
team_NN
of_PIN
30_CD
to_PIN
35_CD
scientists_NN
._.
This_DEMO
We_FPP1
expect_VPRT [PRIV]
to_TO
see_VB [PRIV]
a_DT
significant_JJ
increase_NN
in_PIN
the_DT
already_RB
been_VBN [PASS]
launched_VBN
._.
will_PRMD
focus_VB
on_PIN
new_JJ
therapies_NN
to_TO
treat_VB
neuronumber_NN
of_PIN
major_JJ
new_JJ
compounds_NN
entering_VBG [WZPRES]
degenerative_JJ
diseases_NN
such_JJ
as_IN
Alzheimers_NN
Phase_NN
III_NN
trials_NN
in_PIN
the_DT
next_JJ
three_CD
years_NN
._.
Rotarix_NN
,_,
our_FPP1
two-dose_JJ
oral_JJ
vaccine_NN
against_PIN
disease_NN
,_,
Parkinsons_NN
disease_NN
and_PHC
schizophrenia_NN
._.
rotavirus_NN
,_,
which_WDT [SERE]
causes_VPRT
severe_JJ
diarrhoea_NN
and_CC
New_JJ
product_NN
extensions_NN
in_PIN
2004_CD
vomiting_VBG
in_PIN
infants_NN
,_,
was_VBD [PASS]
launched_VBN
in_PIN
Mexico_NN
Diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
In_PIN
2004_CD
,_,
PLEs_NN
new_JJ
indications_NOMZ
and_PHC
dosage_NN
in_PIN
January_NN
2005_CD
._.
This_DEMO
disease_NN
kills_VPRT
more_EMPH
than_PIN
GSK_NN
is_VPRT [BEMA]
the_DT
only_DWNT
company_NN
that_DEMP
is_VPRT
developing_VBG
forms_NN
for_PIN
existing_VBG
products_NN
continued_VBN [WZPAST]
to_PIN
half_PDT
a_DT
million_CD
children_NN
each_QUAN
year_NN
or_CC
one_CD
child_NN
medicines_NN
and_PHC
vaccines_NN
to_TO
treat_VB
all_QUAN
three_CD
of_PIN
contribute_VPRT
to_PIN
turnover_NN
and_CC
mitigate_VB
every_QUAN
minute_NN
,_,
mainly_RB
in_PIN
developing_VBG
countries_NN
._.
the_DT
World_NN
Health_NN
Organizations_NOMZ
top_JJ
priority_NOMZ
competition_NOMZ
from_PIN
generic_JJ
medicines_NN
._.
New_NN
With_PIN
Rotarix_NN
,_,
GSK_NN
pioneered_VBD
its_PIT
South_NN
First_NN
diseases_NN
:_:
malaria_NN
,_,
tuberculosis_NN
and_PHC
HIV_NN
AIDS_NN
._.
indications_NOMZ
for_PIN
Seretide_NN
Advair_NN
made_VBD
this_DEMO
launch_NN
strategy_NN
,_,
which_WDT [SERE]
focuses_VPRT
first_RB
on_PIN
important_JJ
asthma_NN
medicine_NN
available_JJ
for_PIN
use_NN
countries_NN
where_RB
there_EX
is_VPRT [SPAU]
most_EMPH
need_VB
._.
The_DT
In_PIN
2004_CD
,_,
GSKs_NN
pyridone_NN
project_NN
was_VBD [BYPA]
awarded_VBN
by_PIN
children_NN
aged_VBN
4_CD
to_PIN
11_CD
years_NN
._.
Kivexa_NN
Mexican_NN
government_NOMZ
will_PRMD
pay_VB
for_PIN
a_DT
the_DT
Medicines_NN
for_PIN
Malaria_NN
Venture_NN
Project_NN
of_PIN
Epizicom_NN
,_,
a_DT
single_JJ
tablet_NN
combining_VBG [WZPRES]
two_CD
vaccination_NOMZ
campaign_NN
in_PIN
order_NN
to_TO
eliminate_VB
the_DT
Year_NN
._.
This_DEMO
potential_JJ
medicine_NN
has_VPRT
since_OSUB
successful_JJ
HIV_NN
treatments_NOMZ
,_,
was_VBD [PASS]
introduced_VBN
,_,
the_DT
infection_NOMZ
._.
simplifying_VBG [PRESP]
the_DT
medication_NOMZ
regime_NN
for_PIN
patients_NN
._.
Vesicare_NN
,_,
a_DT
treatment_NOMZ
for_PIN
overactive_JJ
bladder_NN
,_,
GSK_NN
is_VPRT [BEMA]
the_DT
industry_NN
leader_NN
in_PIN
HIV_NN
R&D_NN
and_CC
,_,
was_VBD [PASS]
launched_VBN
in_PIN
the_DT
US_FPP1
in_PIN
January_NN
2005_CD
._.
for_PIN
many_QUAN
years_NN
,_,
our_FPP1
products_NN
have_VPRT [PEAS]
formed_VBN
Best_JJ
news_NN
in_PIN
2004_CD
The_DT
four_CD
other_JJ
new_JJ
products_NN
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
the_DT
core_NN
of_PIN
HIV_NN
AIDS_NN
treatment_NOMZ
guidelines_NN
The_DT
best_JJ
news_NN
in_PIN
2004_CD
was_VBD [BEMA]
the_DT
results_NN
from_PIN
launched_VBN
in_PIN
2005_CD
are_VPRT
:_:
Boniva_NN
a_DT
once-monthly_JJ
around_PLACE
the_DT
world_NN
._.
our_FPP1
clinical_JJ
program_NN
for_PIN
Cervarix_NN
,_,
a_DT
vaccine_NN
treatment_NOMZ
for_PIN
osteoporosis_NN
,_,
Avandaryl_NN
for_PIN
8_CD
8_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
One_CD
of_PIN
the_DT
largest_JJ
pipelines_NN
in_PIN
the_DT
industry_NN
Number_NN
of_PIN
projects_NN
in_PIN
clinical_JJ
trials_NN
in_PIN
each_QUAN
therapeutic_JJ
area_NN
end_NN
February_NN
2005_CD
Clinical_NN
Trial_NN
Register_NN
During_PIN
2004_CD
,_,
GSK_NN
established_VBD [PRIV]
a_DT
website_JJ
called_VBN
the_DT
GSK_NN
Clinical_NN
Phase_NN
I_FPP1
Phase_NN
II_NN
Phase_NN
III_NN
Total_NN
Trial_NN
Register_NN
to_TO
publish_VB
clinical_JJ
Cardiovascular_NN
6_CD
8_CD
8_CD
22_CD
trial_NN
data_NN
relating_VBG [WZPRES]
to_TO
marketed_VBN
&_CC
Metabolic_NN
medicines_NN
._.
Although_CONC
prescribing_VBG
Infectious_JJ
diseases_NN
2_CD
5_CD
4_CD
11_CD
information_NOMZ
approved_VBN [WZPAST]
by_PIN
regulatory_JJ
authorities_NOMZ
will_PRMD
Musculoskeletal_NN
,_,
9_CD
6_CD
8_CD
23_CD
Inammation_NOMZ
,_,
GI_NN
&_CC
Urology_NN
continue_VPRT
to_TO
guide_VB
appropriate_JJ
use_NN
of_PIN
GSK_NN
medicines_NN
,_,
the_DT
13_CD
10_CD
8_CD
Neurosciences_NN
31_CD
Register_NN
serves_VPRT
as_IN
another_DT
resource_NN
for_PIN
researchers_NN
,_,
medical_JJ
Oncology_NN
2_CD
7_CD
5_CD
14_CD
professionals_NN
and_CC
the_DT
public_NN
._.
Along_IN
with_PIN
publications_NOMZ
in_PIN
Respiratory_JJ
3_CD
10_CD
6_CD
19_CD
medical_JJ
journals_NN
and_PHC
presentations_NOMZ
at_PIN
medical_JJ
Vaccines_NN
6_CD
6_CD
8_CD
20_CD
congresses_NN
,_,
the_DT
Register_NN
demonstrates_VPRT [PRIV]
GSKs_NN
Total_NN
41_CD
52_CD
47_CD
140_CD
commitment_NOMZ
to_TO
ensuring_VBG [SUAV] [PRIV]
the_DT
clear_JJ
communication_NOMZ
of_PIN
data_NN
Phase_NN
I_FPP1
Evaluation_NOMZ
of_PIN
clinical_JJ
pharmacology_NN
,_,
usually_RB
conducted_VBN
in_PIN
volunteers_NN
._.
Phase_NN
II_NN
Determination_NOMZ
of_PIN
dose_NN
and_CC
initial_JJ
evaluation_NOMZ
of_PIN
efcacy_NN
,_,
conducted_VBN [PASTP]
in_PIN
a_DT
small_JJ
number_NN
of_PIN
patients_NN
._.
Phase_NN
III_NN
Large_JJ
comparative_JJ
studies_NN
compound_VPRT
versus_PIN
placebo_NN
and_CC
or_CC
established_VBN [PRIV]
treatment_NOMZ
in_PIN
patients_NN
to_TO
determine_VB [SUAV] [PRIV]
clinical_JJ
benefit_NN
and_PHC
safety_NN
._.
The_DT
number_NN
of_PIN
New_NN
Chemical_NN
Entities_NOMZ
NCEs_NN
in_PIN
the_DT
pipeline_NN
has_VPRT [PEAS]
increased_VBN
by_PIN
nearly_DWNT
80_CD
%_NN
since_OSUB
2001_CD
Oct_NN
2001_CD
Dec_NN
2003_CD
Feb_NN
2005_CD
Phase_NN
III_NN
8_CD
Phase_NN
III_NN
12_CD
Phase_NN
III_NN
11_CD
Phase_NN
II_NN
15_CD
Phase_NN
II_NN
32_CD
Phase_NN
II_NN
43_CD
Cervarix_NN
:_:
Our_FPP1
vaccine_NN
candidate_NN
against_PIN
cervical_JJ
cancer_NN
showed_VBD [PRIV]
100_CD
%_NN
efcacy_NN
in_PIN
Phase_NN
Phase_NN
I_FPP1
27_CD
Phase_NN
I_FPP1
38_CD
Phase_NN
I_FPP1
34_CD
II_NN
trials_NN
against_PIN
HPV_NN
16_CD
and_CC
18_CD
._.
Cervical_JJ
cancer_NN
is_VPRT [BEMA]
the_DT
second_JJ
most_EMPH
common_JJ
cancer_NN
in_PIN
women_NN
50_CD
NCEs_NN
82_CD
NCEs_NN
88_CD
NCEs_NN
510,000_CD
are_VPRT [PASS]
diagnosed_VBN
and_CC
288,000_CD
die_NN
Developing_VBG [WZPRES]
new_JJ
from_PIN
the_DT
disease_NN
each_QUAN
year_NN
._.
GSK_NN
believes_VPRT [PRIV]
that_THVC
Cervarix_NN
will_PRMD
save_VB
many_QUAN
lives_NN
and_CC
has_VPRT
the_DT
medicines_NN
potential_JJ
to_TO
be_VB [BEMA]
our_FPP1
best-selling_JJ
vaccine_NN
yet_RB
._.
Planned_NN
GSK_NN
pipeline_NN
lings_NN
,_,
2005-07_JJ
New_NN
Chemical_NN
Entities_NOMZ
Product_NN
Line_NN
Extensions_NN
115_CD
Allermist_NN
Arixtra_NN
Lamictal_NN
XR_NN
TPO_NN
antagonist_NN
-_:
low_JJ
steroid_JJ
rhinitis_NN
acute_JJ
coronary_JJ
syndrome_NN
once_TIME
a_DT
day_NN
platelets_VPRT
Cervarix_NN
140_CD
Avandamet_NN
XR_NN
Requip_NN
CR_NN
HPV_NN
vac_NN
cervical_JJ
cancer_NN
CCR5_CD
antagonist_NN
-_:
HIV_NN
once_TIME
a_DT
day_NN
once_TIME
a_DT
day_NN
Lapatinib_NN
:_:
GSKs_NN
new_JJ
anti-cancer_JJ
compound_NN
Rotarix_NN
Radafaxine_NN
Coreg_NN
CR_NN
Trexima_NN
is_VPRT [PASS]
designed_VBN
to_TO
destroy_VB
cancer_NN
cells_NN
while_OSUB
vaccine_NN
-_:
rotavirus_NN
NDRI_NN
-_:
depression_NN
once_TIME
a_DT
day_NN
migraine_NN
causing_VBG [WZPRES]
less_JJ
toxic_JJ
side-effects_NN
than_PIN
conventional_JJ
chemotherapy_NN
._.
Having_VBG [PEAS]
shown_VBN [PRIV]
Lapatinib_NN
381_CD
Avandia_NN
Wellbutrin_NN
XL_NN
dual_JJ
kinase_NN
inhibitor_NN
-_:
promise_NN
in_PIN
women_NN
with_PIN
advanced_JJ
breast_NN
COX-2_NN
inhibitor_NN
-_:
pain_NN
Alzheimers_NN
disease_NN
EU_NN
ling_NN
cancer_NN
cancer_NN
who_WP [WHSUB]
had_VBD [PEAS]
not_XX0
responded_VBN
to_TO
existing_VBG
381_CD
ling_JJ
date_NN
to_TO
be_VB [PASS]
confirmed_VBN [PUBV]
therapy_NN
,_,
it_PIT
is_VPRT
being_VBG [PASS]
evaluated_VBN
in_PIN
an_DT
expanded_VBN
clinical_JJ
program_NN
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
9_CD
9_CD
9_CD
Sharpening_VBG
our_FPP1
operations_NOMZ
Commercial_JJ
and_PHC
operational_JJ
excellence_NN
initiatives_NN
help_VPRT
GSK_NN
to_TO [SPIN]
continually_RB
improve_VB
performance_NN
Were_VBD
establishing_VBG [PRIV]
global_JJ
standards_NN
for_PIN
the_DT
quality_NOMZ
of_PIN
sales_NN
calls_NN
and_PHC
expectations_NOMZ
for_PIN
our_FPP1
frontline_NN
sales_NN
managers_NN
6_CD
billion_CD
David_NN
Pernock_NN
,_,
Senior_NN
Vice_NN
President_NN
,_,
US_FPP1
Pharmaceuticals_NN
profit_NN
before_IN
tax_NN
grew_VBD
2_CD
%_NN
in_PIN
2004_CD
More_EMPH
than_PIN
2_CD
billion_CD
total_JJ
cost_NN
savings_GER
since_OSUB
the_DT
merger_NN
in_PIN
2001_CD
GSKs_NN
business_NOMZ
comprises_VPRT
Pharmaceuticals_NN
Product_NN
life_NN
cycle_NN
management_NOMZ
Summit_NN
was_VBD [BYPA]
attended_VBN
by_PIN
more_EMPH
than_PIN
400_CD
prescription_NOMZ
medicines_NN
and_PHC
vaccines_NN
and_CC
The_DT
Product_NN
Line_NN
Extension_NN
PLE_NN
approach_NN
people_NN
including_VBG [WZPRES]
patient_JJ
group_NN
Consumer_NN
Healthcare_NN
over-the-counter_JJ
allows_VPRT [SUAV]
GSK_NN
to_TO
create_VB
what_WP
is_VPRT [BEMA]
effectively_RB
an_DT
representatives_NN
from_PIN
23_CD
countries_NN
._.
medicines_NN
,_,
oral_JJ
care_NN
and_CC
nutritional_JJ
entirely_AMP
new_JJ
drug_NN
within_PIN
the_DT
life_NN
cycle_NN
of_PIN
an_DT
Consumer_NN
Healthcare_NN
healthcare_NN
,_,
supported_VBN [PASTP]
by_PIN
Global_JJ
existing_VBG
drug_NN
._.
This_DEMP
offers_VPRT
the_DT
patient_JJ
significant_JJ
In_PIN
2004_CD
,_,
Consumer_NN
Healthcare_NN
developed_VBD
a_DT
Manufacturing_GER
&_CC
Supply_NN
GMS_NN
._.
clinical_JJ
advantages_NN
,_,
such_JJ
as_IN
increased_VBN
new_JJ
business_NOMZ
strategy_NN
and_PHC
operating_GER
model_NN
compliance_NN
and_PHC
safety_NN
,_,
increased_VBD
efcacy_NN
The_DT
Pharmaceutical_NN
and_PHC
Consumer_NN
Healthcare_NN
designed_VBN
to_TO
deliver_VB
faster_JJ
sales_NN
growth_NN
._.
It_PIT
will_PRMD
and_CC
or_CC
more_EMPH
convenient_JJ
dosage_NN
forms_NN
._.
businesses_NOMZ
aim_VPRT
to_TO
maximize_VB
their_TPP3
commercial_JJ
achieve_VB
this_DEMO
through_PIN
a_DT
vigorous_JJ
focus_NN
on_PIN
potential_JJ
by_PIN
introducing_VBG
innovative_JJ
products_NN
to_PIN
In_PIN
recent_JJ
years_NN
,_,
PLEs_NN
such_JJ
as_IN
Wellbutrin_NN
XL_NN
and_PHC
product_NN
innovation_NOMZ
that_DEMP
is_VPRT [SPAU] [PASS]
tightly_RB
aligned_VBN
to_TO
as_RB
many_QUAN
markets_NN
as_IN
possible_JJ
,_,
accelerating_VBG [PRESP]
the_DT
Paxil_NN
CR_NN
have_VPRT [PEAS]
helped_VBN
GSK_NN
mitigate_VB
the_DT
impact_NN
consumer_NN
needs_NN
._.
The_DT
new_JJ
model_NN
more_EMPH
process_NN
of_PIN
bringing_VBG
new_JJ
products_NN
to_PIN
market_NN
,_,
of_PIN
generic_JJ
medicines_NN
and_CC
have_VPRT [PEAS]
contributed_VBN
to_TO
effectively_RB
links_NN
together_RB
R&D_NN
,_,
marketing_GER
and_CC
increasing_VBG
brand_NN
recognition_NOMZ
and_CC
ensuring_VBG [SUAV] [PRIV]
that_THVC
pipeline_NN
momentum_NN
._.
In_PIN
2004_CD
,_,
GSK_NN
lost_VBD
sales_NN
commercial_JJ
operating_VBG
units_NN
,_,
organised_VBN [PASTP]
to_PIN
patients_NN
have_VPRT
access_NN
to_PIN
new_JJ
medicines_NN
._.
of_PIN
1.5_CD
billion_CD
to_PIN
generic_JJ
medicines_NN
,_,
but_CC
this_DEMO
support_NN
three_CD
categories_NN
of_PIN
brands_NN
:_:
was_VBD [SPAU] [BYPA]
partially_DWNT
offset_VBN
by_PIN
sales_NN
of_PIN
PLEs_NN
worth_JJ
Global_NN
brands_NN
:_:
significant_JJ
brands_NN
marketed_VBN
Worldwide_NN
Sales_NN
Force_NN
Excellence_NN
0.6_CD
billion_CD
._.
In_PIN
2005_CD
,_,
GSK_NN
has_VPRT
plans_NN
to_TO
le_FW
four_CD
in_PIN
multiple_JJ
markets_NN
GSKs_NN
sales_NN
force_NN
ranks_VPRT
high_JJ
in_PIN
industry_NN
surveys_NN
new_JJ
PLEs_NN
:_:
Avandamet_NN
XR_NN
,_,
Coreg_NN
CR_NN
,_,
Requip_NN
Lead_JJ
market_NN
brands_NN
:_:
significant_JJ
brands_NN
of_PIN
healthcare_NN
professionals_NN
see_VPRT [PRIV]
opposite_PIN [STPR]
._.
marketed_VBN [PASTP]
in_PIN
a_DT
few_QUAN
markets_NN
The_DT
Worldwide_NN
Sales_NN
Force_NN
Excellence_NN
initiative_NN
Enterprise_NN
brands_NN
:_:
valuable_JJ
local_JJ
brands_NN
._.
WSFE_NN
aims_VPRT
to_TO
improve_VB
customer_NN
satisfaction_NOMZ
Patient_NN
Advocacy_NN
:_:
supporting_VBG [PRESP]
by_PIN
identifying_VBG
and_PHC
sharing_VBG
best_JJ
practice_NN
within_PIN
patient_JJ
needs_NN
Global_JJ
Manufacturing_GER
&_CC
Supply_NN
the_DT
sales_NN
force_NN
,_,
and_ANDC
by_PIN
strengthening_VBG
sales_NN
GSKs_NN
Patient_NN
Advocacy_NN
initiative_NN
is_VPRT [PASS]
designed_VBN
GMS_NN
focuses_VPRT
on_PIN
the_DT
secure_JJ
supply_NN
of_PIN
highrepresentatives_NN
product_NN
knowledge_NN
._.
More_EMPH
to_TO
bring_VB
GSK_NN
closer_JJ
to_PIN
patients_NN
and_PHC
advocacy_NN
quality_NOMZ
products_NN
to_TO
meet_VB
patient_JJ
expectations_NOMZ
._.
than_PIN
25,000_CD
sales_NN
representatives_NN
have_VPRT [PEAS]
been_VBN
groups_NN
,_,
with_PIN
the_DT
goal_NN
of_PIN
improving_VBG
GSKs_NN
It_PIT
continues_VPRT
to_TO
deliver_VB
significant_JJ
and_CC
trained_VBN
through_PIN
this_DEMO
initiative_NN
._.
understanding_GER
of_PIN
patient_JJ
needs_NN
and_CC
sustainable_JJ
efficiency_NN
improvements_NOMZ
across_PLACE
its_PIT
enhancing_VBG
its_PIT
reputation_NOMZ
as_IN
a_DT
patient-centred_JJ
network_NN
of_PIN
more_EMPH
than_PIN
80_CD
factories_NN
._.
For_PIN
The_DT
time_NN
available_JJ
to_PIN
physicians_NN
for_PIN
learning_VBG [PRIV]
company_NN
._.
After_IN
all_QUAN
,_,
there_EX
are_VPRT
no_RB
better_RB
example_NN
,_,
the_DT
global_JJ
program_NN
that_TSUB
focuses_VPRT
about_IN
new_JJ
medicines_NN
and_CC
clinical_JJ
studies_NN
is_VPRT
spokespeople_NN
than_PIN
patients_NN
whose_WPS [WHOBJ]
lives_NN
on_PIN
principles_NN
for_PIN
lean_JJ
manufacturing_GER
and_CC
precious_JJ
._.
GSKs_NN
When_RB
,_,
Why_RB
,_,
How_RB
approach_NN
are_VPRT [BYPA]
affected_VBN
by_PIN
GSK_NN
products_NN
._.
technology_NN
has_VPRT [PEAS]
resulted_VBN
in_PIN
better_JJ
process_NN
see_VPRT [PRIV]
opposite_PIN
enables_VPRT
sales_NN
representatives_NN
to_PIN
yields_NN
,_,
improved_VBN
quality_NOMZ
and_CC
simpler_JJ
business_NOMZ
deliver_VPRT
patient-specic_JJ
treatment_NOMZ
options_NOMZ
more_EMPH
This_DEMO
initiative_NN
originated_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
in_PIN
2002_CD
but_CC
processes_VPRT
._.
Global_JJ
procurement_NOMZ
expenditure_NN
efficiently_RB
and_PHC
effectively_RB
._.
has_VPRT
since_OSUB
been_VBN [PASS]
incorporated_VBN
into_PIN
GSKs_NN
has_VPRT [PEAS]
reduced_VBN
due_JJ
to_PIN
a_DT
continued_VBN
focus_NN
on_PIN
lowstrategic_JJ
plans_NN
throughout_PIN
the_DT
world_NN
._.
In_PIN
2004_CD
,_,
cost_NN
supply_NN
and_PHC
e-procurement_NOMZ
techniques_NN
,_,
the_DT
annual_JJ
Patient_NN
Advocacy_NN
Leadership_NN
such_JJ
as_IN
electronic_JJ
auctions_NOMZ
._.
10_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV] [THATD]
Harnessing_GER
natures_VPRT
power_NN
The_DT
turbines_NN
have_VPRT [PEAS]
contributed_VBN
to_PIN
the_DT
sites_NN
overall_JJ
25_CD
%_NN
reduction_NOMZ
in_PIN
its_PIT
spend_VPRT
on_PIN
energy_NN
and_PHC
utilities_NOMZ
Paul_NN
Londesborough_NN
,_,
Site_NN
Director_NN
,_,
Barnard_NN
Castle_NN
,_,
pictured_VBD
below_PLACE
GSKs_NN
Environment_NOMZ
,_,
Health_NN
&_CC
Safety_NN
Excellence_NN
initiative_NN
includes_VPRT
the_DT
long-term_JJ
goal_NN
to_TO
drive_VB
down_RP
the_DT
environmental_JJ
impact_NN
of_PIN
manufacturing_GER
and_CC
to_TO
switch_VB
to_PIN
renewable_JJ
energy_NN
sources_NN
._.
At_PIN
Barnard_NN
Castle_NN
in_PIN
the_DT
UK_NN
,_,
two_CD
wind_NN
turbines_NN
have_VPRT [PEAS]
been_VBN [PASS]
installed_VBN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
capable_PRED
of_PIN
providing_VBG
10_CD
%_NN
of_PIN
the_DT
sites_NN
electricity_NOMZ
when_RB
running_VBG
at_PIN
full_JJ
speed_NN
._.
Surveys_NN
of_PIN
US_FPP1
physicians_NN
have_VPRT [SPAU] [PEAS]
recently_TIME
rated_VBN
GSK_NN
sales_NN
representatives_NN
number_NN
one_CD
in_PIN
four_CD
physician_NN
specialities_NOMZ
:_:
Sites_NN
reduced_VBN [WZPAST]
by_PIN
allergists_NN
,_,
immunologists_NN
,_,
paediatricians_NN
No._NN
._.
Sales_NN
force_VPRT
ranking_JJ
29_CD
%_NN
Since_OSUB
the_DT
merger_NN
,_,
GSK_NN
has_VPRT [PEAS]
reduced_VBN
the_DT
number_NN
of_PIN
manufacturing_VBG
sites_NN
from_PIN
115_CD
to_PIN
82_CD
through_PIN
rationalisation_NOMZ
and_CC
operational_JJ
excellence_NN
initiatives_NN
._.
When_RB
,_,
Why_RB
,_,
How_RB
GSK_NN
has_VPRT [PEAS]
introduced_VBN
a_DT
global_JJ
sales_NN
call_VPRT
model_NN
that_TSUB
focuses_VPRT
on_PIN
When_RB
a_DT
GSK_NN
medicine_NN
is_VPRT [BEMA]
appropriate_PRED
,_,
Why_RB
a_DT
physician_NN
should_NEMD
consider_VB [PRIV]
it_PIT
for_PIN
a_DT
patient_NN
and_CC
Delivering_VBG
How_RB
to_TO
administer_VB
it_PIT
appropriately_RB
._.
By_PIN
the_DT
end_NN
of_PIN
2004_CD
,_,
all_QUAN
sales_NN
representatives_NN
in_PIN
GSKs_NN
key_JJ
markets_NN
commercial_JJ
and_CC
had_VBD [PEAS]
been_VBN [PASS]
trained_VBN
in_PIN
this_DEMO
approach_NN
._.
operational_JJ
excellence_NN
300m_CD
GMSs_NN
Operational_NN
Excellence_NN
Programme_NN
has_VPRT [PEAS]
realized_VBN [PRIV]
annualised_JJ
cost_NN
savings_GER
of_PIN
300_CD
million_CD
through_PIN
operational_JJ
efficiencies_NN
with_PIN
its_PIT
network_NN
of_PIN
manufacturing_VBG
sites_NN
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
11_CD
Contributing_VBG
to_PIN
society_NN
Our_FPP1
success_NN
as_IN
a_DT
company_NN
and_CC
the_DT
nature_NN
of_PIN
our_FPP1
products_NN
enable_VPRT
us_FPP1
to_TO
invest_VB
in_PIN
under-served_JJ
communities_NOMZ
around_PLACE
the_DT
world_NN
We_FPP1
would_PRMD
be_VB [BEMA]
able_PRED
to_TO
do_VB
only_DWNT
a_DT
tiny_JJ
fraction_NOMZ
of_PIN
what_WP
we_FPP1
do_VPRT [PROD]
without_PIN
reliable_JJ
donations_NOMZ
of_PIN
medicines_NN
from_PIN
328_CD
million_CD
companies_NN
like_IN
GSK_NN
GSKs_NN
global_JJ
community_NOMZ
investment_NOMZ
in_PIN
2004_CD
Curtis_NN
R._NN
Welling_GER
,_,
President_NN
and_PHC
CEO_NN
,_,
AmeriCares_NN
More_EMPH
than_PIN
100_CD
countries_NN
benefited_VBD
from_PIN
humanitarian_JJ
product_NN
donations_NOMZ
from_PIN
GSK_NN
GSKs_NN
biggest_JJ
contribution_NOMZ
to_PIN
society_NN
is_VPRT [BEMA]
the_DT
In_PIN
2004_CD
,_,
the_DT
sixth_JJ
year_NN
of_PIN
the_DT
program_NN
,_,
GSKs_NN
work_NN
on_PIN
behavioural_JJ
change_NN
continues_VPRT
discovery_NN
and_PHC
development_NOMZ
of_PIN
medicines_NN
that_TOBJ
67_CD
million_CD
albendazole_NN
treatments_NOMZ
,_,
worth_NN
through_PIN
its_PIT
award-winning_JJ
Personal_JJ
Hygiene_NN
help_NN
people_NN
to_TO
do_VB
more_EMPH
,_,
feel_VB [PRIV]
better_JJ
and_CC
live_VPRT
7_CD
million_CD
at_PIN
wholesale_JJ
cost_NN
,_,
were_VBD [PASS]
donated_VBN
and_CC
Sanitation_NOMZ
Education_NOMZ
PHASE_NN
program_NN
longer_RB
._.
Our_FPP1
success_NN
as_IN
a_DT
company_NN
and_CC
the_DT
to_PIN
34_CD
countries_NN
._.
Since_OSUB
the_DT
inception_NOMZ
of_PIN
the_DT
for_PIN
children_NN
in_PIN
five_CD
African_JJ
and_PHC
Latin_JJ
American_JJ
nature_NN
of_PIN
our_FPP1
products_NN
also_RB
enable_VPRT
us_FPP1
to_PIN
global_JJ
elimination_NOMZ
program_NN
,_,
GSK_NN
has_VPRT
countries_NN
._.
invest_VB
in_PIN
under-served_JJ
communities_NOMZ
around_PLACE
donated_VBN
a_DT
total_NN
of_PIN
307_CD
million_CD
albendazole_IN
the_DT
world_NN
._.
treatments_NOMZ
,_,
reaching_VBG
more_EMPH
than_PIN
85_CD
million_CD
Humanitarian_JJ
aid_NN
people_NN
living_VBG [WZPRES]
in_PIN
endemic_JJ
areas_NN
._.
During_PIN
2004_CD
,_,
GSK_NN
donated_VBD
50_CD
million_CD
worth_JJ
GSK_NN
contributes_VPRT
to_PIN
society_NN
through_PIN
active_JJ
of_PIN
products_NN
mainly_RB
life-saving_JJ
antibiotics_NN
to_PIN
engagement_NOMZ
with_PIN
numerous_JJ
external_JJ
Support_NN
for_PIN
communities_NOMZ
affected_VBN [WZPAST]
by_PIN
more_EMPH
than_PIN
100_CD
impoverished_JJ
or_CC
disaster-struck_JJ
stakeholders_NN
,_,
including_VBG [PRESP]
the_DT
World_NN
Health_NN
HIV_NN
AIDS_NN
countries_NN
through_PIN
non-profit_JJ
partners_NN
such_JJ
as_IN
Organization_NOMZ
and_CC
not-for-profit_JJ
organizations_NOMZ
._.
2004_CD
marked_VBD
the_DT
12th_JJ
year_NN
of_PIN
Positive_NN
Action_NOMZ
,_,
AmeriCares_NN
and_PHC
Project_NN
HOPE_NN
._.
GSKs_NN
We_FPP1
fund_VPRT
community-led_JJ
initiatives_NN
and_CC
donate_VPRT
GSKs_NN
pioneering_JJ
global_JJ
program_NN
that_TOBJ
donations_NOMZ
were_VBD [BEMA]
critical_PRED
to_PIN
the_DT
medical_JJ
needs_NN
of_PIN
essential_JJ
products_NN
to_TO
support_VB
humanitarian_JJ
partners_NN
with_PIN
grass-roots_JJ
,_,
community-based_JJ
communities_NOMZ
affected_VBN [WZPAST]
by_PIN
the_DT
oods_NN
in_PIN
efforts_NN
and_CC
community-based_JJ
healthcare_NN
in_PIN
organizations_NOMZ
in_PIN
35_CD
countries_NN
._.
Positive_JJ
Action_NOMZ
Bangladesh_NN
,_,
hurricanes_NN
in_PIN
the_DT
US_FPP1
and_CC
the_DT
more_EMPH
than_PIN
100_CD
countries_NN
._.
addresses_NN
the_DT
stigma_NN
of_PIN
HIV_NN
AIDS_NN
through_PIN
Caribbean_NN
,_,
typhoons_NN
in_PIN
the_DT
Philippines_NN
,_,
the_DT
education_NOMZ
,_,
and_ANDC
supports_VPRT
better_JJ
care_NN
for_PIN
people_NN
conict_VPRT
in_PIN
Sudan_NN
and_CC
the_DT
Asian_JJ
tsunami_NN
._.
GSKs_NN
global_JJ
community_NOMZ
investment_NOMZ
activities_NOMZ
living_VBG [WZPRES]
with_PIN
or_CC
affected_VBN
by_PIN
HIV_NN
AIDS_NN
._.
During_PIN
in_PIN
2004_CD
were_VBD [PASS]
valued_VBN
at_PIN
328_CD
million_CD
or_CC
the_DT
2004_CD
,_,
Positive_NN
Action_NOMZ
established_VBD [PRIV] [THATD]
new_JJ
GSK_NN
pledged_VBD [SUAV]
2_CD
million_CD
to_PIN
the_DT
relief_NN
effort_NN
equivalent_NN
of_PIN
5.4_CD
%_NN
of_PIN
profit_NN
before_IN
tax_NN
._.
Not_XX0
programs_NN
in_PIN
Latin_NN
America_NN
,_,
Asia_NN
,_,
and_ANDC
following_VBG
the_DT
earthquake_NN
and_PHC
tsunami_NN
in_PIN
Asia_NN
,_,
surprisingly_RB
,_,
GSK_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
the_DT
central_JJ
and_PHC
eastern_JJ
Europe_NN
._.
as_RB
well_RB
as_IN
donating_VBG
more_EMPH
than_PIN
3.6_CD
million_CD
largest_JJ
giver_NN
of_PIN
any_QUAN
FTSE_NN
100_CD
company_NN
for_PIN
the_DT
doses_NN
of_PIN
antibiotics_NN
and_CC
600,000_CD
doses_NN
of_PIN
the_DT
past_JJ
three_CD
years_NN
._.
Preventing_VBG
childhood_NN
illnesses_NOMZ
hepatitis_NN
A_NN
vaccine_NN
._.
We_FPP1
will_PRMD
continue_VB
to_TO
offer_VB
Malaria_NN
and_CC
diarrhoea_JJ
cause_NN
the_DT
deaths_NN
of_PIN
assistance_NN
throughout_PIN
the_DT
region_NN
._.
The_DT
elimination_NOMZ
of_PIN
lymphatic_JJ
lariasis_NN
millions_NN
of_PIN
African_JJ
children_NN
each_QUAN
year_NN
,_,
yet_RB
GSKs_NN
agship_NN
community_NOMZ
program_NN
aims_VPRT
to_PIN
these_DEMO
deaths_NN
are_VPRT [BEMA]
preventable_PRED
._.
New_NN
malaria_NN
eliminate_VB
the_DT
disguring_GER
,_,
mosquito-borne_JJ
education_NOMZ
programs_NN
in_PIN
eight_CD
African_JJ
disease_NN
lymphatic_JJ
lariasis_NN
LF_NN
from_PIN
the_DT
world_NN
countries_NN
are_VPRT
teaching_VBG
mothers_NN
about_IN
the_DT
by_PIN
2020_CD
._.
GSK_NN
has_VPRT [PEAS]
committed_VBN
to_TO
providing_VBG
as_IN
importance_NN
of_PIN
early_TIME
diagnosis_NN
in_PIN
children_NN
and_CC
much_QUAN
of_PIN
the_DT
anti-parasitic_JJ
drug_NN
albendazole_NN
as_IN
the_DT
value_NN
of_PIN
using_VBG
insecticide-treated_JJ
bed_NN
nets_NN
required_VBN [SUAV]
to_TO
treat_VB
the_DT
one_CD
billion_CD
adults_NN
and_CC
to_TO
prevent_VB
infection_NOMZ
._.
children_NN
at_PIN
risk_NN
in_PIN
more_EMPH
than_PIN
80_CD
countries_NN
._.
12_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
MORE_EMPH
THAN_PIN
MORE_EMPH
THAN_PIN
MILLION_NN
PEOPLE_NN
COUNTRIES_NN
100_CD
have_VPRT [PEAS]
been_VBN [PASS]
protected_VBN
against_PIN
85_CD
have_VPRT [PEAS]
benefited_VBN
from_PIN
GSKs_NN
LF_NN
with_PIN
donated_VBN
albendazole_JJ
community-based_JJ
support_NN
Making_VBG [WZPRES]
a_DT
difference_NN
across_PLACE
the_DT
world_NN
Tsunami_NN
GSK_NN
pledged_VBD [SUAV]
2_CD
million_CD
as_RB
well_RB
as_IN
donating_VBG
more_EMPH
than_PIN
50_CD
MILLION_NN
3.6_CD
million_CD
doses_NN
of_PIN
antibiotics_NN
and_CC
600,000_CD
doses_NN
of_PIN
the_DT
hepatitis_NN
A_DT
value_NN
of_PIN
vital_JJ
medicines_NN
donated_VBN [WZPAST]
for_PIN
vaccine_NN
humanitarian_JJ
causes_NN
This_DEMO
important_JJ
public-private_JJ
sector_NN
collaboration_NOMZ
established_VBN [PRIV] [WZPAST]
between_PIN
WHO_WP
and_CC
GSK_NN
in_PIN
1997_CD
has_VPRT [PEAS]
benefited_VBN
millions_NN
of_PIN
individuals_NN
in_PIN
developing_VBG
countries_NN
Dr_NN
LEE_NN
Jong-wook_NN
World_NN
Health_NN
Organization_NOMZ
Elimination_NOMZ
of_PIN
lymphatic_JJ
lariasis_NN
:_:
In_PIN
2004_CD
,_,
Egypt_NN
completed_VBD
five_CD
rounds_NN
of_PIN
mass_NN
drug_NN
administration_NOMZ
in_PIN
a_DT
bid_NN
to_TO
eliminate_VB
LF_NN
._.
Preliminary_JJ
results_NN
look_VPRT
impressive_JJ
and_CC
it_PIT
is_VPRT [PASS]
anticipated_VBN [PRIV] [THATD]
that_DEMP
this_DEMO
ancient_JJ
disease_NN
will_PRMD [SPAU]
soon_TIME
be_VB [PASS]
eliminated_VBN
in_PIN
Egypt_NN
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
13_CD
13_CD
Business_NOMZ
operating_GER
review_NN
Strong_JJ
performance_NN
of_PIN
key_JJ
products_NN
absorbs_VPRT
lost_VBN
sales_NN
to_PIN
generics_NN
Total_JJ
pharmaceutical_JJ
turnover_NN
grew_VBD
1_CD
%_NN
in_PIN
2004_CD
,_,
despite_PIN
the_DT
loss_NN
of_PIN
1.5_CD
billion_CD
of_PIN
sales_NN
to_PIN
generic_JJ
forms_NN
of_PIN
Paxil_NN
and_PHC
Wellbutrin_NN
._.
Excluding_VBG
sales_NN
of_PIN
these_DEMO
products_NN
,_,
turnover_NN
grew_VBD
7_CD
%_NN
In_PIN
2004_CD
,_,
12_CD
GSK_NN
products_NN
each_QUAN
had_VBD
sales_NN
of_PIN
over_IN
500million_CD
EPS_NN
75.0_CD
pence_NN
GSK_NN
delivered_VBD
EPS_NN
growth_NN
at_PIN
CER_NN
of_PIN
2_CD
%_NN
,_,
in_PIN
line_NN
with_PIN
guidance_NN
The_DT
strong_JJ
growth_NN
of_PIN
GSKs_NN
epilepsy_NN
and_CC
bi-polar_JJ
Anti-bacterial_JJ
sales_NN
,_,
reecting_VBG
generic_JJ
Pharmaceuticals_NN
disorder_NN
treatment_NOMZ
Lamictal_NN
continued_VBD
,_,
with_PIN
sales_NN
competition_NOMZ
in_PIN
all_QUAN
regions_NN
,_,
declined_VBD
9_CD
%_NN
GSK_NN
continues_VPRT
to_TO
be_VB [BEMA]
the_DT
global_JJ
leader_NN
in_PIN
up_RB
32_CD
%_NN
to_PIN
678_CD
million_CD
._.
Ongoing_JJ
US_FPP1
growth_NN
worldwide_NN
and_CC
24_CD
%_NN
in_PIN
the_DT
US_FPP1
._.
respiratory_JJ
pharmaceuticals_NN
with_PIN
sales_NN
of_PIN
its_PIT
three_CD
up_IN
49_CD
%_NN
to_PIN
414_CD
million_CD
is_VPRT
being_VBG [BYPA]
driven_VBN
by_PIN
the_DT
key_JJ
products_NN
,_,
Seretide_NN
Advair_NN
,_,
Flixotide_NN
Flovent_NN
In_PIN
metabolic_JJ
,_,
the_DT
diabetes_NN
treatments_NOMZ
Avandia_NN
indication_NOMZ
for_PIN
the_DT
maintenance_NN
treatment_NOMZ
of_PIN
biand_NN
Serevent_NN
,_,
amounting_VBG [PRESP]
to_PIN
3.4_CD
billion_CD
,_,
up_IN
9_CD
%_NN
._.
Avandamet_NN
continued_VBD
to_TO
perform_VB
very_AMP
strongly_AMP
,_,
polar_JJ
disorder_NN
received_VBN
last_JJ
year_NN
._.
Sales_NN
of_PIN
Seretide_NN
Advair_NN
,_,
the_DT
Groups_NN
largest_JJ
with_PIN
overall_JJ
sales_NN
of_PIN
1.1_CD
billion_CD
up_IN
32_CD
%_NN
._.
product_NN
,_,
grew_VBD
19_CD
%_NN
to_PIN
2.5_CD
billion_CD
,_,
although_CONC
this_DEMO
Sales_NN
in_PIN
the_DT
US_FPP1
grew_VBD
26_CD
%_NN
to_PIN
852_CD
million_CD
._.
contributed_VBD
to_PIN
declines_NN
in_PIN
Serevent_NN
and_PHC
Flixotide_NN
,_,
Encouragingly_RB
,_,
Avandia_NN
Avandamet_NN
are_VPRT
also_RB
GSKs_NN
underlying_VBG [WZPRES]
growth_NN
driven_VBD
its_PIT
constituent_NN
products_NN
._.
In_PIN
the_DT
US_FPP1
,_,
Advair_NN
sales_NN
growing_VBG [WZPRES]
very_AMP
strongly_AMP
in_PIN
Europe_NN
and_PHC
International_NN
by_PIN
strong_JJ
sales_NN
performance_NN
of_PIN
grew_VBD
20_CD
%_NN
to_PIN
1.3_CD
billion_CD
._.
Growth_NN
in_PIN
Europe_NN
was_VBD
markets_NN
with_PIN
sales_NN
up_IN
49_CD
%_NN
and_CC
62_CD
%_NN
respectively_RB
._.
key_JJ
products_NN
:_:
also_RB
strong_JJ
up_RB
18_CD
%_NN
to_PIN
902_CD
million_CD
._.
The_DT
vaccines_NN
business_NOMZ
had_VBD
a_DT
strong_JJ
year_NN
,_,
with_PIN
International_NN
sales_NN
grew_VBD
15_CD
%_NN
to_PIN
229_CD
million_CD
Seretide_NN
Advair_NN
2.5_CD
billion_CD
up_IN
19_CD
%_NN
sales_NN
up_IN
11_CD
%_NN
to_PIN
1.2_CD
billion_CD
._.
Several_QUAN
key_JJ
products_NN
reecting_VBG [WZPRES]
good_JJ
growth_NN
in_PIN
all_QUAN
geographic_JJ
areas_NN
._.
Vaccines_NN
1.2_CD
billion_CD
up_IN
11_CD
%_NN
are_VPRT
driving_VBG
sales_NN
growth_NN
Pediarix_NN
Infanrix_NN
up_IN
Central_NN
Nervous_NN
System_NN
CNS_NN
sales_NN
declined_VBD
12_CD
%_NN
to_PIN
357_CD
million_CD
,_,
Priorix_NN
up_IN
14_CD
%_NN
to_PIN
95_CD
Avandia_NN
Avandamet_NN
1.1_CD
billion_CD
16_CD
%_NN
to_PIN
3.5_CD
billion_CD
with_PIN
declines_NN
in_PIN
all_QUAN
regions_NN
._.
million_CD
and_CC
Fluarix_NN
up_IN
38_CD
%_NN
to_PIN
79_CD
million_CD
._.
up_RB
32_CD
%_NN
Total_JJ
sales_NN
of_PIN
the_DT
Paxil_NN
franchise_NN
were_VBD [BEMA]
down_RB
39_CD
%_NN
In_PIN
oncology_NN
,_,
sales_NN
of_PIN
Zofran_NN
grew_VBD
8_CD
%_NN
,_,
driven_VBN [PASTP]
by_PIN
to_PIN
1.1_CD
billion_CD
as_CONJ
a_NULL
result_NULL
of_PIN
generic_JJ
competition_NOMZ
Lamictal_NN
0.7_CD
billion_CD
up_IN
32_CD
%_NN
a_DT
strong_JJ
US_FPP1
performance_NN
up_IN
10_CD
%_NN
to_PIN
565_CD
million_CD
._.
to_PIN
Paxil_NN
IR_NN
sales_NN
of_PIN
which_WDT [PIRE]
declined_VBD
53_CD
%_NN
to_PIN
667_CD
Valtrex_NN
0.6_CD
billion_CD
up_IN
24_CD
%_NN
million_CD
._.
Mitigating_VBG [PRESP]
this_DEMO
decline_NN
was_VBD [BEMA]
the_DT
strong_JJ
In_PIN
cardiovascular_JJ
and_PHC
urogenital_JJ
,_,
Coreg_NN
sales_NN
performance_NN
of_PIN
the_DT
product_NN
in_PIN
Japan_NN
with_PIN
sales_NN
of_PIN
Coreg_NN
0.4_CD
billion_CD
up_IN
34_CD
%_NN
grew_VBD
34_CD
%_NN
to_PIN
432_CD
million_CD
._.
171_CD
million_CD
up_IN
25_CD
%_NN
and_CC
the_DT
performance_NN
of_PIN
Paxil_NN
CR_NN
which_WDT [WHSUB]
generated_VBD
sales_NN
of_PIN
396_CD
million_CD
up_IN
14_CD
%_NN
._.
Total_JJ
sales_NN
of_PIN
Wellbutrin_NN
products_NN
fell_VBD
Within_PIN
anti-virals_NN
,_,
global_JJ
HIV_NN
product_NN
sales_NN
12_CD
%_NN
to_PIN
751_CD
million_CD
._.
Wellbutrin_NN
IR_NN
and_PHC
SR_NN
sales_NN
rose_VBD
4_CD
%_NN
to_PIN
1.5_CD
billion_CD
and_CC
sales_NN
of_PIN
the_DT
herpes_NN
fell_VBD
64_CD
%_NN
to_PIN
284_CD
million_CD
as_CONJ
a_NULL
result_NULL
of_PIN
generic_JJ
treatment_NOMZ
Valtrex_NN
exceeded_VBD
the_DT
500_CD
million_CD
competition_NOMZ
._.
This_DEMO
impact_NN
was_VBD [SPAU] [PASS]
partially_DWNT
offset_VBN
,_,
mark_NN
for_PIN
the_DT
first_JJ
time_NN
in_PIN
2004_CD
up_IN
24_CD
%_NN
to_TO
however_CONJ
,_,
by_PIN
the_DT
exceptionally_RB
strong_JJ
571_CD
million_CD
._.
The_DT
sales_NN
performance_NN
of_PIN
Valtrex_NN
is_VPRT
performance_NN
of_PIN
Wellbutrin_NN
XL_NN
,_,
the_DT
new_JJ
oncebeing_GER
driven_VBN [WZPAST]
by_PIN
the_DT
US_FPP1
up_IN
30_CD
%_NN
to_PIN
369_CD
million_CD
daily_JJ
product_NN
,_,
which_WDT [SERE]
achieved_VBD
sales_NN
of_PIN
467_CD
where_RB
the_DT
product_NN
is_VPRT [BEMA]
the_DT
clear_JJ
market_NN
leader_NN
in_PIN
million_CD
in_PIN
its_PIT
first_JJ
full_JJ
year_NN
on_PIN
the_DT
market_NN
._.
14_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
These_DEMO
results_NN
confirm_VPRT [PUBV]
the_DT
success_NN
with_PIN
which_WDT [PIRE]
GSK_NN
has_VPRT [PEAS]
navigated_VBN
a_DT
difficult_JJ
year_NN
,_,
absorbing_VBG
over_IN
1.5_CD
billion_CD
of_PIN
lost_VBN
sales_NN
to_PIN
generics_NN
and_CC
still_RB
managing_VBG
to_TO
grow_VB
the_DT
business_NOMZ
._.
The_DT
continuing_VBG
success_NN
of_PIN
our_FPP1
key_JJ
products_NN
means_VPRT [PRIV] [THATD]
we_FPP1
can_POMD [SPAU]
now_TIME
look_VB
forward_RB
to_PIN
a_DT
good_JJ
performance_NN
in_PIN
2005_CD
JP_NN
Garnier_NN
,_,
Chief_NN
Executive_NN
officer_NN
Net_NN
of_PIN
currency_NN
movements_NOMZ
the_DT
margin_NN
declined_VBD
Consumer_NN
Healthcare_NN
Several_QUAN
significant_JJ
product_NN
launches_NN
0.7_CD
percentage_NN
points_NN
,_,
reecting_VBG
higher_JJ
R&D_NN
The_DT
growth_NN
in_PIN
Consumer_NN
Healthcare_NN
sales_NN
of_PIN
planned_VBN
for_PIN
2005_CD
include_VPRT
:_:
expenditure_NN
,_,
a_DT
higher_JJ
cost_NN
of_PIN
goods_NN
due_JJ
to_PIN
a_DT
less_RB
3_CD
%_NN
to_PIN
3.2_CD
billion_CD
comprised_VBD
an_DT
over-thefavourable_JJ
product_NN
mix_NN
and_CC
higher_JJ
provisions_NN
for_PIN
counter_NN
OTC_NN
medicine_NN
sales_NN
increase_NN
of_PIN
2_CD
%_NN
,_,
legal_JJ
matters_NN
._.
These_DEMP
were_VBD [SPAU] [BYPA]
partially_DWNT
offset_VBN
by_PIN
cost_NN
a_DT
Nutritional_NN
healthcare_NN
sales_NN
increase_NN
of_PIN
5_CD
%_NN
Vesicare_NN
for_PIN
overactive_JJ
bladder_NN
savings_GER
initiatives_NN
in_PIN
general_JJ
and_CC
administration_NOMZ
and_CC
Oral_JJ
care_NN
sales_NN
increase_NN
of_PIN
4_CD
%_NN
._.
Rotarix_NN
for_PIN
rotavirus_NN
and_CC
lower_JJ
charges_NN
related_VBN [WZPAST]
to_PIN
programs_NN
to_PIN
OTC_NN
medicine_NN
sales_NN
were_VBD [BEMA]
1.5_CD
billion_CD
,_,
up_RB
2_CD
%_NN
._.
Boniva_NN
for_PIN
osteoporosis_NN
Sales_NN
growth_NN
from_PIN
smoking_GER
control_NN
products_NN
in_PIN
Avandaryl_NN
for_PIN
diabetes_NN
the_DT
US_FPP1
up_IN
12_CD
%_NN
and_PHC
Europe_NN
up_IN
24_CD
%_NN
helped_VBD
to_TO
offset_VB
the_DT
decline_NN
in_PIN
dermatological_JJ
products_NN
,_,
During_PIN
the_DT
years_NN
2000_CD
to_PIN
2003_CD
,_,
business_NOMZ
Requip_NN
for_PIN
restless_JJ
legs_NN
syndrome_NN
performance_NN
was_VBD [BEMA]
the_DT
primary_JJ
performance_NN
measure_NN
which_WDT [WHSUB]
were_VBD [BEMA]
down_RB
14_CD
%_NN
due_JJ
to_PIN
generic_JJ
used_VBN
by_PIN
management_NOMZ
and_CC
was_VBD [PASS]
presented_VBN
after_IN
Entereg_NN
for_PIN
post-operative_JJ
bowel_NN
competition_NOMZ
to_PIN
Cutivate_NN
in_PIN
the_DT
US_FPP1
._.
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
disorders_NN
restructuring_VBG [WZPRES]
costs_NN
and_PHC
disposals_NN
of_PIN
businesses_NOMZ
,_,
as_IN
In_PIN
2004_CD
,_,
GSK_NN
obtained_VBD
the_DT
OTC_NN
marketing_GER
rights_NN
management_NOMZ
believes_VPRT [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
items_NN
provides_VPRT
a_DT
better_JJ
comparison_NN
of_PIN
business_NOMZ
in_PIN
the_DT
US_FPP1
for_PIN
orlistat_NN
,_,
an_DT
FDA-approved_JJ
performance_NN
for_PIN
the_DT
periods_NN
presented_VBN
._.
For_PIN
2004_CD
,_,
prescription_NOMZ
product_NN
for_PIN
obesity_NOMZ
management_NOMZ
,_,
with_PIN
the_DT
completion_NOMZ
of_PIN
these_DEMO
programs_NN
,_,
the_DT
PHARMACEUTICAL_NN
TURNOVER_NN
BY_PIN
marketed_VBN
by_PIN
Roche_NN
as_IN
Xenical_NN
._.
Group_NN
is_VPRT
reporting_VBG [PUBV]
results_NN
on_PIN
a_DT
statutory_JJ
basis_NN
only_DWNT
._.
THERAPEUTIC_NN
AREA_NN
Growth_NN
rates_NN
are_VPRT [PASS]
presented_VBN
comparing_VBG
2004_CD
results_NN
Oral_JJ
care_NN
sales_NN
were_VBD [BEMA]
1.1_CD
billion_CD
,_,
up_RB
4_CD
%_NN
._.
Strong_JJ
with_PIN
2003_CD
business_NOMZ
performance_NN
results_NN
as_IN
2004_CD
2003_CD
Growth_NN
management_NOMZ
considers_VPRT [PRIV] [THATD]
that_DEMP
this_DEMP
gives_VPRT
the_DT
most_EMPH
m_JJ
m_NN
CER_NN
%_NN
sales_NN
growth_NN
in_PIN
International_NN
of_PIN
9_CD
%_NN
was_VBD [BYPA]
led_VBN
by_PIN
appropriate_JJ
indication_NOMZ
of_PIN
the_DT
Group_NN
's_POS
performance_NN
the_DT
Sensodyne_NN
,_,
Polident_NN
and_PHC
Poligrip_NN
brands_NN
._.
for_PIN
the_DT
period_NN
under_IN
review_NN
and_ANDC
therefore_CONJ
Respiratory_JJ
4,415_CD
4,417_CD
7_CD
commentaries_NN
are_VPRT [PASS]
presented_VBN
on_PIN
this_DEMO
basis_NN
unless_COND
CNS_NN
3,463_CD
4,455_CD
16_CD
Sales_NN
of_PIN
Nutritional_NN
healthcare_NN
products_NN
grew_VBD
otherwise_CONJ
stated_VBN [PUBV]
._.
Lucozade_NN
grew_VBD
7_CD
%_NN
to_PIN
In_PIN
order_NN
to_TO
illustrate_VB
underlying_VBG
performance_NN
,_,
it_PIT
is_VPRT [BEMA]
Anti-bacterials_PRED
1,561_CD
1,815_CD
9_CD
268_CD
million_CD
._.
the_DT
Groups_NN
practice_NN
to_TO
discuss_VB
its_PIT
results_NN
in_PIN
terms_NN
Metabolic_NN
1,253_CD
1,079_CD
27_CD
of_PIN
constant_JJ
exchange_NN
rate_NN
CER_NN
growth_NN
._.
This_DEMP
Vaccines_VPRT
1,196_CD
1,123_CD
11_CD
represents_VPRT
growth_NN
calculated_VBN [PRIV]
as_IN
if_COND
the_DT
exchange_NN
rates_NN
Trading_GER
profit_NN
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
results_NN
of_PIN
overseas_PLACE
companies_NN
Oncology_NN
and_PHC
emesis_NN
934_CD
1,001_CD
2_CD
Trading_GER
profit_NN
was_VBD [BEMA]
6,150_CD
million_CD
,_,
a_DT
1_CD
%_NN
decrease_NN
in_PIN
sterling_GER
had_VBD [PEAS]
remained_VBN
unchanged_JJ
from_PIN
those_DEMP
used_VBN
Cardiovascular_NN
and_CC
in_PIN
the_DT
previous_JJ
year_NN
._.
All_QUAN
commentaries_NN
are_VPRT [PASS]
presented_VBN
11_CD
%_NN
decline_NN
in_PIN
sterling_GER
terms_NN
compared_VBN [WZPAST]
with_PIN
in_PIN
terms_NN
of_PIN
CER_NN
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
The_DT
trading_GER
margin_NN
Other_JJ
1,031_CD
1,171_CD
7_CD
declined_VBD
two_CD
percentage_NN
points_NN
compared_VBN [WZPAST]
with_PIN
17,146_CD
18,181_CD
1_CD
2003_CD
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
15_CD
Business_NOMZ
operating_GER
review_NN
continued_VBD
Main_NN
differences_NN
:_:
Legal_NN
proceedings_GER
Earnings_GER
per_PIN
share_NN
The_DT
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
patent_NN
litigation_NOMZ
with_PIN
Full_NN
year_NN
earnings_GER
per_PIN
share_NN
EPS_NN
of_PIN
75.0_CD
pence_NN
Share-based_JJ
payments_NOMZ
:_:
Under_IN
IFRS_NN
the_DT
fair_JJ
manufacturers_NN
seeking_VBG [WZPRES]
to_PIN
market_NN
generic_JJ
versions_NN
increased_VBD
2_CD
%_NN
,_,
compared_VBN [PASTP]
to_PIN
business_NOMZ
performance_NN
value_NN
of_PIN
share_NN
options_NOMZ
and_PHC
awards_NN
granted_VBN [SUAV] [WZPAST]
of_PIN
many_QUAN
of_PIN
the_DT
Groups_NN
most_EMPH
important_JJ
products_NN
,_,
EPS_NN
in_PIN
2003_CD
._.
In_PIN
sterling_JJ
terms_NN
,_,
EPS_NN
declined_VBD
9_CD
%_NN
,_,
to_PIN
employees_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
including_VBG [WZPRES]
Wellbutrin_NN
,_,
Seretide_NN
,_,
Avandia_NN
,_,
Imitrex_NN
,_,
reecting_VBG [PRESP]
a_DT
weakening_GER
of_PIN
the_DT
US_FPP1
dollar_NN
._.
On_PIN
a_DT
statement_NOMZ
,_,
whereas_OSUB
only_DWNT
the_DT
intrinsic_JJ
loss_NN
Valtrex_NN
,_,
Lamictal_NN
and_PHC
Zofran_NN
,_,
prior_RB
to_PIN
the_DT
expiration_NOMZ
statutory_JJ
basis_NN
EPS_NN
increased_VBD
8_CD
%_NN
,_,
but_CC
declined_VBD
usually_RB
a_DT
smaller_JJ
amount_NN
is_VPRT [PASS]
charged_VBN
under_IN
of_PIN
the_DT
Groups_NN
patents_NN
._.
The_DT
Group_NN
is_VPRT [BEMA]
currently_RB
a_DT
3_CD
%_NN
in_PIN
sterling_GER
terms_NN
._.
defendant_NN
in_PIN
a_DT
number_NN
of_PIN
product_NN
liability_NOMZ
lawsuits_NN
,_,
Amortisation_NOMZ
of_PIN
intangible_JJ
assets_NN
and_CC
including_VBG
class_NN
actions_NOMZ
,_,
that_DEMP
involve_VPRT
substantial_JJ
Taxation_NOMZ
goodwill_NN
:_:
Under_IN
IFRS_NN
amortisation_NOMZ
of_PIN
claims_NN
for_PIN
damages_NN
related_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
GSK_NN
has_VPRT
open_JJ
issues_NN
with_PIN
the_DT
taxation_NOMZ
authorities_NOMZ
intangible_JJ
assets_NN
may_POMD [SPAU]
only_DWNT
start_VB
when_RB
the_DT
pharmaceutical_JJ
products_NN
._.
The_DT
Group_NN
is_VPRT [BEMA]
also_RB
a_DT
in_PIN
the_DT
US_FPP1
,_,
UK_NN
,_,
Japan_NN
and_PHC
Canada_NN
._.
By_PIN
far_PLACE
the_DT
asset_NN
is_VPRT [BEMA]
available_PRED
for_PIN
use_NN
,_,
whereas_OSUB
it_PIT
starts_VPRT
defendant_NN
in_PIN
anti-trust_JJ
actions_NOMZ
led_VBD
following_VBG
largest_JJ
relates_VPRT
to_PIN
Glaxo_NN
heritage_NN
products_NN
,_,
in_PIN
immediately_TIME
under_IN
UK_NN
GAAP_NN
._.
Goodwill_NN
is_VPRT [BEMA]
adverse_JJ
outcomes_NN
in_PIN
prosecution_NOMZ
of_PIN
patent_NN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
US_FPP1
Internal_NN
Revenue_NN
Service_NN
regarded_VBD
as_IN
having_VBG
an_DT
indefinite_JJ
life_NN
under_IN
infringement_NOMZ
actions_NOMZ
._.
Further_RB
,_,
the_DT
Group_NN
is_VPRT
IRS_NN
and_PHC
UK_NN
Inland_NN
Revenue_NN
have_VPRT [PEAS]
made_VBN
IFRS_NN
and_CC
is_VPRT [PASS]
therefore_CONJ
not_XX0
amortised_VBN
._.
Any_QUAN
UK_NN
responding_VBG [WZPRES]
to_PIN
federal_JJ
and_CC
state_NN
governmental_JJ
competing_VBG
and_CC
contradictory_JJ
claims_NN
._.
GAAP_NN
goodwill_NN
amortisation_NOMZ
has_VPRT
to_TO
be_VB
investigations_NOMZ
in_PIN
the_DT
US_FPP1
into_PIN
pricing_GER
,_,
marketing_GER
and_PHC
GSK_NN
has_VPRT [PEAS]
attempted_VBN
to_TO
settle_VB
the_DT
US_FPP1
dispute_NN
,_,
first_JJ
reversed_JJ
._.
reimbursement_NOMZ
of_PIN
a_DT
number_NN
of_PIN
prescription_NOMZ
drug_NN
through_PIN
direct_JJ
discussion_NN
with_PIN
the_DT
IRS_NN
and_PHC
products_NN
._.
See_VB [PRIV]
Note_VB [PRIV]
30_CD
to_PIN
the_DT
Financial_NN
statements_NOMZ
Deferred_JJ
tax_NN
:_:
The_DT
deferred_VBN
tax_NN
difference_NN
subsequently_TIME
through_PIN
discussions_NN
between_PIN
the_DT
US_FPP1
Legal_NN
proceedings_GER
in_PIN
the_DT
Annual_JJ
Report_NN
2004_CD
for_PIN
a_DT
principally_RB
relates_VPRT
to_PIN
intercompany_NN
items_NN
on_PIN
and_CC
UK_NN
authorities_NOMZ
under_IN
the_DT
terms_NN
of_PIN
the_DT
double_JJ
discussion_NN
of_PIN
proceedings_GER
and_CC
governmental_JJ
which_WDT
a_DT
deferred_JJ
tax_NN
credit_NN
is_VPRT [BEMA]
available_PRED
under_IN
tax_NN
convention_NOMZ
between_PIN
the_DT
two_CD
countries_NN
and_PHC
investigations_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
is_VPRT
currently_RB
UK_NN
GAAP_NN
,_,
but_CC
not_XX0
under_IN
IFRS_NN
._.
This_DEMO
particular_JJ
discussions_NN
were_VBD [PASS]
terminated_VBN
in_PIN
July_NN
2003_CD
._.
difference_NN
in_PIN
taxation_NOMZ
treatment_NOMZ
is_VPRT
not_XX0
January_NN
2004_CD
,_,
the_DT
IRS_NN
issued_VBD
a_DT
Notice_NN
of_PIN
expected_VBN [PRIV]
to_TO
recur_VB
._.
deficiency_NN
for_PIN
the_DT
years_NN
1989-1996_CD
claiming_VBG [PUBV]
International_NN
Financial_NN
Reporting_GER
additional_JJ
taxes_NN
of_PIN
$_$
2.7_CD
billion_CD
._.
On_PIN
2_CD
April_NN
2004_CD
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
:_:
Standards_NN
IFRS_NN
the_DT
Group_NN
led_VBD
a_DT
petition_NOMZ
in_PIN
the_DT
US_FPP1
Tax_NN
Court_NN
IFRS_NN
adopts_VPRT
a_DT
different_JJ
valuation_NOMZ
approach_NN
In_PIN
June_NN
2002_CD
,_,
the_DT
Council_NN
of_PIN
the_DT
European_NN
Union_NN
disputing_VBG [WZPRES]
the_DT
IRS_NN
claim_NN
and_CC
seeking_VBG
a_DT
refund_NN
of_PIN
than_PIN
UK_NN
GAAP_NN
and_CC
this_DEMO
usually_RB
results_NN
in_PIN
a_DT
adopted_VBN
a_DT
Regulation_NOMZ
requiring_VBG [SUAV] [WZPRES]
listed_VBN
companies_NN
$_$
1_CD
billion_CD
in_PIN
taxes_NN
._.
On_PIN
25_CD
January_NN
2005_CD
the_DT
IRS_NN
higher_JJ
charge_NN
._.
In_CONJ
addition_NULL
IFRS_NN
recognizes_VPRT [PRIV]
the_DT
in_PIN
the_DT
EU_NN
Member_NN
States_NN
to_TO
prepare_VB
their_TPP3
issued_VBN
a_DT
further_JJ
Notice_NN
of_PIN
deficiency_NN
for_PIN
the_DT
years_NN
funding_VBG [WZPRES]
surplus_JJ
deficit_NN
immediately_TIME
through_PIN
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
1997-2000_CD
claiming_VBG [PUBV]
additional_JJ
taxes_NN
of_PIN
$_$
1.9_CD
reserves_NN
,_,
whereas_OSUB
UK_NN
GAAP_NN
spreads_VPRT
the_DT
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
billion_CD
._.
If_COND
the_DT
IRS_NN
claims_NN
for_PIN
the_DT
years_NN
1989-2000_CD
surplus_NN
deficit_NN
over_IN
the_DT
members_NN
average_JJ
IFRS_NN
with_PIN
effect_NN
from_PIN
1_CD
January_NN
2005_CD
._.
were_VBD [PASS]
upheld_VBN
,_,
the_DT
Group_NN
would_PRMD [SPAU]
additionally_RB
be_VB [PASS]
expected_VBN [PRIV]
service_NN
lives_NN
through_PIN
the_DT
income_NN
liable_JJ
for_PIN
interest_NN
on_PIN
late_TIME
payment_NOMZ
,_,
estimated_VBN [PRIV] [PASTP]
to_PIN
GSK_NN
initiated_VBD
its_PIT
IFRS_NN
conversion_NN
project_NN
in_PIN
2002_CD
statement_NOMZ
._.
amount_NN
to_TO
$_$
3.0_CD
billion_CD
net_NN
of_PIN
federal_JJ
tax_NN
relief_NN
at_PIN
and_CC
this_DEMP
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
completed_VBN
._.
Brief_NN
31_CD
December_NN
2004_CD
,_,
giving_VBG [PRESP]
a_DT
total_NN
of_PIN
$_$
7.6_CD
billion_CD
._.
explanations_NOMZ
of_PIN
the_DT
main_JJ
IFRS_NN
adjustments_NOMZ
to_PIN
The_DT
Group_NN
expects_VPRT [PRIV]
to_TO
le_FW
a_DT
petition_NOMZ
against_PIN
these_DEMO
profit_NN
are_VPRT [PASS]
given_VBN
below_PLACE
,_,
together_RB
with_PIN
the_DT
impact_NN
further_JJ
claims_NN
in_PIN
April_NN
2005_CD
,_,
including_VBG [PRESP]
a_DT
further_RB
on_PIN
profit_NN
before_IN
tax_NN
and_PHC
EPS_NN
for_PIN
2004_CD
and_CC
2003_CD
._.
claim_NN
for_PIN
refund_NN
of_PIN
taxes_NN
,_,
and_ANDC
will_PRMD
ask_VB [SUAV]
the_DT
Tax_NN
Fuller_NN
details_NN
are_VPRT [PASS]
given_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
2004_CD
Court_NN
to_TO
consolidate_VB
the_DT
IRS_NN
claims_NN
for_PIN
all_QUAN
the_DT
and_CC
on_PIN
the_DT
companys_NN
website_VPRT
._.
EFFECT_NN
OF_PIN
IFRS_NN
ON_PIN
PROFIT_NN
BEFORE_IN
TAX_NN
AND_PHC
EPS_NN
Business_NOMZ
performance_NN
A_DT
provisional_JJ
trial_NN
date_NN
for_PIN
the_DT
1989-1996_CD
Statutory_JJ
restated_VBN
claims_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
for_PIN
October_NN
2006_CD
._.
As_IN
2004_CD
2003_CD
similar_JJ
tax_NN
issues_NN
remain_VPRT
open_JJ
for_PIN
2001_CD
to_PIN
date_NN
,_,
profit_NN
profit_NN
GSK_NN
expects_VPRT [PRIV]
to_TO
receive_VB
further_JJ
substantial_JJ
claims_NN
before_IN
tax_NN
EPS_NN
before_IN
tax_NN
EPS_NN
from_PIN
the_DT
IRS_NN
for_PIN
these_DEMO
years_NN
._.
m_NN
pence_NN
m_NN
pence_NN
UK_NN
GAAP_NN
6,119_CD
75.0_CD
6,703_CD
82.0_CD
GSK_NN
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
the_DT
profits_NN
reported_VBD [PUBV]
IFRS_NN
adjustments_NOMZ
:_:
by_PIN
its_PIT
US_FPP1
subsidiaries_NN
for_PIN
the_DT
period_NN
1989_CD
to_PIN
date_NN
,_,
Share-based_JJ
payments_NOMZ
309_CD
5.5_CD
368_CD
5.9_CD
on_PIN
which_WDT [PIRE]
it_PIT
has_VPRT [PEAS]
paid_VBN
taxes_NN
in_PIN
the_DT
US_FPP1
,_,
are_VPRT
more_EMPH
Amortisation_NOMZ
of_PIN
intangible_JJ
assets_NN
and_PHC
goodwill_NN
54_CD
0.9_CD
38_CD
0.6_CD
than_PIN
sufficient_JJ
to_TO
reect_VB
the_DT
activities_NOMZ
of_PIN
its_PIT
US_FPP1
Deferred_NN
tax_NN
on_PIN
intercompany_NN
items_NN
1.9_CD
operations_NOMZ
._.
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_VPRT
36_CD
0.4_CD
11_CD
GSK_NN
is_VPRT [BEMA]
in_PIN
continuing_VBG
discussions_NN
with_PIN
the_DT
Inland_NN
Other_JJ
adjustments_NOMZ
49_CD
35_CD
0.5_CD
Revenue_NN
in_PIN
respect_NN
of_PIN
UK_NN
transfer_NN
pricing_GER
disputes_NN
._.
IFRS_NN
5,779_CD
68.1_CD
6,349_CD
77.2_CD
See_VB [PRIV]
Note_VB [PRIV]
12_CD
of_PIN
Annual_JJ
Report_NN
2004_CD
for_PIN
further_JJ
details_NN
._.
16_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_GER
Product_NN
overview_VBD
GSKs_NN
underlying_VBG [WZPRES]
growth_NN
in_PIN
2004_CD
was_VBD [BYPA]
driven_VBN
by_PIN
the_DT
strong_JJ
performance_NN
of_PIN
our_FPP1
key_JJ
products_NN
Total_JJ
turnover_NN
Consumer_NN
Healthcare_NN
16_CD
%_NN
turnover_NN
3.2_CD
bn_NN
,_,
Consumer_NN
Healthcare_NN
grew_VBD
3_CD
%_NN
20.3_CD
bn_NN
Pharmaceuticals_NN
84_CD
%_NN
turnover_NN
grew_VBD
1_CD
%_NN
,_,
despite_PIN
the_DT
loss_NN
Pharmaceutical_NN
turnover_NN
17.1_CD
bn_NN
,_,
of_PIN
1.5_CD
billion_CD
of_PIN
sales_NN
to_PIN
generics_NN
grew_VBD
1_CD
%_NN
KEY_NN
PHARMACEUTICAL_NN
PRODUCTS_NN
CONSUMER_NN
HEALTHCARE_NN
3.2_CD
bn_NN
GSKs_NN
Consumer_NN
Healthcare_NN
6.5_CD
bn_NN
business_NOMZ
grew_VBD
3_CD
%_NN
._.
turnover_NN
of_PIN
five_CD
key_JJ
products_NN
Top_JJ
5_CD
Consumer_NN
Healthcare_NN
products_NN
and_PHC
vaccines_NN
grew_VBD
by_PIN
22_CD
%_NN
total_JJ
turnover_NN
Seretide_NN
Advair_NN
Valtrex_NN
Coreg_NN
1_CD
Nicotine_JJ
replacement_NOMZ
therapy_NN
341m_CD
2,461_CD
m_NN
571m_NN
2_CD
Aquafresh_NN
329m_CD
432m_JJ
grew_VBD
19_CD
%_NN
grew_VBD
24_CD
%_NN
3_CD
Lucozade_NN
268m_CD
grew_VBD
34_CD
%_NN
Strong_JJ
growth_NN
has_VPRT [PEAS]
been_VBN [BEMA]
GSKs_RB
largest_PRED
selling_VBG
Continues_NN
to_TO
benefit_VB
from_PIN
4_CD
Sensodyne_NN
213m_CD
driven_VBN
by_PIN
the_DT
genital_JJ
herpes_NN
product_NN
for_PIN
asthma_NN
and_CC
its_PIT
wide_JJ
range_NN
of_PIN
indications_NOMZ
5_CD
Panadol_NN
208m_JJ
medication_NOMZ
in_PIN
the_DT
US_FPP1
._.
chronic_JJ
obstructive_JJ
in_PIN
heart_NN
disease_NN
._.
pulmonary_JJ
disease_NN
COPD_NN
Avandia_NN
Avandamet_NN
is_VPRT [BEMA]
the_DT
sixth_JJ
largest_JJ
Lamictal_JJ
pharmaceutical_JJ
product_NN
1,116_CD
m_NN
globally_RB
and_CC
the_DT
second_JJ
678m_JJ
Over-the-counter_NN
largest_JJ
in_PIN
Europe_NN
._.
grew_VBD
32_CD
%_NN
grew_VBD
32_CD
%_NN
grew_VBD
2_CD
%_NN
to_PIN
1,489_CD
million_CD
GSKs_NN
diabetes_NN
treatment_NOMZ
Indicated_VBN [PRIV] [WZPAST]
for_PIN
epilepsy_NN
continues_VPRT
to_TO
perform_VB
strongly_AMP
._.
and_ANDC
bipolar_JJ
disorder_NN
Nutritional_NN
healthcare_NN
Lamictal_NN
continues_VPRT
to_TO
grew_VBD
5_CD
%_NN
to_PIN
636_CD
million_CD
grow_VPRT
strongly_AMP
._.
Oral_JJ
healthcare_NN
grew_VBD
4_CD
%_NN
to_PIN
1,088_CD
million_CD
VACCINES_NN
Infanrix_NN
Pediarix_NN
grew_VBD
12_CD
%_NN
to_PIN
357_CD
million_CD
._.
1,196_CD
m_NN
Fluarix_NN
GSKs_NN
vaccines_NN
business_NOMZ
had_VBD [PEAS]
grew_VBN
38_CD
%_NN
to_PIN
79_CD
million_CD
._.
a_DT
strong_JJ
year_NN
,_,
with_PIN
sales_NN
up_IN
11_CD
%_NN
._.
12_CD
GSK_NN
products_NN
achieved_VBD
sales_NN
of_PIN
more_EMPH
than_PIN
500_CD
million_CD
in_PIN
2004_CD
1_CD
Seretide_NN
Advair_NN
2,461_CD
m_NN [BEMA]
5_CD
Wellbutrin_NN
751m_CD
9_CD
Flixotide_NN
Flovent_NN
618m_NN
2_CD
Avandia_NN
Avandamet_NN
1,116_CD
m_NN [BEMA]
6_CD
Augmentin_NN
708m_CD
10_CD
Flixonase_NN
Flonase_NN
578m_JJ
3_CD
Seroxat_NN
Paxil_NN
1,063_CD
m_NN [BEMA]
7_CD
Imigran_NN
Imitrex_NN
682m_CD
11_CD
Valtrex_NN
571m_CD
4_CD
Zofran_NN
763m_CD
8_CD
Lamictal_NN
678m_CD
12_CD
Combivir_NN
571m_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
17_CD
THE_DT
BOARD_NN
The_NN
Board_NN
of_PIN
Directors_NN
is_VPRT [BEMA]
ultimately_RB
accountable_PRED
for_PIN
the_DT
Groups_NN
activities_NOMZ
,_,
strategy_NN
and_CC
financial_JJ
performance_NN
._.
Sir_NN
Christopher_NN
Gent_NN
Dr_NN
Jean-Pierre_NN
Garnier_NN
John_NN
Coombe_NN
Lawrence_NN
Culp_NN
Sir_NN
Crispin_NN
Davis_NN
Sir_NN
Deryck_NN
Maughan_NN
Sir_NN
Ian_NN
Prosser_NN
Dr_NN
Ronaldo_NN
Schmitz_NN
Dr_NN
Lucy_NN
Shapiro_NN
Sir_NN
Robert_NN
Wilson_NN
Dr_NN
Tachi_NN
Yamada_NN
Sir_NN
Christopher_NN
Gent_NN
Aged_VBD
56_CD
Sir_NN
Crispin_NN
Davis_NN
Aged_VBD
55_CD
Dr_NN
Lucy_NN
Shapiro_NN
Aged_VBD
64_CD
Chief_NN
Financial_NN
officer_NN
Designate_NN
Appointed_VBN [WZPAST]
on_PIN
1_CD
June_NN
2004_CD
Appointed_VBN
on_PIN
1_CD
July_NN
2003_CD
Appointed_VBN
on_PIN
23_CD
May_POMD
2000_CD
Julian_NN
Heslop_NN
Aged_VBD
51_CD
Chairman_NN
._.
Sir_NN
Christopher_NN
was_VBD [BEMA]
the_DT
Non-Executive_NN
Director_NN
._.
Sir_NN
Crispin_NN
is_VPRT [BEMA]
Non-Executive_JJ
Director_NN
._.
Dr_NN
Shapiro_NN
was_VBD
Mr_NN
Heslop_NN
will_PRMD
succeed_VB
Mr_NN
Coombe_NN
Chief_NN
Executive_NN
officer_NN
of_PIN
Vodafone_NN
Chief_NN
Executive_NN
of_PIN
Reed_NN
Elsevier_NN
PLC._NN
._.
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
as_IN
Chief_NN
Financial_NN
officer_NN
with_PIN
effect_NN
plc_NN
,_,
until_IN
his_TPP3
retirement_NOMZ
in_PIN
July_NN
2003_CD
._.
Prior_RB
to_PIN
that_DEMP
,_,
he_TPP3
was_VBD
Chief_NN
Executive_NN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
She_TPP3
is_VPRT
Ludwig_NN
from_PIN
1_CD
April_NN
2005_CD
when_RB
he_TPP3
will_PRMD
also_RB
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Aegis_NN
Group_NN
plc_NN
,_,
which_WDT [SERE]
he_TPP3
joined_VBD
from_PIN
Professor_NN
of_PIN
Cancer_NN
Research_NN
in_PIN
the_DT
join_VB
the_DT
Board_NN
._.
Mr_NN
Heslop_NN
joined_VBD
Lehman_NN
Brothers_NN
Holdings_GER
Inc_NN
,_,
a_DT
Guinness_NOMZ
plc_NN
,_,
where_RB
he_TPP3
was_VBD [BEMA]
a_DT
member_NN
Department_NOMZ
of_PIN
Developmental_NN
Biology_NN
Glaxo_NN
Wellcome_NN
as_IN
Financial_NN
Controller_NN
Director_NN
of_PIN
the_DT
International_NN
Advisory_NN
of_PIN
the_DT
main_JJ
board_NN
and_PHC
Group_NN
Managing_VBG [WZPRES]
and_CC
Director_NN
of_PIN
the_DT
Beckman_NN
Center_NN
in_PIN
April_NN
1998_CD
._.
In_PIN
January_NN
2001_CD
,_,
Board_NN
of_PIN
Hakluyt_NN
&_CC
Co_NN
,_,
and_ANDC
is_VPRT [BEMA]
a_DT
Senior_JJ
Director_NN
of_PIN
United_NN
Distillers_NN
._.
He_TPP3
spent_VBD
for_PIN
Molecular_JJ
and_PHC
Genetic_JJ
Medicine_NN
at_PIN
following_VBG
the_DT
merger_NN
,_,
he_TPP3
was_VBD
Adviser_NN
at_PIN
Bain_NN
&_CC
Co._NN
his_TPP3
early_TIME
career_NN
with_PIN
Procter_NN
&_CC
Gamble_NN
._.
the_DT
Stanford_NN
University_NOMZ
School_NN
of_PIN
appointed_VBN
Senior_JJ
Vice_NN
President_NN
,_,
Medicine_NN
and_CC
a_DT
Non-Executive_JJ
Director_NN
Operations_NOMZ
Controller_NN
at_PIN
GSK_NN
._.
Prior_RB
to_PIN
Dr_NN
Jean-Pierre_NN
Garnier_NN
Aged_VBD
57_CD
Sir_NN
Deryck_NN
Maughan_NN
Aged_VBD
57_CD
of_PIN
Anacor_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
She_TPP3
joining_VBG
Glaxo_NN
Wellcome_NN
,_,
he_TPP3
held_VBD [PRIV]
senior_JJ
Appointed_VBN
on_PIN
23_CD
May_POMD
2000_CD
Appointed_VBN
on_PIN
1_CD
June_NN
2004_CD
holds_VPRT [PRIV]
a_DT
PhD_NN
in_PIN
molecular_JJ
biology_NN
from_PIN
finance_NN
roles_NN
at_PIN
Grand_NN
Metropolitan_NN
Chief_NN
Executive_NN
officer_NN
._.
Dr_NN
Garnier_NN
was_VBD [BEMA]
Non-Executive_JJ
Director_NN
._.
Sir_NN
Deryck_NN
was_VBD
Albert_NN
Einstein_NN
College_NN
of_PIN
Medicine_NN
._.
appointed_VBN
an_DT
Executive_NN
Director_NN
of_PIN
formerly_TIME
Chairman_NN
and_PHC
Chief_NN
SmithKline_NN
Beecham_NN
plc_NN
in_PIN
1992_CD
,_,
and_ANDC
Executive_NN
officer_NN
of_PIN
Citigroup_NN
Sir_NN
Robert_NN
Wilson_NN
Aged_VBD
61_CD
Other_JJ
Directors_NN
became_VBD
Chief_NN
Executive_NN
officer_NN
in_PIN
April_NN
International_NN
and_CC
of_PIN
Salomon_NN
Brothers_NN
Appointed_VBN [WZPAST]
on_PIN
1_CD
November_NN
2003_CD
Dr_NN
Michle_NN
Barzach_NN
,_,
Mr_NN
Donald_NN
2000_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_NN
Director_NN
Inc._NN
._.
He_TPP3
serves_VPRT
on_PIN
the_DT
Boards_NN
of_PIN
Non-Executive_NN
Director_NN
._.
Sir_NN
Robert_NN
is_VPRT
McHenry_NN
and_PHC
Mr_NN
John_NN
McArthur_NN
,_,
all_QUAN
of_PIN
United_NN
Technologies_NN
Corporation_NOMZ
Directors_NN
of_PIN
Carnegie_NN
Hall_NN
,_,
Lincoln_NN
Non-Executive_NN
Chairman_NN
of_PIN
BG_NN
Group_NN
Non-Executive_NN
Directors_NN
,_,
retired_VBN [PASTP]
from_PIN
and_CC
a_DT
member_NN
of_PIN
the_DT
Board_NN
of_PIN
Trustees_NN
Center_NN
and_PHC
NYU_NN
Medical_NN
Center_NN
._.
He_TPP3
is_VPRT
plc_NN
and_CC
the_DT
Economist_NN
Group_NN
and_CC
was_VBD [BEMA]
the_DT
Board_NN
following_VBG [WZPRES]
the_DT
conclusion_NN
of_PIN
of_PIN
the_DT
Eisenhower_NN
Exchange_NN
Fellowships_NN
._.
also_RB
an_DT
International_NN
Advisory_NN
Board_NN
previously_TIME
Executive_NN
Chairman_NN
of_PIN
Rio_NN
the_DT
AGM_NN
on_PIN
17_CD
May_POMD
2004_CD
and_CC
Sir_NN
He_TPP3
holds_VPRT [PRIV]
a_DT
PhD_NN
in_PIN
pharmacology_NN
from_PIN
member_NN
of_PIN
British_JJ
American_NN
Business_NOMZ
Tinto_NN
plc._NN
._.
Christopher_NN
Hogg_NN
the_DT
former_JJ
the_DT
University_NOMZ
of_PIN
Louis_NN
Pasteur_NN
in_PIN
Inc._NN
and_CC
a_DT
Board_NN
member_NN
of_PIN
the_DT
Chairman_NN
and_PHC
Sir_NN
Peter_NN
Job_NN
,_,
both_DT
Dr_NN
Tachi_NN
Yamada_NN
Aged_VBD
59_CD
France_NN
and_CC
an_DT
MBA_NN
from_PIN
Stanford_NN
American_NN
Academy_NN
in_PIN
Berlin_NN
and_CC
the_DT
Non-Executive_JJ
Directors_NN
,_,
retired_VBN [PASTP]
from_PIN
Appointed_VBN
on_PIN
1_CD
January_NN
2004_CD
University_NOMZ
in_PIN
the_DT
US_FPP1
._.
He_TPP3
served_VBD
as_IN
the_DT
Board_NN
on_PIN
31_CD
December_NN
2004_CD
._.
Vice_NN
Chairman_NN
of_PIN
the_DT
New_NN
York_NN
Stock_NN
John_NN
Coombe_NN
Aged_VBD
59_CD
Dr_NN
Yamada_NN
was_VBD [BEMA]
a_DT
Non-Executive_NN
Exchange_NN
from_PIN
1996_CD
to_PIN
2000_CD
._.
Details_NN
of_PIN
membership_NN
of_PIN
the_DT
Board_NN
Appointed_VBN
23_CD
May_POMD
2000_CD
._.
Retiring_GER
Director_NN
,_,
and_ANDC
subsequently_TIME
an_DT
Executive_NN
Committees_NN
may_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
on_PIN
31_CD
March_NN
2005_CD
._.
Sir_NN
Ian_NN
Prosser_NN
Aged_VBD
61_CD
Director_NN
,_,
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
Mr_NN
Coombe_NN
Appointed_VBN [WZPAST]
on_PIN
23_CD
May_POMD
2000_CD
Prior_RB
to_TO
joining_VBG
SmithKline_NN
Beecham_NN
he_TPP3
was_VBD [BEMA]
formerly_TIME
an_DT
Executive_NN
Director_NN
of_PIN
Senior_NN
Independent_NN
Director_NN
._.
Sir_NN
Ian_NN
was_VBD
Chairman_NN
of_PIN
the_DT
Department_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
where_RB
he_TPP3
was_VBD [PASS]
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
Internal_NN
Medicine_NN
at_PIN
the_DT
University_NOMZ
of_PIN
responsible_JJ
for_PIN
Finance_NN
and_PHC
Investor_NN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
was_VBD
Michigan_NN
Medical_NN
School_NN
and_PHC
Relations_NOMZ
._.
He_TPP3
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Chairman_NN
and_PHC
Chief_NN
Executive_NN
of_PIN
Bass_NN
Physician-in-Chief_NN
of_PIN
the_DT
University_NOMZ
of_PIN
Supervisory_NN
Board_NN
of_PIN
Siemens_NN
AG_NN
and_PHC
PLC_NN
latterly_RB
Intercontinental_NN
Hotels_NN
Michigan_NN
Medical_NN
Center_NN
._.
He_TPP3
was_VBD [BEMA]
a_DT
the_DT
Code_NN
Committee_NN
of_PIN
the_DT
UK_NN
PLC_NN
and_PHC
Chairman_NN
of_PIN
the_DT
World_NN
Travel_NN
member_NN
of_PIN
the_DT
Board_NN
of_PIN
Directors_NN
of_PIN
Takeover_NN
Panel_NN
and_CC
was_VBD [PASS]
appointed_VBN
a_DT
&_CC
Tourism_NN
Council_NN
._.
He_TPP3
is_VPRT
NondiaDexus_NN
,_,
Inc._NN
until_IN
December_NN
2004_CD
Non-Executive_NN
Director_NN
of_PIN
HSBC_NN
Executive_NN
Deputy_NN
Chairman_NN
of_PIN
BP_NN
plc_NN
and_CC
is_VPRT [BEMA]
a_DT
Trustee_NN
of_PIN
the_DT
Rockefeller_NN
Holdings_GER
plc_NN
on_PIN
1_CD
March_NN
2005_CD
._.
and_ANDC
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Sara_NN
Brothers_NN
Fund_NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
member_NN
Lawrence_NN
Culp_NN
Aged_VBD
41_CD
of_PIN
the_DT
CBI_NN
Presidents_NN
Committee_NN
._.
Corporate_JJ
Appointed_VBN
on_PIN
1_CD
July_NN
2003_CD
Audit_NN
Remuneration_NOMZ
Nominations_NOMZ
Responsibility_NOMZ
Non-Executive_NN
Director_NN
._.
Mr_NN
Culp_NN
is_VPRT
Dr_NN
Ronaldo_NN
Schmitz_NN
Aged_VBD
66_CD
Sir_NN
Christopher_NN
Gent_NN
C_NN
C_NN
President_NN
and_PHC
Chief_NN
Executive_NN
officer_NN
Appointed_VBN [WZPAST]
on_PIN
23_CD
May_POMD
2000_CD
Mr_NN
L_NN
Culp_NN
M_NN [BEMA]
of_PIN
Danaher_NN
Corporation_NOMZ
._.
Dr_NN
Schmitz_NN
Sir_NN
Crispin_NN
Davis_NN
M_NN
joining_VBG [WZPRES]
Danaher_NN
,_,
he_TPP3
held_VBD [PRIV]
positions_NOMZ
in_PIN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
Sir_NN
Deryck_NN
Maughan_NN
M_NN
Accenture_NN
,_,
previously_TIME
Andersen_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
NonSir_NN
Ian_NN
Prosser_NN
M_NN
M_NN
M_NN
Consulting_GER
._.
Executive_NN
Director_NN
of_PIN
Legal_NN
&_CC
General_NN
Dr_NN
R_NN
Schmitz_NN
C_NN
M_NN
Group_NN
plc_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Boards_NN
Dr_NN
L_NN
Shapiro_NN
M_NN [BEMA]
of_PIN
Directors_NN
of_PIN
Rohm_NN
and_PHC
Haas_NN
Sir_NN
Robert_NN
Wilson_NN
M_NN
C_NN
Company_NN
and_PHC
Cabot_NN
Corporation_NOMZ
._.
In_CONJ
addition_NULL
,_,
each_QUAN
Director_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Corporate_NN
Administration_NOMZ
&_CC
Transactions_NOMZ
and_CC
Financial_JJ
Results_NN
Committees_NN
._.
18_CD
18_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
THE_DT
CORPORATE_JJ
EXECUTIVE_NN
TEAM_NN
The_DT
executive_NN
management_NOMZ
of_PIN
the_DT
Group_NN
is_VPRT [BEMA]
through_PIN
the_DT
Corporate_NN
Executive_NN
Team_NN
CET_NN
,_,
comprising_VBG [PRESP]
the_DT
Chief_NN
Executive_NN
officer_NN
,_,
the_DT
Chief_NN
Financial_NN
officer_NN
and_CC
other_JJ
senior_JJ
managers_NN
._.
JP_NN
Garnier_NN
Rupert_NN
Bondy_NN
Ford_NN
Calhoun_NN
John_NN
Coombe_NN
Marc_NN
Dunoyer_NN
Russell_NN
Greig_NN
Dan_NN
Phelan_NN
David_NN
Pulman_NN
David_NN
Stout_NN
Chris_NN
Viehbacher_NN
Andrew_NN
Witty_NN
Tachi_NN
Yamada_NN
Jennie_NN
Younger_NN
Jack_NN
Ziegler_NN
JP_NN
Garnier_NN
Marc_NN
Dunoyer_NN
David_NN
Stout_NN
Jennie_NN
Younger_NN
Chief_NN
Executive_NN
officer_NN
President_NN
President_NN
Senior_NN
Vice_NN
President_NN
As_IN
Chief_NN
Executive_NN
officer_NN
,_,
JP_NN
is_VPRT
Pharmaceuticals_NN
Japan_NN
Pharmaceutical_NN
Operations_NOMZ
Corporate_NN
Communications_NOMZ
responsible_JJ
for_PIN
the_DT
management_NOMZ
of_PIN
Marc_NN
was_VBD [PASS]
appointed_VBN
President_NN
,_,
David_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
global_JJ
&_CC
Community_NOMZ
Partnerships_NN
the_DT
Group_NN
._.
He_TPP3
oversees_VPRT
all_QUAN
operational_JJ
Pharmaceuticals_NN
Japan_NN
in_PIN
March_NN
2003_CD
._.
pharmaceuticals_NN
and_PHC
vaccines_NN
Jennie_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
aspects_NN
including_VBG [WZPRES]
establishing_VBG [PRIV]
policies_NN
,_,
He_TPP3
joined_VBD
the_DT
Group_NN
in_PIN
1999_CD
and_CC
was_VBD
businesses_NOMZ
._.
He_TPP3
joined_VBD
SmithKline_NN
internal_JJ
and_PHC
external_JJ
communications_NOMZ
,_,
objectives_NN
and_PHC
initiatives_NN
,_,
and_ANDC
he_TPP3
Senior_JJ
Vice_NN
President_NN
and_PHC
Regional_NN
Beecham_NN
in_PIN
1996_CD
as_IN
head_NN
of_PIN
its_PIT
US_FPP1
its_PIT
image_NN
and_PHC
partnerships_NN
with_PIN
global_JJ
directs_VPRT
long-term_JJ
strategy_NN
._.
He_TPP3
was_VBD
Director_NN
,_,
Japan_NN
until_IN
his_TPP3
current_JJ
Sales_NN
and_PHC
Marketing_GER
,_,
and_ANDC
was_VBD
communities_NOMZ
._.
She_TPP3
joined_VBD
Glaxo_NN
formerly_TIME
Chief_NN
Executive_NN
officer_NN
of_PIN
appointment_NOMZ
._.
President_NN
US_FPP1
Pharmaceuticals_NN
until_IN
his_TPP3
Wellcome_NN
in_PIN
1996_CD
as_IN
Director_NN
of_PIN
SmithKline_NN
Beecham_NN
,_,
having_VBG [PEAS]
joined_VBN
current_JJ
appointment_NOMZ
in_PIN
January_NN
2003_CD
._.
Investor_NN
Relations_NOMZ
and_CC
was_VBD [PASS]
appointed_VBN
Russell_NN
Greig_NN
the_DT
Group_NN
in_PIN
1990_CD
._.
to_PIN
her_TPP3
current_JJ
position_NOMZ
in_PIN
2001_CD
._.
In_PIN
President_NN
Chris_NN
Viehbacher_NN
2004_CD
,_,
she_TPP3
won_VBD
the_DT
European_JJ
Women_NN
Rupert_NN
Bondy_NN
Pharmaceuticals_NN
International_NN
President_NN
of_PIN
Achievement_NOMZ
Award_NN
for_PIN
Business_NOMZ
._.
Senior_JJ
Vice_NN
President_NN
and_PHC
General_NN
Russell_NN
leads_VPRT
the_DT
pharmaceutical_JJ
US_FPP1
Pharmaceuticals_NN
Counsel_NN
operations_NOMZ
outside_PLACE
the_DT
US_FPP1
and_CC
most_EMPH
Chris_NN
has_VPRT [PEAS]
been_VBN [BEMA]
responsible_PRED
for_PIN
US_FPP1
Jack_NN
Ziegler_NN
Rupert_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
legal_JJ
matters_NN
of_PIN
Europe_NN
,_,
covering_VBG
more_EMPH
than_PIN
100_CD
Pharmaceuticals_NN
since_OSUB
January_NN
2003_CD
._.
President_NN
across_PLACE
the_DT
Group_NN
,_,
together_RB
with_PIN
countries_NN
._.
He_TPP3
joined_VBD
the_DT
Group_NN
in_PIN
He_TPP3
joined_VBD
Wellcome_NN
in_PIN
1988_CD
and_CC
Consumer_NN
Healthcare_NN
environmental_JJ
,_,
health_NN
and_PHC
safety_NN
1980_CD
and_CC
was_VBD [BEMA]
Senior_JJ
Vice_NN
President_NN
,_,
became_VBD
Director_NN
,_,
Continental_NN
Europe_NN
,_,
Jack_NN
is_VPRT
head_NN
of_PIN
the_DT
global_JJ
Consumer_NN
issues_NN
,_,
insurance_NN
and_PHC
security_NOMZ
._.
He_TPP3
was_VBD
Worldwide_NN
Business_NOMZ
Development_NOMZ
for_PIN
at_PIN
Glaxo_NN
Wellcome_NN
in_PIN
1999_CD
._.
He_TPP3
was_VBD
Healthcare_NN
business_NOMZ
,_,
which_WDT [SERE]
produces_VPRT
a_DT
lawyer_NN
in_PIN
private_JJ
practice_NN
before_IN
R&D_NN
prior_RB
to_PIN
his_TPP3
current_JJ
appointment_NOMZ
responsible_JJ
for_PIN
GSKs_NN
European_NN
oral_JJ
healthcare_NN
,_,
over-the-counter_JJ
joining_VBG
SmithKline_NN
Beecham_NN
in_PIN
1995_CD
._.
in_PIN
March_NN
2003_CD
._.
Pharmaceuticals_NN
business_NOMZ
before_IN
his_TPP3
medicines_NN
and_CC
nutritional_JJ
healthcare_NN
current_JJ
appointment_NOMZ
._.
He_TPP3
joined_VBD
SmithKline_NN
Ford_NN
Calhoun_NN
Dan_NN
Phelan_NN
Beecham_NN
in_PIN
1991_CD
and_CC
in_PIN
1998_CD
was_VBD
Chief_NN
Information_NOMZ
officer_NN
Senior_JJ
Vice_NN
President_NN
Andrew_NN
Witty_NN
appointed_VBD
President_NN
of_PIN
the_DT
Consumer_NN
Ford_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
information_NOMZ
Human_NN
Resources_NN
President_NN
Healthcare_NN
business_NOMZ
._.
technology_NN
,_,
a_DT
global_JJ
function_NOMZ
that_TOBJ
Dan_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
benets_NN
,_,
Pharmaceuticals_NN
Europe_NN
enables_VPRT
key_JJ
business_NOMZ
processes_VPRT
across_PLACE
compensation_NOMZ
,_,
recruitment_NOMZ
,_,
Andrew_NN
has_VPRT [PEAS]
been_VBN [BEMA]
responsible_PRED
for_PIN
the_DT
Julian_NN
Heslop_NN
all_QUAN
parts_NN
of_PIN
the_DT
Group_NN
._.
With_PIN
doctoral_JJ
organization_NOMZ
development_NOMZ
,_,
leadership_NN
Groups_NN
pharmaceuticals_NN
operations_NOMZ
in_PIN
Chief_NN
Financial_NN
officer_NN
Designate_NN
and_CC
post-doctoral_JJ
training_GER
in_PIN
development_NOMZ
and_PHC
succession_NN
planning_GER
,_,
Europe_NN
since_OSUB
January_NN
2003_CD
._.
He_TPP3
joined_VBD
Julian_NN
Heslop_NN
will_PRMD
succeed_VB
John_NN
microbiology_NN
,_,
genetics_NN
,_,
human_JJ
resource_NN
information_NOMZ
systems_NN
Glaxo_NN
in_PIN
1985_CD
and_CC
at_PIN
GSK_NN
was_VBD [BEMA]
Senior_JJ
Coombe_NN
as_IN
Chief_NN
Financial_NN
officer_NN
with_PIN
biomathematics_NN
and_PHC
computer_NN
and_PHC
employee_NN
health_NN
management_NOMZ
._.
Vice_NN
President_NN
,_,
Asia_NN
Pacic_NN
,_,
until_IN
his_TPP3
effect_NN
from_PIN
1_CD
April_NN
2005_CD
when_RB
he_TPP3
will_PRMD
science_NN
,_,
he_TPP3
joined_VBD
Smith_NN
Kline_NN
&_CC
He_TPP3
was_VBD [BEMA]
a_DT
lawyer_NN
in_PIN
private_JJ
practice_NN
,_,
current_JJ
appointment_NOMZ
._.
Julian_NN
joined_VBD
Glaxo_NN
French_NN
in_PIN
1984_CD
._.
before_IN
joining_VBG
Smith_NN
Kline_NN
&_CC
French_NN
in_PIN
Wellcome_NN
as_IN
Financial_NN
Controller_NN
in_PIN
Tachi_NN
Yamada_NN
1981_CD
and_CC
in_PIN
1994_CD
was_VBD [PASS]
appointed_VBN
April_NN
1998_CD
._.
Following_VBG
completion_NOMZ
of_PIN
John_NN
Coombe_NN
Chairman_NN
Senior_NN
Vice_NN
President_NN
and_PHC
Director_NN
,_,
the_DT
merger_NN
he_TPP3
was_VBD [PASS]
appointed_VBN
Senior_JJ
Chief_NN
Financial_NN
officer_NN
Research_NN
&_CC
Development_NOMZ
Human_NN
Resources_NN
,_,
SmithKline_NN
Vice_NN
President_NN
,_,
Operations_NOMZ
Controller_NN
._.
retiring_VBG [PRESP]
on_PIN
31_CD
March_NN
2005_CD
Tachi_NN
leads_VPRT
the_DT
Groups_NN
complex_JJ
Beecham_NN
._.
As_IN
head_NN
of_PIN
the_DT
finance_NN
function_NOMZ
,_,
business_NOMZ
of_PIN
drug_NN
discovery_NN
and_CC
Other_JJ
members_NN
John_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
activities_NOMZ
such_JJ
David_NN
Pulman_NN
development_NOMZ
,_,
creating_VBG
new_JJ
medicines_NN
Robert_NN
Ingram_NN
continues_VPRT
to_TO
work_VB
partas_NN
financial_JJ
reporting_GER
and_PHC
control_NN
,_,
President_NN
through_PIN
research_NN
._.
He_TPP3
joined_VBD
time_NN
as_IN
Vice_NN
Chairman_NN
of_PIN
tax_NN
and_PHC
treasury_NN
,_,
investor_NN
relations_NOMZ
,_,
Global_JJ
Manufacturing_GER
&_CC
Supply_NN
SmithKline_NN
Beecham_NN
in_PIN
1994_CD
as_IN
a_DT
NonPharmaceuticals_NN
,_,
acting_VBG
as_IN
a_DT
special_JJ
finance_NN
systems_NN
,_,
internal_JJ
audit_NN
and_PHC
David_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Global_NN
Executive_NN
member_NN
of_PIN
the_DT
Board_NN
and_PHC
advisor_NN
to_PIN
the_DT
Group_NN
,_,
and_ANDC
attends_VPRT
CET_NN
real_JJ
estate_NN
._.
He_TPP3
joined_VBD
Glaxo_NN
in_PIN
1986_CD
Manufacturing_GER
and_PHC
Supply_NN
became_VBD
Chairman_NN
,_,
R&D_NN
,_,
meetings_GER
in_PIN
that_DEMO
capacity_NOMZ
._.
as_IN
Group_NN
Financial_NN
Controller_NN
and_CC
was_VBD
organization_NOMZ
and_CC
Global_JJ
Procurement_NOMZ
._.
He_TPP3
was_VBD [PASS]
appointed_VBN
Group_NN
Finance_NN
Director_NN
He_TPP3
joined_VBD
Glaxo_NN
in_PIN
1978_CD
and_CC
was_VBD [PASS]
appointed_VBN
to_PIN
the_DT
Board_NN
of_PIN
Directors_NN
on_PIN
in_PIN
1992_CD
._.
responsible_JJ
for_PIN
the_DT
North_PLACE
American_JJ
1_CD
January_NN
2004_CD
._.
supply_NN
network_NN
,_,
manufacturing_VBG
strategy_NN
and_PHC
logistics_NN
until_IN
his_TPP3
current_JJ
appointment_NOMZ
in_PIN
2002_CD
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
19_CD
19_CD
SUMMARY_NN
REMUNERATION_NOMZ
REPORT_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
Overall_JJ
,_,
the_DT
policy_NN
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
provide_VB
median_JJ
total_JJ
remuneration_NOMZ
for_PIN
Introduction_NOMZ
median_NN
performance_NN
._.
Poor_NN
performance_NN
will_PRMD
result_VB
in_PIN
total_JJ
remuneration_NOMZ
signicantly_RB
below_PLACE
the_DT
pay_NN
comparator_NN
group_NN
median_NN
,_,
with_PIN
the_DT
opportunity_NOMZ
The_DT
Summary_NN
Remuneration_NOMZ
Report_NN
sets_VPRT
out_PIN
the_DT
annual_JJ
remuneration_NOMZ
to_TO
earn_VB
upper_JJ
quartile_JJ
total_JJ
remuneration_NOMZ
for_PIN
exceptional_JJ
performance_NN
._.
of_PIN
the_DT
Board_NN
earned_VBD
in_PIN
2004_CD
,_,
together_RB
with_PIN
any_QUAN
gains_NN
under_IN
long-term_JJ
incentive_NN
arrangements_NOMZ
._.
It_PIT
also_RB
describes_VPRT
the_DT
background_NN
and_CC
outlines_VPRT
the_DT
This_DEMO
strong_JJ
alignment_NOMZ
with_PIN
performance_NN
is_VPRT [BEMA]
demonstrably_RB
in_PIN
the_DT
interests_NN
of_PIN
Groups_NN
remuneration_VPRT
policy_NN
,_,
together_RB
with_PIN
the_DT
performance_NN
graph_NN
required_VBN [SUAV]
shareholders_NN
and_CC
provides_VPRT
the_DT
Executives_NN
with_PIN
unambiguous_JJ
signals_NN
about_IN
by_PIN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
the_DT
Regulations_NOMZ
._.
the_DT
importance_NN
of_PIN
delivering_VBG
success_NN
to_PIN
the_DT
Companys_NN
shareholders_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
the_DT
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
making_VBG
COMMITMENT_NOMZ
recommendations_NOMZ
to_PIN
the_DT
Board_NN
on_PIN
the_DT
Companys_NN
remuneration_NOMZ
policy_NN
and_CC
,_,
The_DT
Committee_NN
will_PRMD
apply_VB
this_DEMO
policy_NN
on_PIN
a_DT
consistent_JJ
and_PHC
transparent_JJ
basis_NN
._.
within_PIN
the_DT
terms_NN
of_PIN
the_DT
agreed_JJ
policy_NN
,_,
determining_VBG [SUAV] [PRIV] [PRESP]
the_DT
total_JJ
individual_JJ
Any_QUAN
significant_JJ
change_NN
will_PRMD
be_VB [PASS]
discussed_VBN
with_PIN
shareholders_NN
in_PIN
advance_NN
of_PIN
remuneration_NOMZ
packages_NN
of_PIN
the_DT
Executive_NN
Directors_NN
and_PHC
members_NN
of_PIN
the_DT
implementation_NOMZ
._.
The_DT
members_NN
of_PIN
the_DT
Committee_NN
are_VPRT [PASS]
set_VBN
out_PIN
on_PIN
page_NN
18_CD
._.
PAY_NN
AND_PHC
PERFORMANCE_NN
COMPARATORS_NN
The_DT
Committee_NN
has_VPRT [PEAS]
developed_VBN
the_DT
remuneration_NOMZ
policy_NN
to_TO
align_VB
executive_JJ
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
companies_NN
used_VBN [WZPAST]
for_PIN
pay_NN
and_PHC
performance_NN
remuneration_NOMZ
with_PIN
the_DT
interests_NN
of_PIN
shareholders_NN
whilst_OSUB
meeting_VBG
the_DT
comparison_NN
:_:
imperative_NN
of_PIN
recruiting_GER
and_CC
retaining_VBG
the_DT
executive_NN
talent_NN
essential_JJ
to_PIN
the_DT
Market_NN
leadership_NN
of_PIN
the_DT
Company_NN
._.
Capitalisation_NOMZ
31.12.04_CD
Company_NN
Country_NN
m_NN [BEMA]
The_DT
remuneration_NOMZ
policy_NN
was_VBD [PASS]
nalised_VBN
after_IN
undertaking_VBG
an_DT
extensive_JJ
consultation_NOMZ
process_NN
with_PIN
shareholders_NN
and_CC
institutional_JJ
bodies_NN
during_PIN
the_DT
Abbott_NN
Laboratories_NN
US_FPP1
37,840_CD
course_NN
of_PIN
2003_CD
and_CC
2004_CD
._.
AstraZeneca_NN
UK_NN
31,075_CD
Bristol-Myers_NN
Squibb_NN
US_FPP1
25,962_CD
The_DT
remuneration_NOMZ
policy_NN
is_VPRT [PASS]
designed_VBN
to_TO
establish_VB [PRIV]
a_DT
framework_NN
for_PIN
Eli_NN
Lilly_NN
US_FPP1
33,448_CD
remuneration_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
Companys_NN
scale_NN
and_PHC
scope_NN
of_PIN
GlaxoSmithKline_NN
UK_NN
71,704_CD
operations_NOMZ
,_,
meets_VPRT
the_DT
recruitment_NOMZ
needs_NN
of_PIN
the_DT
business_NOMZ
and_CC
is_VPRT
closely_RB
Johnson_NN
&_CC
Johnson_NN
US_FPP1
98,028_CD
aligned_VBN
with_PIN
shareholder_NN
guidelines_NN
._.
Merck_NN
US_FPP1
37,123_CD
Novartis_NN
Switzerland_NN
70,077_CD
Deloitte_NN
&_CC
Touche_NN
LLP_NN
have_VPRT [PEAS]
been_VBN [BYPA]
appointed_VBN
by_PIN
the_DT
Committee_NN
to_TO
provide_VB
it_PIT
Pzer_NN
US_FPP1
105,473_CD
with_PIN
independent_JJ
advice_NN
on_PIN
executive_NN
remuneration_NOMZ
._.
Roche_NN
Holdings_GER
Switzerland_NN
42,122_CD
Sano-Aventis_NN
France_NN
57,954_CD
Schering-Plough_NN
US_FPP1
16,016_CD
Remuneration_NOMZ
policy_NN
Takeda_NN
Pharmaceutical_NN
Company_NN
Japan_NN
23,323_CD
Wyeth_NN
US_FPP1
29,596_CD
PRINCIPLES_NN
The_NN
Committee_NN
has_VPRT [PEAS]
established_VBN [PRIV]
four_CD
core_NN
principles_NN
which_WDT [WHSUB]
underpin_VPRT
the_DT
The_DT
merger_NN
of_PIN
Aventis_NN
and_PHC
Sano-Synthelabo_NN
during_PIN
2004_CD
reduced_VBD
the_DT
new_JJ
remuneration_NOMZ
policy_NN
for_PIN
GSK_NN
._.
These_DEMP
are_VPRT
:_:
size_NN
of_PIN
the_DT
comparator_NN
group_NN
to_PIN
13_CD
companies_NN
and_PHC
GSK_NN
._.
The_DT
Committee_NN
subsequently_TIME
determined_VBD [SUAV] [PRIV]
that_THVC
for_PIN
a_DT
number_NN
of_PIN
reasons_NN
,_,
including_VBG
focus_NN
of_PIN
securing_VBG
outstanding_JJ
executive_NN
talent_NN
:_:
operation_NOMZ
and_PHC
market_NN
capitalization_NOMZ
,_,
there_EX
was_VBD
no_SYNE
other_JJ
suitable_JJ
company_NN
pay_NN
for_PIN
performance_NN
and_CC
only_DWNT
for_PIN
performance_NN
:_:
to_TO
add_VB [PUBV]
to_PIN
the_DT
group_NN
._.
robust_JJ
and_PHC
transparent_JJ
governance_NN
structures_NN
:_:
and_ANDC
a_DT
commitment_NOMZ
to_TO
be_VB [BEMA]
a_DT
leader_NN
of_PIN
good_JJ
remuneration_NOMZ
practice_NN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
In_PIN
formulating_VBG
the_DT
policy_NN
,_,
the_DT
Committee_NN
decided_VBD [SUAV] [PRIV] [THATD]
that_DEMP
:_:
the_DT
remuneration_NOMZ
structure_NN
must_NEMD
support_VB
the_DT
business_NOMZ
in_PIN
a_DT
very_AMP
competitive_JJ
market_NN
place_NN
:_:
UK_NN
shareholder_NN
guidelines_NN
will_PRMD
be_VB [PASS]
followed_VBN
to_PIN
the_DT
maximum_NN
extent_NN
consistent_JJ
with_PIN
the_DT
needs_NN
of_PIN
the_DT
business_NOMZ
and_CC
the_DT
Company_NN
would_PRMD
maintain_VB [PUBV]
a_DT
regular_JJ
dialogue_NN
with_PIN
shareholders_NN
:_:
global_JJ
pharmaceutical_JJ
companies_NN
are_VPRT [BEMA]
the_DT
primary_JJ
pay_NN
comparator_NN
group_NN
:_:
performance_NN
conditions_NOMZ
would_PRMD
be_VB [PASS]
based_VBN
on_PIN
the_DT
measurable_JJ
delivery_NN
of_PIN
strong_JJ
financial_JJ
performance_NN
and_CC
the_DT
delivery_NN
of_PIN
superior_JJ
returns_NN
to_PIN
shareholders_NN
as_IN
compared_VBN
with_PIN
other_JJ
pharmaceutical_JJ
companies_NN
:_:
a_DT
high_JJ
proportion_NOMZ
of_PIN
the_DT
total_JJ
remuneration_NOMZ
opportunity_NOMZ
will_PRMD
be_VB [PASS]
based_VBN
on_PIN
performance-related_JJ
remuneration_NOMZ
,_,
which_WDT [SERE]
will_PRMD
be_VB [PASS]
delivered_VBN
over_IN
the_DT
medium-term_JJ
to_PIN
long-term_JJ
:_:
and_ANDC
no_SYNE
ex-gratia_NN
payments_NOMZ
will_PRMD
be_VB [PASS]
made_VBN
._.
20_CD
20_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
SUMMARY_NN
REMUNERATION_NOMZ
REPORT_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
GSKS_NN
EXECUTIVE_NN
REMUNERATION_NOMZ
CONSISTS_NN
OF_PIN
THE_DT
FOLLOWING_VBG
Performance_NN
is_VPRT [PASS]
measured_VBN
over_IN
the_DT
three_CD
financial_JJ
years_NN
following_VBG [WZPRES]
the_DT
COMPONENTS_NN
:_:
grant_NN
of_PIN
an_DT
option_NOMZ
._.
The_DT
Committee_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
for_PIN
the_DT
2004_CD
grant_NN
that_THVC
there_EX
will_PRMD
be_VB
no_SYNE
performance_NN
retesting_GER
,_,
so_RB
if_COND
the_DT
performance_NN
condition_NOMZ
is_VPRT
BASE_NN
SALARY_NN
not_XX0
met_VBD
after_IN
the_DT
three-year_JJ
period_NN
,_,
the_DT
option_NOMZ
will_PRMD
lapse_NN
._.
Base_NN
salaries_NN
will_PRMD
be_VB [BYPA]
set_VBN
by_PIN
reference_NN
to_PIN
the_DT
median_NN
for_PIN
the_DT
relevant_JJ
market_NN
._.
For_PIN
Executives_NN
this_DEMP
is_VPRT [BEMA]
the_DT
pharmaceutical_JJ
pay_NN
comparator_NN
group_NN
._.
Base_NN
salary_NN
The_DT
performance_NN
criteria_NN
relating_VBG [WZPRES]
to_PIN
performance_NN
shares_NN
and_PHC
share_NN
options_NOMZ
is_VPRT [BEMA]
the_DT
only_DWNT
element_NOMZ
of_PIN
remuneration_NOMZ
that_DEMP
is_VPRT [PASS]
xed_VBN
._.
awarded_VBN
and_PHC
granted_VBN [SUAV]
prior_RB
to_PIN
2004_CD
are_VPRT [PASS]
given_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
2004_CD
._.
ANNUAL_JJ
BONUS_NN
PENSIONS_NN
All_QUAN
bonuses_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
on_PIN
the_DT
basis_NN
of_PIN
a_DT
formal_JJ
review_NN
of_PIN
annual_JJ
The_DT
Executives_NN
participate_VB
in_PIN
GSK_NN
senior_JJ
executive_NN
pension_NN
plans_NN
._.
The_DT
performance_NN
against_PIN
stretching_VBG
financial_JJ
targets_NN
based_VBN [WZPAST]
on_PIN
profit_NN
before_IN
pension_NN
arrangements_NOMZ
are_VPRT [PASS]
structured_VBN
in_PIN
accordance_NN
with_PIN
the_DT
plans_NN
operated_VBD
interest_NN
and_PHC
tax_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_PIN
detailed_JJ
assessment_NOMZ
of_PIN
individual_JJ
,_,
for_PIN
Executives_NN
in_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
Executives_NN
are_VPRT [BEMA]
likely_PRED
to_TO
retire_VB
._.
business_NOMZ
unit_NN
and_PHC
group_NN
achievements_NOMZ
against_PIN
objectives_NN
._.
Benets_NN
are_VPRT [BEMA]
normally_RB
payable_PRED
at_PIN
age_NN
60_CD
,_,
although_CONC
it_PIT
has_VPRT [PEAS]
been_VBN [PASS]
agreed_VBN [SUAV] [PUBV]
that_THVC
Dr_NN
Yamada_NN
will_PRMD
retire_VB
at_PIN
age_NN
62_CD
._.
In_PIN
setting_VBG
the_DT
bonus_NN
awards_NN
for_PIN
2004_CD
,_,
the_DT
Committee_NN
took_VBD
into_PIN
account_NN
the_DT
achievement_NOMZ
of_PIN
management_NOMZ
in_PIN
maintaining_VBG [PUBV]
growth_NN
on_PIN
a_DT
CER_NN
basis_NN
,_,
whilst_OSUB
absorbing_VBG
1.5_CD
billion_CD
of_PIN
lost_VBN
sales_NN
to_PIN
generics_NN
._.
Executive_NN
Director_NN
terms_NN
and_CC
LONG-TERM_JJ
INCENTIVES_NN
conditions_NOMZ
The_DT
remuneration_NOMZ
policy_NN
provides_VPRT
that_DEMO
annual_JJ
long-term_JJ
incentive_NN
awards_NN
will_PRMD [SPAU]
normally_RB
be_VB [PASS]
made_VBN
up_IN
of_PIN
a_DT
performance_NN
share_NN
award_NN
and_CC
a_DT
share_NN
option_NOMZ
The_DT
policy_NN
regarding_VBG [WZPRES]
the_DT
Executive_NN
Directors_NN
contracts_NN
was_VBD [BEMA]
the_DT
subject_JJ
award_NN
._.
The_DT
remuneration_NOMZ
policy_NN
places_NN
greater_JJ
emphasis_NN
on_PIN
the_DT
use_NN
of_PIN
of_PIN
extensive_JJ
review_NN
and_PHC
change_NN
during_PIN
2003_CD
._.
This_DEMP
resulted_VBD
in_PIN
a_DT
new_JJ
performance_NN
shares_NN
rather_RB
than_PIN
share_NN
options_NOMZ
._.
framework_NN
for_PIN
contracts_NN
for_PIN
Executive_NN
Directors_NN
appointed_VBN [WZPAST]
in_PIN
the_DT
future_NN
._.
The_DT
Committee_NN
has_VPRT [PEAS]
considered_VBN [PRIV]
which_WDT [WHCL]
performance_NN
conditions_NOMZ
should_NEMD
be_VB
Dr_NN
Garnier_NN
,_,
Mr_NN
Coombe_NN
and_PHC
Dr_NN
Yamada_NN
agreed_VBD [SUAV] [PUBV]
to_PIN
changes_NN
in_PIN
their_TPP3
applied_VBN
to_PIN
the_DT
long-term_JJ
incentives_NN
._.
The_DT
Committee_NN
concluded_VBD [PRIV]
that_THVC
it_PIT
was_VBD [BEMA]
contractual_JJ
terms_NN
without_PIN
compensation_NOMZ
to_TO
bring_VB
their_TPP3
contractual_JJ
appropriate_JJ
to_TO
measure_VB
performance_NN
using_VBG [WZPRES]
a_DT
combination_NOMZ
of_PIN
absolute_JJ
terms_NN
broadly_RB
in_PIN
line_NN
with_PIN
the_DT
new_JJ
contractual_JJ
framework_NN
,_,
including_VBG [PRESP]
the_DT
financial_JJ
results_NN
based_VBN [WZPAST]
on_PIN
earnings_GER
per_PIN
share_NN
-_:
EPS_NN
and_CC
the_DT
delivery_NN
of_PIN
reduction_NOMZ
of_PIN
contractual_JJ
notice_NN
period_NN
from_PIN
24_CD
to_PIN
12_CD
calendar_NN
months_NN
._.
superior_JJ
value_NN
to_PIN
shareholders_NN
based_VBN [WZPAST]
on_PIN
Total_JJ
Shareholder_NN
Return_NN
-_:
TSR_NN
._.
However_CONJ
,_,
to_TO
honor_VB
certain_JJ
aspects_NN
of_PIN
their_TPP3
old_JJ
contractual_JJ
terms_NN
,_,
there_EX
are_VPRT
a_DT
number_NN
of_PIN
individual_JJ
features_NN
which_WDT [WHSUB]
will_PRMD
be_VB [PASS]
retained_VBN
._.
In_PIN
the_DT
event_NN
For_PIN
the_DT
Executives_NN
,_,
the_DT
level_NN
of_PIN
performance_NN
shares_NN
vesting_VBG [WZPRES]
is_VPRT [PASS]
based_VBN
on_PIN
of_PIN
early_TIME
termination_NOMZ
by_PIN
the_DT
Company_NN
,_,
Dr_NN
Garnier_NN
and_PHC
Dr_NN
Yamada_NN
would_PRMD
the_DT
Companys_NN
TSR_NN
relative_JJ
to_PIN
the_DT
performance_NN
comparator_NN
group_NN
over_IN
receive_VB
a_DT
cash_NN
sum_NN
equivalent_NN
to_PIN
the_DT
total_NN
of_PIN
their_TPP3
annual_JJ
salary_NN
,_,
on_PIN
target_NN
a_DT
three-year_JJ
measurement_NOMZ
period_NN
._.
In_PIN
respect_NN
of_PIN
the_DT
awards_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
bonus_NN
and_PHC
pension_NN
contributions_NOMZ
for_PIN
the_DT
12_CD
months_NN
notice_VPRT [PRIV]
period_NN
._.
2004_CD
,_,
if_COND
GSK_NN
is_VPRT [PASS]
ranked_VBN
at_PIN
position_NOMZ
7_CD
the_DT
mid-point_NN
of_PIN
the_DT
performance_NN
Mr_NN
Coombe_NN
will_PRMD
retire_VB
from_PIN
the_DT
company_NN
on_PIN
31_CD
March_NN
2005_CD
._.
comparator_NN
group_NN
,_,
35_CD
%_NN
of_PIN
the_DT
shares_NN
will_PRMD
vest_NN
and_ANDC
if_COND
it_PIT
is_VPRT
below_PLACE
that_DEMO
position_NOMZ
then_RB
none_INPR
of_PIN
the_DT
shares_NN
will_PRMD
vest_NN
._.
Only_DWNT
if_COND
GSK_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
top_JJ
two_CD
companies_NN
will_PRMD
all_QUAN
of_PIN
the_DT
shares_NN
vest_NN
._.
When_RB
determining_VBG [SUAV] [PRIV]
vesting_GER
levels_NN
,_,
the_DT
TSR_NN
PERFORMANCE_NN
GRAPH_NN
Committee_NN
will_PRMD
have_VB
regard_NN
for_PIN
the_DT
Companys_NN
underlying_VBG [WZPRES]
financial_JJ
The_DT
graph_NN
below_PLACE
sets_NN
out_PIN
the_DT
performance_NN
of_PIN
the_DT
Company_NN
relative_JJ
performance_NN
._.
to_PIN
the_DT
FTSE_NN
100_CD
index_NN
of_PIN
which_WDT [PIRE]
the_DT
Company_NN
is_VPRT [BEMA]
a_DT
constituent_NN
and_CC
,_,
for_PIN
information_NOMZ
,_,
to_PIN
the_DT
median_NN
of_PIN
the_DT
performance_NN
comparator_NN
group_NN
since_OSUB
The_DT
share_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
2004_CD
to_PIN
the_DT
Executives_NN
are_VPRT [PASS]
linked_VBN
to_PIN
the_DT
the_DT
merger_NN
on_PIN
27_CD
December_NN
2000_CD
._.
The_DT
graph_NN
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
achievement_NOMZ
of_PIN
compound_JJ
annual_JJ
EPS_NN
growth_NN
in_PIN
excess_NN
of_PIN
the_DT
Retail_NN
accordance_NN
with_PIN
the_DT
Regulations_NOMZ
and_CC
is_VPRT [BEMA]
not_XX0
an_DT
indication_NOMZ
of_PIN
the_DT
likely_JJ
Prices_NN
Index_NN
RPI_NN
over_IN
the_DT
performance_NN
period_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
three_CD
years_NN
vesting_VBG [WZPRES]
of_PIN
awards_NN
granted_VBN [SUAV]
under_IN
any_QUAN
of_PIN
the_DT
Companys_NN
incentive_NN
plans_NN
._.
following_VBG [PRESP]
the_DT
grant_NN
of_PIN
an_DT
option_NOMZ
._.
When_RB
setting_VBG
EPS_NN
targets_NN
,_,
the_DT
Committee_NN
considers_VPRT [PRIV]
the_DT
Companys_NN
internal_JJ
100_CD
projections_NOMZ
and_PHC
analysts_NN
forecasts_NN
for_PIN
GSKs_NN
EPS_NN
performance_NN
,_,
as_RB
well_RB
as_IN
analysts_NN
forecasts_NN
for_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
90_CD
For_PIN
the_DT
2004_CD
grant_NN
,_,
vesting_VBG
increases_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
for_PIN
EPS_NN
80_CD
performance_NN
between_PIN
the_DT
hurdles_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
table_NN
below_PLACE
._.
70_CD
Annualised_NN
Percentage_NN
of_PIN
growth_NN
in_PIN
EPS_NN
award_NN
vesting_VBG [WZPRES]
60_CD
31_CD
12_CD
00_CD
31_CD
12_CD
01_CD
31_CD
12_CD
02_CD
31_CD
12_CD
03_CD
31_CD
12_CD
04_CD
RPI_NN
5_CD
%_NN
100_CD
%_NN
GlaxoSmithKline_NN
Total_NN
Return_NN
FTSE_NN
100_CD
Total_JJ
Return_NN
Index_NN
RPI_NN
4_CD
%_NN
75_CD
%_NN
GlaxoSmithKline_NN
Pharma_NN
Peers_NN
Return_NN
Index_NN
RPI_NN
3_CD
%_NN
50_CD
%_NN
RPI_NN
3_CD
%_NN
0_CD
%_NN
This_DEMO
performance_NN
condition_NOMZ
is_VPRT [BEMA]
substantially_RB
consistent_PRED
with_PIN
UK_NN
shareholder_NN
guidelines_NN
and_PHC
expectations_NOMZ
and_CC
is_VPRT
demanding_VBG [SUAV]
when_RB [WHCL]
compared_VBN
with_PIN
those_DEMP
operated_VBN
by_PIN
other_JJ
global_JJ
pharmaceutical_JJ
companies_NN
._.
This_DEMP
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
policy_NN
of_PIN
providing_VBG
pay_NN
for_PIN
performance_NN
and_CC
only_DWNT
for_PIN
performance_NN
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
21_CD
21_CD
SUMMARY_NN
REMUNERATION_NOMZ
REPORT_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
Annual_JJ
remuneration_NOMZ
2004_CD
2003_CD
Total_JJ
Total_JJ
Fees_NN
and_CC
Other_JJ
Annual_JJ
annual_JJ
annual_JJ
salary_NN
benets_NN
bonus_NN
remuneration_NOMZ
remuneration_NOMZ
Directors_NN
of_PIN
GSK_NN
000 000 000 000_CD
000_CD
Executive_NN
Directors_NN
Dr_VPRT
JP_NN
Garnier_NN
$_$
1,523_CD
$_$
786_CD
$_$
2,250_CD
$_$
4,559_CD
$_$
4,570_CD
Dr_NN
T_NN
Yamada_NN
$_$
725_CD
$_$
577_CD
$_$
1,001_CD
$_$
2,303_CD
Mr_NN
J_NN
Coombe_NN
506_CD
9_CD
515_CD
1,237_CD
Total_NN
Executive_NN
Directors_NN
1,734_CD
754_CD
1,777_CD
4,265_CD
4,024_CD
Current_JJ
Non-Executive_JJ
Directors_NN
Mr_NN
L_NN
Culp_NN
$_$
97_CD
$_$
97_CD
$_$
48_CD
Sir_NN
Deryck_NN
Maughan_NN
$_$
57_CD
$_$
57_CD
Dr_NN
L_NN
Shapiro_NN
$_$
182_CD
$_$
182_CD
$_$
179_CD
Sir_NN
Christopher_NN
Gent_NN
175_CD
175_CD
Sir_NN
Crispin_NN
Davis_NN
57_CD
57_CD
29_CD
Sir_NN
Ian_NN
Prosser_NN
65_CD
65_CD
66_CD
Dr_NN
R_NN
Schmitz_NN
72_CD
72_CD
67_CD
Sir_NN
Robert_NN
Wilson_NN
66_CD
66_CD
10_CD
Total_JJ
Current_JJ
Non-Executive_JJ
Directors_NN
618 618 310_CD
Former_JJ
Non-Executive_JJ
Directors_NN
Mr_NN
J_NN
McArthur_NN
$_$
42_CD
$_$
18_CD
$_$
60_CD
$_$
102_CD
Mr_NN
D_NN
McHenry_NN
$_$
42_CD
$_$
42_CD
$_$
106_CD
Mr_NN
P_NN
Allaire_NN
28_CD
Dr_NN
M_NN
Barzach_NN
78_CD
78_CD
107_CD
Sir_NN
Christopher_NN
Hogg_NN
369_CD
1_CD
370_CD
374_CD
Sir_NN
Roger_NN
Hurn_NN
50_CD
Sir_NN
Peter_NN
Job_NN
57_CD
57_CD
57_CD
Sir_NN
Richard_NN
Sykes_NN
1_CD
1_CD
958_CD
Total_JJ
Former_JJ
Non-Executive_JJ
Directors_NN
550_CD
12_CD
562_CD
1,701_CD
Total_JJ
Non-Executive_JJ
Directors_NN
1,168_CD
12_CD
1,180_CD
2,011_CD
Total_JJ
remuneration_NOMZ
2,902_CD
766_CD
1,777_CD
5,445_CD
6,035_CD
Remuneration_NOMZ
for_PIN
Directors_NN
on_PIN
the_DT
US_FPP1
payroll_NN
is_VPRT [PASS]
reported_VBN [PUBV]
in_PIN
Dollars_NN
._.
Amounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
converted_VBN
to_PIN
Sterling_GER
at_PIN
the_DT
average_JJ
exchange_NN
rates_NN
for_PIN
the_DT
year_NN
._.
Following_VBG [PRESP]
the_DT
merger_NN
,_,
those_DEMO
participants_NN
in_PIN
the_DT
legacy_NN
schemes_NN
who_WP [WHSUB]
elected_VBD
to_TO
exchange_VB
their_TPP3
legacy_NN
options_NOMZ
for_PIN
options_NOMZ
over_IN
GSK_NN
shares_NN
were_VBD [PASS]
granted_VBN [SUAV]
an_DT
additional_JJ
cash_NN
benefit_NN
equal_JJ
to_PIN
10_CD
%_NN
of_PIN
the_DT
grant_NN
price_NN
of_PIN
the_DT
original_JJ
option_NOMZ
._.
This_DEMO
additional_JJ
benefit_NN
is_VPRT [PASS]
known_VBN [PRIV]
as_IN
the_DT
Exchange_NN
Offer_NN
Incentive_NN
EOI_NN
and_CC
is_VPRT [BEMA]
only_DWNT
payable_PRED
when_RB
the_DT
new_JJ
option_NOMZ
is_VPRT [PASS]
exercised_VBN
or_CC
lapses_NN
above_PLACE
market_NN
value_NN
._.
To_TO
qualify_VB
for_PIN
this_DEMO
additional_JJ
cash_NN
benefit_NN
,_,
participants_NN
would_PRMD
have_VB [PEAS]
had_VBN
to_TO
retain_VB
these_DEMO
options_NOMZ
until_IN
at_PIN
least_JJ
the_DT
second_JJ
anniversary_NN
of_PIN
the_DT
effective_JJ
date_NN
of_PIN
the_DT
merger_NN
._.
During_PIN
the_DT
year_NN
Dr_NN
Garnier_NN
received_VBD
$_$
335,730_CD
2003_CD
$_$
299,311_CD
relating_VBG
to_PIN
options_NOMZ
exercised_VBN
under_IN
the_DT
EOI_NN
._.
Those_DEMO
amounts_NN
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
benets_NN
in_PIN
the_DT
table_NN
above_PLACE
._.
In_CONJ
addition_NULL
to_PIN
the_DT
remuneration_NOMZ
received_VBD
as_IN
a_DT
former_JJ
Director_NN
,_,
as_IN
set_VBN
out_PIN
above_PLACE
,_,
Sir_NN
Richard_NN
Sykes_NN
received_VBD
20,417_CD
2003_CD
49,000_CD
for_PIN
the_DT
period_NN
1_CD
January_NN
to_PIN
30_CD
May_POMD
2004_CD
relating_VBG
to_PIN
his_TPP3
appointment_NOMZ
as_IN
Senior_JJ
Advisor_NN
._.
Non-Executive_JJ
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
receive_VB
a_DT
significant_JJ
part_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
or_CC
ADSs_NN
and_CC
may_POMD [SPAU]
also_RB
elect_VB
to_TO
invest_VB
part_NN
or_CC
all_QUAN
of_PIN
the_DT
balance_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
or_CC
ADSs_NN
._.
The_DT
value_NN
of_PIN
these_DEMO
shares_NN
and_PHC
ADSs_NN
at_PIN
the_DT
dates_NN
of_PIN
award_NN
are_VPRT [PASS]
included_VBN
in_PIN
fees_NN
and_PHC
salary_NN
above_PLACE
._.
These_DEMO
shares_NN
and_PHC
ADSs_NN
are_VPRT [PASS]
not_XX0
paid_VBN
out_PIN
until_IN
the_DT
Director_NN
leaves_VPRT
the_DT
Board_NN
._.
Dr_NN
Barzach_NN
,_,
Mr_NN
McHenry_NN
and_PHC
Mr_NN
McArthur_NN
left_VBD
the_DT
Board_NN
on_PIN
17_CD
May_POMD
2004_CD
._.
Sir_NN
Christopher_NN
Hogg_NN
and_PHC
Sir_NN
Peter_NN
Job_NN
left_VBD
the_DT
Board_NN
on_PIN
31_CD
December_NN
2004_CD
._.
These_DEMO
Directors_NN
elected_VBN
to_TO
receive_VB
their_TPP3
full_JJ
entitlement_NOMZ
on_PIN
leaving_VBG
the_DT
Board_NN
._.
In_CONJ
addition_NULL
to_PIN
annual_JJ
compensation_NOMZ
,_,
GSK_NN
operates_VPRT
share_NN
plans_NN
to_TO
provide_VB
incentives_NN
to_PIN
Executive_NN
Directors_NN
to_TO
achieve_VB
longer-term_JJ
growth_NN
in_PIN
shareholder_NN
value_NN
._.
Gains_NN
under_IN
such_JJ
plans_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
exercise_NN
or_CC
maturity_NOMZ
of_PIN
the_DT
award_NN
,_,
but_CC
reect_JJ
value_NN
earned_VBN
over_IN
a_DT
period_NN
of_PIN
years_NN
._.
The_DT
timing_NN
of_PIN
exercise_NN
is_VPRT [BEMA]
normally_RB
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Director_NN
._.
Gains_NN
in_PIN
2004_CD
on_PIN
exercise_NN
of_PIN
options_NOMZ
were_VBD
:_:
share_NN
option_NOMZ
plans_VPRT
3,618,060_CD
2003_CD
3,097,260_CD
:_:
long-term_JJ
incentive_NN
plan_NN
nil_NN
2003_CD
256,134_CD
:_:
Performance_NN
Share_NN
Plan_NN
PSP_NN
475,149_CD
2003_CD
nil_NN
._.
Dr_NN
Garnier_NN
deferred_VBD
receipt_NN
of_PIN
PSPs_NN
vesting_VBG [WZPRES]
in_PIN
2004_CD
with_PIN
a_DT
value_NN
at_PIN
vesting_GER
of_PIN
$_$
1,496,608_CD
._.
Full_JJ
details_NN
of_PIN
the_DT
awards_NN
granted_VBN [SUAV]
under_IN
the_DT
Companys_NN
share_NN
plans_NN
during_PIN
2004_CD
may_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Annual_JJ
Report_NN
2004_CD
._.
In_PIN
2001_CD
,_,
following_VBG [PRESP]
the_DT
merger_NN
,_,
Dr_NN
Garnier_NN
,_,
Mr_NN
Coombe_NN
and_PHC
Dr_NN
Yamada_NN
were_VBD [PASS]
awarded_VBN
a_DT
one-off_PIN
special_JJ
deferred_VBN
bonus_NN
as_IN
members_NN
of_PIN
the_DT
CET_NN
._.
Each_QUAN
was_VBD [PASS]
awarded_VBN
an_DT
amount_NN
equivalent_NN
to_PIN
his_TPP3
salary_NN
on_PIN
31_CD
December_NN
2001_CD
and_CC
this_DEMP
was_VBD [SPAU] [PASS]
notionally_RB
invested_VBN
in_PIN
GSK_NN
shares_NN
or_CC
ADSs_NN
on_PIN
15_CD
February_NN
2002_CD
._.
The_DT
amount_NN
of_PIN
the_DT
bonus_NN
vesting_VBG [WZPRES]
on_PIN
15_CD
February_NN
2005_CD
was_VBD [BEMA]
equivalent_PRED
to_PIN
the_DT
then_RB
value_NN
of_PIN
shares_NN
or_CC
ADSs_NN
notionally_RB
acquired_VBN
in_PIN
February_NN
2002_CD
plus_PIN
dividends_NN
reinvested_VBN
over_IN
the_DT
period_NN
._.
These_DEMO
amounts_NN
were_VBD [PASS]
paid_VBN
in_PIN
February_NN
2005_CD
and_CC
are_VPRT [PASS]
not_XX0
included_VBN
in_PIN
the_DT
table_NN
above_PLACE
._.
Mr_NN
Coombe_NN
has_VPRT [PEAS]
waived_VBN
his_TPP3
entitlements_NOMZ
to_PIN
the_DT
2001_CD
special_JJ
deferred_VBN
bonus_NN
of_PIN
383,924_CD
and_CC
2004_CD
annual_JJ
bonus_NN
of_PIN
650,370_CD
._.
The_DT
Company_NN
will_PRMD
make_VB
a_DT
contribution_NOMZ
to_PIN
the_DT
pension_NN
plan_NN
of_PIN
1,034,294_CD
in_PIN
2005_CD
to_TO
enhance_VB
his_TPP3
pension_NN
entitlement_NOMZ
._.
The_DT
accrued_VBN
annual_JJ
benets_NN
under_IN
the_DT
dened_VBN
benefit_NN
pension_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
were_VBD
:_:
Dr_NN
Garnier_NN
$_$
1,039,718_CD
541,520_CD
:_:
Mr_NN
Coombe_NN
345,417_CD
:_:
and_ANDC
Dr_NN
Yamada_NN
$_$
165,000_CD
85,938_CD
._.
In_CONJ
addition_NULL
,_,
Dr_NN
Garnier_NN
and_PHC
Dr_NN
Yamada_NN
are_VPRT
members_NN
of_PIN
a_DT
money_NN
purchase_NN
scheme_NN
into_PIN
which_WDT [PIRE]
contributions_NOMZ
of_PIN
$_$
66,173_CD
36,160_CD
and_CC
$_$
82,057_CD
44,840_CD
,_,
respectively_RB
,_,
were_VBD [PASS]
paid_VBN
during_PIN
2004_CD
._.
None_INPR
of_PIN
the_DT
above_PLACE
Directors_NN
received_VBD
expenses_NN
during_PIN
the_DT
year_NN
requiring_VBG [SUAV] [WZPRES]
separate_JJ
disclosure_NN
as_IN
dened_VBN
by_PIN
the_DT
Regulations_NOMZ
._.
22_CD
22_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
CORPORATE_JJ
GOVERNANCE_NN
NOMINATIONS_NOMZ
COMMITTEE_NN
Governance_NN
and_PHC
policy_NN
The_DT
Nominations_NOMZ
Committee_NN
reviews_VPRT
the_DT
structure_NN
,_,
size_NN
and_PHC
composition_NOMZ
of_PIN
the_DT
Board_NN
and_CC
the_DT
appointment_NOMZ
of_PIN
members_NN
of_PIN
the_DT
Board_NN
and_CC
the_DT
THE_DT
BOARD_NN
AND_CC
CORPORATE_JJ
EXECUTIVE_NN
TEAM_NN
CET_NN
,_,
and_ANDC
makes_VPRT
recommendations_NOMZ
to_PIN
the_DT
Board_NN
as_IN
appropriate_JJ
._.
The_DT
The_DT
Directors_NN
are_VPRT [PASS]
listed_VBN
under_IN
The_DT
Board_NN
on_PIN
page_NN
18_CD
._.
Committee_NN
also_RB
monitors_VPRT
the_DT
planning_GER
of_PIN
succession_NN
to_PIN
the_DT
Board_NN
and_PHC
Senior_NN
Management_NOMZ
._.
The_DT
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
Non-Executive_JJ
The_NN
Board_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
system_NN
of_PIN
corporate_JJ
governance_NN
Directors_NN
,_,
of_PIN
whom_WP [PIRE]
a_DT
majority_NOMZ
are_VPRT [BEMA]
independent_PRED
,_,
and_ANDC
meets_VPRT
at_PIN
least_JJ
once_TIME
and_CC
is_VPRT [BEMA]
ultimately_RB
accountable_PRED
for_PIN
the_DT
Groups_NN
activities_NOMZ
,_,
strategy_NN
and_CC
a_DT
year_NN
to_TO
consider_VB [PRIV]
succession_NN
planning_GER
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
CORPORATE_JJ
RESPONSIBILITY_NOMZ
COMMITTEE_NN
The_NN
CEO_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
executive_JJ
management_NOMZ
of_PIN
the_DT
Group_NN
and_CC
is_VPRT [BEMA]
The_DT
Corporate_JJ
Responsibility_NOMZ
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
Non-Executive_JJ
assisted_VBN
in_PIN
this_DEMO
by_PIN
the_DT
CET_NN
._.
The_DT
CET_NN
meets_VPRT
11_CD
times_NN
per_PIN
year_NN
and_ANDC
otherwise_CONJ
Directors_NN
and_CC
provides_VPRT
a_DT
Board_NN
level_NN
forum_NN
for_PIN
the_DT
regular_JJ
review_NN
of_PIN
as_RB
necessary_JJ
._.
The_DT
members_NN
and_CC
their_TPP3
responsibilities_NOMZ
are_VPRT [PASS]
listed_VBN
under_IN
external_JJ
issues_NN
that_TSUB
have_VPRT
the_DT
potential_NN
for_PIN
serious_JJ
impact_NN
upon_PIN
the_DT
Groups_NN
Corporate_JJ
Executive_NN
Team_NN
on_PIN
page_NN
19_CD
._.
business_NOMZ
and_PHC
reputation_NOMZ
and_CC
the_DT
oversight_NN
of_PIN
reputation_NOMZ
management_NOMZ
._.
The_DT
Committee_NN
is_VPRT [BEMA]
also_RB
responsible_PRED
for_PIN
annual_JJ
governance_NN
oversight_NN
of_PIN
the_DT
The_NN
Board_NN
comprises_VPRT
three_CD
Executive_NN
and_CC
eight_CD
Non-Executive_JJ
Directors_NN
._.
Groups_NN
worldwide_JJ
donations_NOMZ
and_PHC
community_NOMZ
support_NN
._.
The_DT
Committee_NN
Whilst_OSUB
the_DT
Board_NN
considers_VPRT [PRIV]
all_QUAN
of_PIN
its_PIT
Non-Executive_JJ
Directors_NN
to_TO
be_VB
meets_VPRT
formally_RB
three_CD
times_NN
a_DT
year_NN
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
independent_JJ
in_PIN
character_NN
and_PHC
judgement_NOMZ
,_,
it_PIT
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
Dr_NN
Shapiro_NN
should_NEMD
not_XX0
be_VB [PASS]
considered_VBN [PRIV]
as_IN
independent_JJ
under_IN
the_DT
Combined_VBN
FINANCIAL_NN
RESULTS_NN
COMMITTEE_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
Combined_NN
Code_NN
._.
This_DEMP
is_VPRT [BEMA]
The_DT
Financial_NN
Results_NN
Committee_NN
reviews_VPRT
and_PHC
approves_VPRT
,_,
on_PIN
behalf_NN
of_PIN
the_DT
due_JJ
to_PIN
the_DT
remuneration_NOMZ
that_TOBJ
she_TPP3
receives_VPRT
from_PIN
the_DT
Group_NN
as_IN
a_DT
member_NN
Board_NN
,_,
the_DT
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_NN
,_,
the_DT
Annual_JJ
Review_NN
and_CC
the_DT
of_PIN
the_DT
GSK_NN
scientific_JJ
Advisory_NN
Board_NN
._.
convening_VBG [PRESP]
of_PIN
the_DT
AGM_NN
,_,
together_RB
with_PIN
the_DT
preliminary_JJ
and_PHC
quarterly_JJ
statements_NOMZ
of_PIN
trading_GER
results_NN
._.
Each_QUAN
Director_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Committee_NN
The_NN
Board_NN
considers_VPRT [PRIV]
that_THVC
Mr_NN
Culp_NN
,_,
Sir_NN
Crispin_NN
Davis_NN
,_,
Sir_NN
Deryck_NN
Maughan_NN
,_,
and_ANDC
the_DT
quorum_NN
for_PIN
a_DT
meeting_GER
is_VPRT [BEMA]
any_QUAN
three_CD
members_NN
._.
To_TO
be_VB [BEMA]
quorate_PRED
,_,
each_QUAN
Sir_NN
Ian_NN
Prosser_NN
,_,
Dr_NN
Schmitz_NN
and_PHC
Sir_NN
Robert_NN
Wilson_NN
are_VPRT [BEMA]
independent_PRED
under_IN
meeting_GER
must_NEMD
include_VB
the_DT
Chairman_NN
or_CC
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
the_DT
Combined_NN
Code_NN
._.
Sir_NN
Ian_NN
Prosser_NN
is_VPRT [BEMA]
the_DT
Senior_JJ
Independent_NN
Director_NN
._.
Committee_NN
and_CC
the_DT
CEO_NN
or_CC
the_DT
CFO_NN
._.
The_DT
Committee_NN
meets_VPRT
as_RB
necessary_JJ
._.
At_PIN
the_DT
date_NN
of_PIN
publication_NOMZ
and_CC
throughout_PIN
2004_CD
,_,
a_DT
majority_NOMZ
of_PIN
the_DT
Board_NN
CORPORATE_JJ
ADMINISTRATION_NOMZ
&_CC
TRANSACTIONS_NOMZ
COMMITTEE_NN
members_NN
,_,
excluding_VBG [PRESP]
the_DT
Chairman_NN
,_,
were_VBD [BEMA]
independent_JJ
Non-Executive_JJ
The_DT
Corporate_JJ
Administration_NOMZ
&_CC
Transactions_NOMZ
Committee_NN
reviews_VPRT
and_CC
Directors_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
recommendations_NOMZ
of_PIN
the_DT
Combined_NN
approves_VPRT
matters_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
administration_NOMZ
of_PIN
the_DT
Groups_NN
Code_NN
._.
business_NOMZ
,_,
and_ANDC
of_PIN
certain_JJ
corporate_JJ
transactions_NOMZ
._.
The_DT
Committee_NN
consists_VPRT
of_PIN
the_DT
Directors_NN
,_,
CET_NN
members_NN
and_CC
the_DT
Company_NN
Secretary_NN
._.
The_DT
Committee_NN
BOARD_NN
PROCESS_NN
meets_VPRT
as_RB
necessary_JJ
._.
The_DT
Board_NN
meets_VPRT
at_PIN
least_JJ
six_CD
times_NN
a_DT
year_NN
._.
It_PIT
has_VPRT
a_DT
formal_JJ
schedule_NN
of_PIN
matters_NN
reserved_VBN [WZPAST]
to_PIN
it_PIT
for_PIN
decision_NN
but_CC
otherwise_CONJ
delegates_NN
specic_JJ
responsibilities_NOMZ
REMUNERATION_NOMZ
OF_PIN
DIRECTORS_NN
to_PIN
Board_NN
committees_NN
,_,
as_IN
described_VBN
below_PLACE
._.
The_DT
Board_NN
works_VPRT
to_PIN
an_DT
agreed_VBN [SUAV] [PUBV]
Information_NOMZ
on_PIN
the_DT
remuneration_NOMZ
of_PIN
Directors_NN
is_VPRT [PASS]
given_VBN
in_PIN
the_DT
Summary_NN
business_NOMZ
agenda_NN
in_PIN
reviewing_VBG
the_DT
key_JJ
activities_NOMZ
of_PIN
the_DT
business_NOMZ
,_,
and_ANDC
receives_VPRT
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
20_CD
to_PIN
22_CD
._.
papers_NN
and_PHC
presentations_NOMZ
to_TO
enable_VB
it_PIT
to_TO
do_VB
so_RB
effectively_RB
._.
The_DT
Board_NN
considers_VPRT [PRIV]
and_PHC
reviews_VPRT
the_DT
work_NN
undertaken_VBN [WZPAST]
by_PIN
its_PIT
Committees_NN
._.
The_DT
Company_NN
Secretary_NN
is_VPRT [BEMA]
responsible_PRED
to_PIN
the_DT
Board_NN
and_CC
is_VPRT [BEMA]
available_PRED
to_PIN
individual_JJ
Directors_NN
in_PIN
respect_NN
of_PIN
Board_NN
procedures_NN
._.
The_DT
Company_NN
Secretary_NN
is_VPRT
Mr_NN
Simon_NN
Bicknell_NN
who_WP [WHSUB]
was_VBD [PASS]
appointed_VBN
in_PIN
May_POMD
2000_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
barrister_NN
and_CC
joined_VBD
the_DT
Group_NN
in_PIN
1984_CD
._.
He_TPP3
is_VPRT
secretary_NN
to_PIN
all_QUAN
the_DT
Board_NN
Committees_NN
._.
BOARD_NN
COMMITTEES_NN
AUDIT_NN
COMMITTEE_NN
The_NN
Audit_NN
Committee_NN
reviews_VPRT
the_DT
financial_JJ
and_PHC
internal_JJ
reporting_GER
process_NN
,_,
the_DT
system_NN
of_PIN
internal_JJ
control_NN
and_PHC
management_NOMZ
of_PIN
risks_NN
and_CC
the_DT
external_JJ
and_PHC
internal_JJ
audit_NN
process_NN
._.
The_DT
Committee_NN
also_RB
proposes_VPRT [SUAV]
to_PIN
shareholders_NN
the_DT
appointment_NOMZ
of_PIN
the_DT
external_JJ
auditors_NN
and_CC
is_VPRT [BEMA]
directly_RB
responsible_PRED
for_PIN
their_TPP3
remuneration_NOMZ
and_PHC
oversight_NN
of_PIN
their_TPP3
work_NN
._.
The_DT
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
independent_JJ
Non-Executive_JJ
Directors_NN
._.
It_PIT
meets_VPRT
at_PIN
least_JJ
four_CD
times_NN
a_DT
year_NN
._.
REMUNERATION_NOMZ
COMMITTEE_NN
The_NN
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
the_DT
terms_NN
of_PIN
service_NN
and_PHC
remuneration_NOMZ
of_PIN
the_DT
Executive_NN
Directors_NN
and_PHC
members_NN
of_PIN
the_DT
CET_NN
and_CC
,_,
with_PIN
the_DT
assistance_NN
of_PIN
external_JJ
independent_JJ
advisors_NN
,_,
it_PIT
evaluates_VPRT
and_PHC
makes_VPRT
recommendations_NOMZ
to_PIN
the_DT
Board_NN
on_PIN
overall_JJ
executive_NN
remuneration_NOMZ
policy_NN
._.
It_PIT
meets_VPRT
at_PIN
least_JJ
four_CD
times_NN
a_DT
year_NN
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
23_CD
23_CD
RESPONSIBILITY_NOMZ
STATEMENTS_NOMZ
Annual_JJ
Review_NN
Corporate_NN
governance_NN
The_DT
Annual_JJ
Review_NN
is_VPRT [BEMA]
a_DT
summary_NN
report_NN
and_CC
does_VPRT
not_XX0
contain_VB
sufficient_JJ
The_DT
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
is_VPRT [BYPA]
specified_VBN
by_PIN
the_DT
Listing_GER
information_NOMZ
to_TO
allow_VB [SUAV]
as_IN
full_JJ
an_DT
understanding_GER
of_PIN
the_DT
results_NN
and_PHC
state_NN
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
for_PIN
the_DT
guidance_NN
of_PIN
listed_VBN
of_PIN
affairs_NN
of_PIN
the_DT
Group_NN
as_IN
is_VPRT [BYPA]
provided_VBN
by_PIN
the_DT
Annual_JJ
Report_NN
2004_CD
._.
companies_NN
Combined_VBN
Code_NN
._.
The_DT
Board_NN
considers_VPRT [PRIV]
that_THVC
throughout_PIN
2004_CD
Shareholders_NN
requiring_VBG [SUAV] [WZPRES]
more_EMPH
detailed_JJ
information_NOMZ
may_POMD
obtain_VB
,_,
free_JJ
of_PIN
and_CC
up_IN
to_PIN
the_DT
date_NN
of_PIN
approval_NN
of_PIN
this_DEMO
review_NN
,_,
GlaxoSmithKline_NN
plc_NN
applied_VBD
charge_NN
,_,
a_DT
copy_NN
of_PIN
the_DT
Annual_JJ
Report_NN
2004_CD
and_CC
may_POMD [SPAU]
also_RB
elect_VB
to_TO
receive_VB
the_DT
principles_NN
of_PIN
the_DT
Combined_NN
Code_NN
and_CC
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
matters_NN
a_DT
copy_NN
of_PIN
the_DT
Annual_JJ
Report_NN
in_PIN
future_JJ
years_NN
refer_VPRT
to_PIN
Shareholder_NN
where_RB
the_DT
Companys_NN
position_NOMZ
is_VPRT [PASS]
described_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
,_,
complied_VBD
information_NOMZ
._.
with_PIN
the_DT
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
,_,
and_ANDC
the_DT
guidance_NN
on_PIN
internal_JJ
control_NN
issued_VBN [WZPAST]
by_PIN
the_DT
1998_CD
Turnbull_NN
Committee_NN
._.
The_DT
Independent_NN
Auditors_NN
report_VPRT [PUBV]
on_PIN
the_DT
full_JJ
financial_JJ
statements_NOMZ
of_PIN
the_DT
Group_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
is_VPRT [BEMA]
unqualied_PRED
and_CC
does_VPRT [PROD]
The_DT
Annual_JJ
Review_NN
,_,
including_VBG
Summary_NN
financial_JJ
statements_NOMZ
,_,
has_VPRT [PEAS]
been_VBN
not_XX0
contain_VB
any_QUAN
statement_NOMZ
concerning_VBG [WZPRES]
inadequate_JJ
accounting_GER
records_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
or_CC
failure_NN
to_TO
obtain_VB
necessary_JJ
information_NOMZ
and_PHC
explanations_NOMZ
._.
Sir_NN
Christopher_NN
Gent_NN
Chairman_NN
2_CD
March_NN
2005_CD
Summary_NN
financial_JJ
statements_NOMZ
A_DT
columnar_NN
presentation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
in_PIN
the_DT
Summary_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
order_NN
to_TO
illustrate_VB
2004_CD
statutory_JJ
performance_NN
Independent_NN
auditors_NN
against_PIN
2003_CD
business_NOMZ
performance_NN
._.
During_PIN
the_DT
years_NN
2000_CD
to_PIN
2003_CD
,_,
statement_NOMZ
to_PIN
the_DT
members_NN
business_NOMZ
performance_NN
was_VBD [BEMA]
the_DT
primary_JJ
performance_NN
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
and_CC
was_VBD [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
of_PIN
GlaxoSmithKline_NN
plc_NN
and_PHC
restructuring_GER
costs_NN
and_PHC
disposals_NN
of_PIN
businesses_NOMZ
._.
Management_NOMZ
believed_VBD [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
items_NN
provided_VBD
a_DT
better_JJ
comparison_NN
of_PIN
the_DT
way_NN
in_PIN
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
which_WDT [WHSUB]
comprise_VPRT
which_WDT
the_DT
business_NOMZ
was_VBD [PASS]
managed_VBN
and_PHC
gave_VBD
an_DT
indication_NOMZ
of_PIN
the_DT
the_DT
Summary_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
,_,
Summary_NN
consolidated_JJ
performance_NN
of_PIN
the_DT
Group_NN
in_PIN
terms_NN
of_PIN
those_DEMO
elements_NOMZ
of_PIN
revenue_NN
and_PHC
balance_NN
sheet_NN
and_PHC
Summary_NN
consolidated_JJ
cash_NN
ow_NN
statement_NOMZ
and_CC
the_DT
expenditure_NN
which_WDT [WHOBJ]
local_JJ
management_NOMZ
was_VBD [BEMA]
able_PRED
to_PIN
inuence_NN
._.
For_PIN
2004_CD
,_,
Summary_NN
Report_NN
of_PIN
the_DT
Directors_NN
including_VBG [WZPRES]
the_DT
Summary_NN
Remuneration_NOMZ
with_PIN
the_DT
completion_NOMZ
of_PIN
these_DEMO
programs_NN
,_,
the_DT
Group_NN
is_VPRT
reporting_VBG [PUBV]
results_NN
on_PIN
Report_NN
._.
Growth_NN
rates_NN
are_VPRT [PASS]
presented_VBN
comparing_VBG
2004_CD
statutory_JJ
results_NN
with_PIN
2003_CD
business_NOMZ
performance_NN
results_NN
._.
Management_NOMZ
RESPECTIVE_NN
RESPONSIBILITIES_NOMZ
OF_PIN
DIRECTORS_NN
AND_PHC
AUDITORS_NN
considers_VPRT [PRIV]
that_THVC
the_DT
comparison_NN
of_PIN
2004_CD
statutory_JJ
results_NN
with_PIN
2003_CD
business_NOMZ
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
Annual_JJ
Review_NN
in_PIN
accordance_NN
performance_NN
results_NN
gives_VPRT
the_DT
most_EMPH
appropriate_JJ
indication_NOMZ
of_PIN
the_DT
Groups_NN
with_PIN
applicable_JJ
law_NN
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
performance_NN
for_PIN
the_DT
period_NN
under_IN
review_NN
._.
consistency_NN
of_PIN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
within_PIN
the_DT
Annual_JJ
Review_NN
with_PIN
the_DT
Annual_JJ
financial_JJ
statements_NOMZ
,_,
the_DT
Report_NN
of_PIN
the_DT
Directors_NN
and_CC
the_DT
In_PIN
2004_CD
,_,
the_DT
Group_NN
adopted_VBD
UITF_NN
Abstract_NN
38_CD
and_CC
the_DT
revised_VBN
Abstract_NN
17_CD
Directors_NN
Remuneration_NOMZ
Report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
the_DT
relevant_JJ
relating_VBG
to_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
and_PHC
share_NN
options_NOMZ
and_PHC
awards_NN
._.
requirements_NOMZ
of_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
United_NN
Kingdom_NN
Companies_NN
Act_NN
1985_CD
Comparative_JJ
information_NOMZ
for_PIN
2003_CD
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
accordingly_RB
._.
Trading_GER
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
information_NOMZ
profit_NN
and_PHC
profit_NN
before_IN
tax_NN
in_PIN
2003_CD
have_VPRT [PEAS]
been_VBN [BYPA]
reduced_VBN
by_PIN
16_CD
million_CD
and_CC
contained_VBN
in_PIN
the_DT
Annual_JJ
Review_NN
and_CC
consider_VB [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
net_JJ
assets_NN
at_PIN
31_CD
December_NN
2003_CD
by_PIN
2,661_CD
million_CD
._.
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
inconsistencies_NN
with_PIN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
._.
Earnings_GER
and_PHC
shareholders_NN
funds_NN
are_VPRT [SPAU] [PASS]
also_RB
restated_VBN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
as_IN
additional_JJ
information_NOMZ
provided_VBN [WZPAST]
to_PIN
US_FPP1
shareholders_NN
._.
This_DEMO
statement_NOMZ
,_,
including_VBG [PRESP]
the_DT
opinion_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
and_CC
only_DWNT
for_PIN
the_DT
Companys_NN
members_NN
as_IN
a_DT
body_NN
in_PIN
accordance_NN
with_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
We_FPP1
do_VPRT
not_XX0
,_,
in_PIN
giving_VBG
this_DEMO
opinion_NN
,_,
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
for_PIN
any_QUAN
other_JJ
purpose_NN
or_CC
to_PIN
any_QUAN
Statement_NOMZ
by_PIN
the_DT
Directors_NN
other_JJ
person_NN
to_PIN
whom_WP [PIRE]
this_DEMO
statement_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
or_CC
into_PIN
whose_WPS [PIRE]
hands_NN
it_PIT
may_POMD
come_VB
save_IN
where_RB
expressly_RB
agreed_VBN [SUAV] [PUBV]
by_PIN
our_FPP1
prior_JJ
consent_NN
in_PIN
writing_VBG [PUBV]
._.
The_DT
Annual_JJ
Review_NN
2004_CD
is_VPRT [BEMA]
the_DT
Summary_NN
Directors_NN
report_NN
and_CC
includes_VPRT
the_DT
Summary_NN
financial_JJ
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
BASIS_NN
OF_PIN
OPINION_NN
31_CD
December_NN
2004_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
published_VBN
in_PIN
hard-copy_JJ
printed_VBN
form_NN
and_CC
on_PIN
We_FPP1
conducted_VBD
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
Bulletin_NN
1999_CD
6_CD
,_,
The_DT
auditors_NN
the_DT
website_NN
._.
The_DT
Business_NOMZ
operating_VBG [WZPRES]
review_NN
,_,
the_DT
Summary_NN
financial_JJ
statements_NOMZ
,_,
statement_NOMZ
on_PIN
the_DT
Summary_NN
financial_JJ
statement_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
Auditing_VBG
the_DT
Summary_NN
Remuneration_NOMZ
Report_NN
and_CC
the_DT
Statement_NOMZ
on_PIN
corporate_JJ
Practices_NN
Board_NN
for_PIN
use_NN
in_PIN
the_DT
United_NN
Kingdom_NN
._.
governance_NN
are_VPRT
summaries_NN
of_PIN
information_NOMZ
in_PIN
the_DT
Annual_JJ
Report_NN
2004_CD
._.
OPINION_NN
The_NN
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
maintenance_NN
and_PHC
integrity_NOMZ
of_PIN
the_DT
In_PIN
our_FPP1
opinion_NN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
consistent_PRED
with_PIN
Annual_JJ
Review_NN
on_PIN
the_DT
website_NN
in_PIN
accordance_NN
with_PIN
the_DT
UK_NN
legislation_NOMZ
the_DT
Annual_JJ
financial_JJ
statements_NOMZ
,_,
the_DT
Report_NN
of_PIN
the_DT
Directors_NN
and_CC
the_DT
governing_VBG
the_DT
preparation_NOMZ
and_PHC
dissemination_NOMZ
of_PIN
financial_JJ
statements_NOMZ
._.
Remuneration_NOMZ
Report_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
Access_NN
to_PIN
the_DT
website_NN
is_VPRT [BEMA]
available_PRED
from_PIN
outside_PLACE
the_DT
UK_NN
,_,
where_RB
comparable_JJ
31_CD
December_NN
2004_CD
and_CC
comply_VB
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
Section_NOMZ
legislation_NOMZ
may_POMD
be_VB [BEMA]
different_PRED
._.
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
LLP_NN
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
Embankment_NOMZ
Place_NN
,_,
London_NN
,_,
England_NN
._.
2_CD
March_NN
2005_CD
24_CD
24_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
SUMMARY_NN
FINANCIAL_NN
STATEMENTS_NOMZ
Summary_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
2004_CD
2003_CD
Business_NOMZ
performance_NN
Merger_NN
,_,
restructuring_GER
and_PHC
Statutory_NN
Statutory_NN
Growth_NN
restated_VBD
disposal_NN
of_PIN
subsidiaries_NN
restated_VBN [WZPAST]
m_NN [BEMA]
CER_CD
%_NN
m_NN
m_FW
m_FW
Turnover_NN
Pharmaceuticals_NN
17,146_CD
1_CD
18,181_CD
18,181_CD
Consumer_NN
Healthcare_NN
3,213_CD
3_CD
3,260_CD
3,260_CD
Total_JJ
turnover_NN
20,359_CD
1_CD
21,441_CD
21,441_CD
Cost_NN
of_PIN
sales_NN
4,309_CD
7_CD
4,188_CD
356_CD
4,544_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
7,061_CD
2_CD
7,579_CD
18_CD
7,597_CD
Research_NN
and_PHC
development_NOMZ
expenditure_NN
2,839_CD
8_CD
2,770_CD
21_CD
2,791_CD
Trading_GER
profit_NN
6,150_CD
1_CD
6,904_CD
395_CD
6,509_CD
Other_JJ
operating_GER
income_NN
expenses_NN
60 133 133_CD
Disposal_NN
of_PIN
interests_NN
in_PIN
associates_NN
138_CD
profits_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
95_CD
93_CD
93_CD
Loss_NN
profit_NN
on_PIN
disposal_NN
of_PIN
products_NN
and_PHC
businesses_NOMZ
1_CD
5_CD
5_CD
Net_JJ
interest_NN
payable_JJ
203 161 161_CD
profit_NN
before_IN
taxation_NOMZ
6,119_CD
2_CD
6,703_CD
390_CD
6,313_CD
Taxation_NOMZ
1,701_CD
1,838_CD
109_CD
1,729_CD
profit_NN
after_IN
taxation_NOMZ
4,418_CD
1_CD
4,865_CD
281_CD
4,584_CD
Minority_NOMZ
interests_NN
114_CD
94_CD
94_CD
Preference_NN
share_NN
dividends_NN
2_CD
12_CD
12_CD
Earnings_GER
4,302_CD
1_CD
4,759_CD
281_CD
4,478_CD
Earnings_GER
per_PIN
share_NN
pence_NN
75.0_CD
p_NN
2_CD
82.0_CD
p_NN
4.9_CD
p_NN
77.1_CD
p_NN
Dividends_NN
Per_PIN
share_NN
42.0_CD
p_VPRT
41.0_CD
p_JJ
Total_JJ
2,402_CD
2,374_CD
During_PIN
the_DT
years_NN
2000_CD
to_PIN
2003_CD
,_,
business_NOMZ
performance_NN
was_VBD [BEMA]
the_DT
primary_JJ
management_NOMZ
performance_NN
measure_NN
and_CC
was_VBD [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposal_NN
of_PIN
businesses_NOMZ
._.
For_PIN
2004_CD
,_,
the_DT
Group_NN
is_VPRT
reporting_VBG [PUBV]
results_NN
on_PIN
a_DT
statutory_JJ
basis_NN
._.
Management_NOMZ
considers_VPRT [PRIV]
that_THVC
the_DT
comparison_NN
of_PIN
2004_CD
statutory_JJ
results_NN
and_CC
2003_CD
business_NOMZ
performance_NN
gives_VPRT
the_DT
most_EMPH
appropriate_JJ
indication_NOMZ
of_PIN
the_DT
groups_NN
performance_NN
for_PIN
the_DT
period_NN
._.
Summary_JJ
consolidated_JJ
balance_NN
sheet_NN
2003_CD
2004_CD
restated_VBN
m_NN [PASS]
m_NN [PASS]
Fixed_VBN
assets_NN
8,945_CD
8,575_CD
Current_JJ
assets_NN
13,633_CD
12,625_CD
Creditors_NN
:_:
amounts_NN
due_JJ
within_PIN
one_CD
year_NN
8,722_CD
8,471_CD
Net_JJ
current_JJ
assets_NN
4,911_CD
4,154_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
13,856_CD
12,729_CD
Creditors_NN
:_:
amounts_NN
due_RB
after_IN
one_CD
year_NN
4,625_CD
3,883_CD
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
3,029_CD
3,042_CD
Net_JJ
assets_NN
6,202_CD
5,804_CD
Capital_NN
and_PHC
reserves_NN
Equity_NOMZ
shareholders_NN
funds_NN
5,925_CD
5,059_CD
Minority_NOMZ
interests_NN
277_CD
745_CD
Capital_NN
employed_VBN
6,202_CD
5,804_CD
Summary_NN
consolidated_JJ
cash_NN
ow_NN
statement_NOMZ
2003_CD
2004_CD
restated_VBN
m_NN
m_NN [BEMA]
Net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
6,527_CD
7,005_CD
Dividends_NN
from_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
11_CD
1_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
252_CD
231_CD
Taxation_NOMZ
paid_VBD
1,583_CD
1,917_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
1,035_CD
954_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
69_CD
12_CD
Equity_NOMZ
dividends_NN
paid_VBD
2,475_CD
2,333_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_CC
nancing_VBG
867_CD
1,586_CD
Increase_VPRT
decrease_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
257_CD
27_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
25_CD
25_CD
SUMMARY_NN
INFORMATION_NOMZ
UNDER_IN
US_FPP1
GAAP_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2004_CD
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_TO
profit_VB
and_CC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
profit_NN
2003_CD
2004_CD
restated_VBN
m_NN
m_NN
profit_NN
attributable_JJ
to_PIN
shareholders_NN
under_IN
UK_NN
GAAP_NN
4,302_CD
4,478_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Product_NN
rights_NN
and_PHC
goodwill_NN
1,620_CD
2,371_CD
Fixed_VBN
assets_NN
19_CD
28_CD
Inventory_NN
13_CD
Disposal_NN
of_PIN
interests_NN
in_PIN
associates_NN
and_PHC
subsidiaries_NN
78_CD
Equity_NOMZ
investments_NOMZ
30_CD
31_CD
Employee_NN
costs_NN
458_CD
494_CD
Derivative_JJ
instruments_NOMZ
and_CC
hedging_VBG
33_CD
41_CD
Guarantor_NN
obligations_NOMZ
19_CD
21_CD
Restructuring_GER
12_CD
98_CD
Taxation_NOMZ
651_CD
774_CD
Variable_JJ
interest_NN
entities_NOMZ
and_PHC
minority_NOMZ
shareholders_NN
put_VBD
option_NOMZ
43_CD
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
2,732_CD
2,420_CD
Basic_JJ
income_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
47.6_CD
p_NN
41.7_CD
p_VPRT
Diluted_JJ
income_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
47.5_CD
p_NN
41.6_CD
p_NN
Equity_NOMZ
shareholders_NN
funds_NN
2003_CD
2004_CD
restated_VBN
m_NN
m_NN
Equity_NOMZ
shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
5,925_CD
5,059_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Product_NN
rights_NN
and_PHC
goodwill_NN
31,976_CD
33,638_CD
Fixed_VBN
assets_NN
223_CD
243_CD
Marketable_JJ
securities_NOMZ
49_CD
84_CD
Other_JJ
investments_NOMZ
554_CD
832_CD
Inventory_NN
1_CD
Employee_NN
costs_NN
1,185_CD
1,574_CD
Derivative_JJ
instruments_NOMZ
15_CD
26_CD
Guarantor_NN
obligations_NOMZ
2_CD
21_CD
Restructuring_GER
80_CD
92_CD
Dividends_NN
683_CD
808_CD
Deferred_JJ
taxation_NOMZ
4,204_CD
5,071_CD
Variable_JJ
interest_NN
entities_NOMZ
and_PHC
minority_NOMZ
shareholders_NN
put_VBD
option_NOMZ
43_CD
Shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
34,042_CD
34,116_CD
A_DT
summary_NN
of_PIN
the_DT
material_NN
differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
that_TSUB
apply_VB
to_PIN
the_DT
Group_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Annual_JJ
Report_NN
2004_CD
._.
During_PIN
the_DT
year_NN
,_,
the_DT
Group_NN
implemented_VBD
FASB_NN
Staff_NN
Position_NOMZ
FSP_NN
FAS_NN
106-2_CD
,_,
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
Related_NN
to_PIN
the_DT
Medicare_NN
Prescription_NOMZ
Drug_NN
,_,
Improvement_NOMZ
and_PHC
Modernization_NOMZ
Act_NN
of_PIN
2003_CD
the_DT
Act_NN
,_,
superseding_VBG
FSP_NN
106-1_CD
._.
FSP_NN
106-2_CD
addresses_NN
the_DT
accounting_GER
implications_NOMZ
of_PIN
the_DT
Act_NN
for_PIN
an_DT
entity_NOMZ
that_TSUB
sponsors_VPRT
a_DT
post-retirement_JJ
health_NN
care_NN
plan_NN
providing_VBG [WZPRES]
prescription_NOMZ
drug_NN
benets_NN
._.
26_CD
26_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
SHAREHOLDER_NN
INFORMATION_NOMZ
SHARE_NN
PRICE_NN
INFORMATION_NOMZ
Ordinary_NN
shares_NN
Share_NN
price_NN
information_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
the_DT
website_NN
at_PIN
www_NN
._.
Information_NOMZ
made_VBD
available_JJ
on_PIN
the_DT
website_NN
does_VPRT
not_XX0
constitute_VB
part_NN
of_PIN
The_DT
Companys_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
LSE_NN
._.
Information_NOMZ
in_PIN
the_DT
UK_NN
is_VPRT [BEMA]
also_RB
available_PRED
on_PIN
Ceefax_NN
,_,
REGISTRAR_NN
Teletext_NN
,_,
and_ANDC
from_PIN
FT_NN
Cityline_NN
by_PIN
calling_VBG
0906 003 5694_CD
or_CC
0906 843 5694_CD
The_DT
Companys_NN
share_NN
register_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
Lloyds_NN
TSB_NN
Registrars_NN
,_,
calls_VPRT
charged_VBN
at_PIN
60p_CD
a_DT
minute_NN
plus_PIN
VAT_NN
at_PIN
all_QUAN
times_NN
._.
which_WDT [SERE]
also_RB
provides_VPRT
the_DT
following_JJ
services_NN
:_:
GlaxoSmithKline_NN
Investment_NOMZ
Plan_NN
enables_VPRT
shareholders_NN
to_TO
reinvest_VB
quarterly_JJ
dividends_NN
and_CC
or_CC
make_VB
monthly_JJ
investments_NOMZ
in_PIN
the_DT
Company_NN
's_POS
Share_NN
buy-back_NN
program_NN
ordinary_JJ
shares_NN
using_VBG [WZPRES]
a_DT
special_JJ
dealing_GER
arrangement_NOMZ
._.
In_PIN
October_NN
2002_CD
,_,
following_VBG [PRESP]
the_DT
completion_NOMZ
of_PIN
the_DT
first_JJ
4_CD
billion_CD
share_NN
GlaxoSmithKline_NN
Individual_NN
Savings_GER
Account_NN
is_VPRT [BEMA]
a_DT
tax-efficient_JJ
way_NN
buy-back_NN
program_NN
announced_VBN [PUBV] [WZPAST]
in_PIN
2001_CD
,_,
the_DT
Company_NN
announced_VBD [PUBV]
plans_NN
to_TO
invest_VB
in_PIN
the_DT
Companys_NN
ordinary_JJ
shares_NN
._.
for_PIN
a_DT
new_JJ
4_CD
billion_CD
share_NN
buy-back_JJ
program_NN
._.
Of_PIN
this_DEMO
second_JJ
program_NN
GlaxoSmithKline_NN
Corporate_NN
Sponsored_NN
Nominee_NN
provides_VPRT
a_DT
facility_NOMZ
219_CD
million_CD
was_VBD [PASS]
accounted_VBN
for_PIN
in_PIN
2002_CD
,_,
980_CD
million_CD
in_PIN
2003_CD
and_CC
for_PIN
shareholders_NN
to_TO
hold_VB [PRIV]
shares_NN
without_PIN
the_DT
need_NN
for_PIN
share_NN
certicates_NN
._.
The_DT
program_NN
covers_VPRT
purchases_NN
by_PIN
the_DT
Company_NN
Shareholders_NN
details_NN
will_PRMD
not_XX0
be_VB [PASS]
held_VBN [PRIV]
on_PIN
the_DT
main_JJ
share_NN
register_NN
,_,
and_ANDC
so_RB
of_PIN
shares_NN
for_PIN
cancellation_NOMZ
or_CC
to_TO
be_VB [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
authority_NOMZ
given_VBN [WZPAST]
by_PIN
shareholders_NN
at_PIN
the_DT
AGM_NN
in_PIN
2004_CD
._.
will_PRMD
remain_VB
condential_JJ
._.
Shareview_NN
service_NN
provides_VPRT
shareholders_NN
with_PIN
information_NOMZ
on_PIN
their_TPP3
In_PIN
May_POMD
2004_CD
the_DT
Company_NN
was_VBD [PASS]
authorised_VBN
to_TO
purchase_VB
a_DT
maximum_NN
of_PIN
investment_NOMZ
in_PIN
the_DT
Company_NN
._.
Shareholders_NN
may_POMD
register_VB
for_PIN
this_DEMO
service_NN
594.6_CD
million_CD
shares_NN
600_CD
million_CD
shares_NN
in_PIN
May_POMD
2003_CD
._.
18_CD
million_CD
shares_NN
were_VBD [PASS]
purchased_VBN
for_PIN
cancellation_NOMZ
and_CC
70_CD
million_CD
shares_NN
were_VBD [PASS]
purchased_VBN
to_TO
be_VB [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
see_VPRT [PRIV]
Note_NN
27_CD
to_PIN
the_DT
Financial_NN
Shareview_NN
dealing_VBG [WZPRES]
service_NN
is_VPRT [BEMA]
a_DT
telephone_NN
and_PHC
internet_NN
share_NN
dealing_VBG [WZPRES]
statements_NOMZ
,_,
Share_NN
capital_NN
and_PHC
share_NN
premium_NN
account_NN
in_PIN
the_DT
Companys_NN
facility_NOMZ
available_JJ
to_PIN
ordinary_JJ
shareholders_NN
by_PIN
logging_VBG
on_PIN
to_PIN
Annual_JJ
Report_NN
2004_CD
._.
The_DT
exact_JJ
amount_NN
and_PHC
timing_NN
of_PIN
future_JJ
purchases_NN
,_,
www_NN
._.
co._FW
uk_FW
dealing_VBG
or_CC
by_PIN
calling_VBG
0870 850 0852_CD
._.
and_ANDC
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
repurchased_VBD
shares_NN
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
as_IN
Treasury_NN
shares_NN
rather_RB
than_PIN
being_VBG [PASS]
canceled_VBN
,_,
will_PRMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Company_NN
and_CC
is_VPRT [BEMA]
dependent_PRED
on_PIN
market_NN
conditions_NOMZ
and_CC
other_JJ
factors_NN
._.
American_JJ
Depositary_NN
Shares_NN
The_NN
Companys_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
NYSE_NN
in_PIN
the_DT
form_NN
of_PIN
American_JJ
Depositary_NN
Shares_NN
ADSs_NN
and_CC
these_DEMP
are_VPRT [PASS]
evidenced_VBN
SmithKline_NN
Beecham_NN
plc_NN
Floating_VBG [WZPRES]
by_PIN
American_JJ
Depositary_NN
Receipts_NN
ADRs_NN
,_,
each_QUAN
one_CD
of_PIN
which_WDT [PIRE]
represents_VPRT
two_CD
ordinary_JJ
shares_NN
._.
Rate_NN
Unsecured_NN
Loan_NN
Stock_NN
1990_CD
2010_CD
In_PIN
general_JJ
,_,
the_DT
NYSEs_NN
rules_NN
permit_VPRT
the_DT
Company_NN
to_TO
follow_VB
UK_NN
corporate_JJ
governance_NN
practices_NN
instead_CONJ
of_NULL
those_DEMO
that_DEMP
apply_VPRT
in_PIN
the_DT
US_FPP1
,_,
provided_VBD
The_DT
loan_NN
stock_NN
is_VPRT [PASS]
not_XX0
listed_VBN
on_PIN
any_QUAN
exchange_NN
but_CC
holders_NN
may_POMD
require_VB [SUAV]
that_THVC
the_DT
Company_NN
explains_VPRT [PUBV]
any_QUAN
significant_JJ
variations_NOMZ
._.
This_DEMO
explanation_NOMZ
is_VPRT
SmithKline_NN
Beecham_NN
plc_NN
to_TO
redeem_VB
their_TPP3
loan_NN
stock_NN
at_PIN
par_NN
,_,
i._FW
e._FW
1_CD
for_PIN
every_QUAN
provided_VBN
on_PIN
the_DT
Companys_NN
website_NN
._.
1_CD
of_PIN
loan_NN
stock_NN
held_VBN [PRIV]
,_,
on_PIN
the_DT
first_JJ
business_NOMZ
day_NN
of_PIN
March_NN
,_,
June_NN
,_,
September_NN
and_PHC
December_NN
._.
Holders_NN
wishing_VBG [WZPRES]
to_TO
redeem_VB
all_QUAN
or_CC
part_NN
of_PIN
their_TPP3
loan_NN
stock_NN
ADR_NN
PROGRAMME_NN
ADMINISTRATOR_NN
should_NEMD
complete_VB
the_DT
notice_NN
on_PIN
the_DT
back_NN
of_PIN
their_TPP3
loan_NN
stock_NN
certicate_NN
and_CC
The_DT
ADR_NN
program_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
The_DT
Bank_NN
of_PIN
New_NN
York_NN
,_,
which_WDT [SERE]
return_VPRT
it_PIT
to_PIN
the_DT
registrar_NN
,_,
to_TO
arrive_VB
at_PIN
least_JJ
30_CD
days_NN
before_IN
the_DT
relevant_JJ
provides_VPRT
Global_JJ
BuyDIRECT_NN
,_,
a_DT
direct_JJ
ADS_NN
purchase_NN
sale_NN
and_PHC
dividend_NN
redemption_NOMZ
date_NN
._.
reinvestment_NOMZ
plan_NN
for_PIN
ADR_NN
holders_NN
._.
SHARE_NN
DEALING_GER
SERVICE_NN
Hoare_NN
Govett_NN
Limited_NN
operates_VPRT
a_DT
postal_JJ
dealing_VBG
service_NN
in_PIN
the_DT
Companys_NN
Cautionary_NN
statement_NOMZ
ordinary_JJ
shares_NN
._.
It_PIT
enables_VPRT
investors_NN
to_TO
buy_VB
or_CC
sell_VB
shares_NN
at_PIN
competitive_JJ
commission_NN
charges_NN
._.
Transactions_NOMZ
are_VPRT [PASS]
executed_VBN
and_PHC
settled_VBN
by_PIN
Pershing_GER
Under_IN
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
the_DT
US_FPP1
Private_NN
Securities_NOMZ
Litigation_NOMZ
Securities_NOMZ
Limited_NN
._.
Further_JJ
details_NN
of_PIN
this_DEMO
service_NN
,_,
together_RB
with_PIN
purchase_NN
Reform_NN
Act_NN
of_PIN
1995_CD
,_,
the_DT
Company_NN
cautions_VPRT
investors_NN
that_TOBJ
any_QUAN
forwardand_JJ
sale_NN
forms_NN
,_,
may_POMD
be_VB [BYPA]
obtained_VBN
by_PIN
telephoning_VBG
44_CD
0_CD
207 661 6555_NN
._.
looking_VBG
statements_NOMZ
or_CC
projections_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
Company_NN
,_,
including_VBG [PRESP]
those_DEMP
made_VBN
in_PIN
this_DEMO
Annual_JJ
Review_NN
,_,
are_VPRT [BEMA]
subject_PRED
to_PIN
risks_NN
and_PHC
uncertainties_NN
that_TSUB
may_POMD
cause_VB
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
those_DEMP
projected_VBN
._.
Factors_NN
that_TOBJ
Smith_NN
Barney_NN
,_,
part_NN
of_PIN
Citigroup_NN
,_,
also_RB
offers_VPRT
a_DT
share_NN
dealing_VBG [WZPRES]
service_NN
in_PIN
the_DT
may_POMD
affect_VB
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
described_VBN
under_IN
Legal_NN
proceedings_GER
Companys_NN
ordinary_JJ
shares_NN
and_PHC
ADSs_NN
._.
Further_JJ
details_NN
of_PIN
this_DEMO
service_NN
can_POMD
be_VB
and_CC
Risk_NN
factors_NN
in_PIN
the_DT
Companys_NN
Annual_JJ
Report_NN
2004_CD
._.
obtained_VBN [PASTP]
by_PIN
contacting_VBG
their_TPP3
ofces_NN
in_PIN
the_DT
UK_NN
or_CC
US_FPP1
see_VPRT [PRIV]
contact_NN
details_NN
on_PIN
the_DT
inside_PLACE
back_JJ
cover_NN
for_PIN
further_JJ
information_NOMZ
._.
The_DT
provision_NN
of_PIN
the_DT
details_NN
above_PLACE
are_VPRT [PASS]
not_XX0
intended_VBN [SUAV]
to_TO
be_VB [BEMA]
an_DT
invitation_NOMZ
or_CC
inducement_NOMZ
to_TO
engage_VB
in_PIN
an_DT
investment_NOMZ
activity_NOMZ
._.
Advice_NN
on_PIN
share_NN
dealing_GER
,_,
should_NEMD
be_VB [PASS]
obtained_VBN
from_PIN
a_DT
stockbroker_NN
or_CC
independent_JJ
financial_JJ
adviser_NN
._.
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
27_CD
27_CD
SHAREHOLDER_NN
INFORMATION_NOMZ
continued_VBD
Financial_JJ
reporting_GER
Dividends_NN
FINANCIAL_NN
REPORTING_GER
CALENDAR_NN
2005_CD
GSK_NN
pays_VPRT
dividends_NN
quarterly_RB
._.
Announcement_NOMZ
of_PIN
1st_CD
Quarter_NN
Results_NN
28_CD
April_NN
2005_CD
The_NN
Board_NN
has_VPRT [PEAS]
declared_VBN [PUBV]
dividends_NN
for_PIN
2004_CD
as_IN
follows_VPRT
:_:
Announcement_NOMZ
of_PIN
2nd_CD
Quarter_NN
Results_NN
28_CD
July_NN
2005 2004 2003_CD
Announcement_NOMZ
of_PIN
3rd_CD
Quarter_NN
Results_NN
27_CD
October_NN
2005_CD
Dividends_NN
per_PIN
share_NN
pence_NN
pence_NN
Preliminary_JJ
Announcement_NOMZ
of_PIN
Annual_JJ
Results_NN
9_CD
February_NN
2006_CD
First_NN
interim_JJ
paid_VBN
1_CD
July_NN
2004_CD
10_CD
9_CD
Publication_NOMZ
of_PIN
Annual_JJ
Report_NN
Review_NN
March_NN
2006_CD
Second_JJ
interim_JJ
paid_VBN
30_CD
September_NN
2004_CD
10_CD
9_CD
Third_NN
interim_JJ
paid_VBN
6_CD
January_NN
2005_CD
10_CD
9_CD
RESULTS_NN
ANNOUNCEMENTS_NOMZ
Fourth_JJ
interim_JJ
payable_JJ
7_CD
April_NN
2005_CD
12_CD
14_CD
Results_NN
Announcements_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
,_,
and_ANDC
Total_JJ
42_CD
41_CD
made_VBN
available_JJ
on_PIN
their_TPP3
news_NN
service_NN
,_,
and_ANDC
at_PIN
the_DT
same_JJ
time_NN
,_,
or_CC
shortly_TIME
afterwards_TIME
,_,
they_TPP3
are_VPRT [PASS]
issued_VBN
to_PIN
the_DT
media_NN
,_,
are_VPRT [PASS]
made_VBN
available_JJ
on_PIN
the_DT
website_JJ
As_IN
a_DT
guide_NN
to_PIN
holders_NN
of_PIN
ADRs_NN
,_,
the_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
dividends_NN
paid_VBN
and_PHC
are_VPRT [PASS]
submitted_VBN [PUBV]
to_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
in_PIN
the_DT
US_FPP1
per_PIN
ADS_NN
in_PIN
US_FPP1
dollars_NN
in_PIN
the_DT
last_JJ
five_CD
years_NN
._.
The_DT
dividends_NN
are_VPRT [PASS]
adjusted_VBN
for_PIN
and_CC
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
UK_NN
tax_NN
credit_NN
less_RB
withholding_VBG
tax_NN
,_,
where_RB
applicable_JJ
,_,
and_ANDC
are_VPRT [PASS]
translated_VBN
into_PIN
US_FPP1
dollars_NN
at_PIN
applicable_JJ
exchange_NN
rates_NN
._.
FINANCIAL_NN
REPORTS_NN
The_DT
Company_NN
publishes_VPRT
an_DT
Annual_JJ
Report_NN
and_CC
,_,
for_PIN
the_DT
investor_NN
not_XX0
needing_VBG
Since_OSUB
6_CD
April_NN
1999_CD
,_,
claims_VPRT [PUBV]
for_PIN
refunds_NN
of_PIN
tax_NN
credits_NN
on_PIN
dividends_NN
from_PIN
the_DT
the_DT
full_JJ
detail_NN
of_PIN
the_DT
Report_NN
,_,
an_DT
Annual_JJ
Review_NN
._.
These_DEMP
are_VPRT [BEMA]
available_PRED
on_PIN
the_DT
UK_NN
tax_NN
authorities_NOMZ
are_VPRT [BEMA]
of_PIN
negligible_JJ
benefit_NN
to_PIN
US_FPP1
shareholders_NN
._.
The_DT
Annual_JJ
Review_NN
is_VPRT [PASS]
sent_VBN
to_PIN
all_QUAN
shareholders_NN
on_PIN
the_DT
date_NN
of_PIN
publication_NOMZ
._.
Shareholders_NN
may_POMD [SPAU]
also_RB
elect_VB
to_TO
receive_VB
the_DT
Report_NN
by_PIN
writing_VBG [PUBV]
to_PIN
Year_NN
GSK_NN
$_$
GW_CD
$_$
SB_CD
$_$
the_DT
Companys_NN
registrars_NN
._.
Alternatively_CONJ
,_,
shareholders_NN
may_POMD
elect_VB
to_TO
receive_VB
2004_CD
1.53_CD
notication_NOMZ
by_PIN
email_NN
of_PIN
the_DT
publication_NOMZ
of_PIN
financial_JJ
reports_NN
by_PIN
registering_VBG
on_PIN
2003_CD
1.39_CD
www_NN
._.
Copies_NN
of_PIN
previous_JJ
financial_JJ
reports_NN
are_VPRT [BEMA]
available_PRED
on_PIN
2002_CD
1.24_CD
the_DT
website_NN
._.
Printed_NN
copies_NN
can_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
Registrar_NN
in_PIN
the_DT
UK_NN
and_CC
2001_CD
1.11_CD
from_PIN
the_DT
Customer_NN
Response_NN
Center_NN
in_PIN
the_DT
US_FPP1
._.
2000_CD
1.10_CD
0.87_CD
PUBLICATIONS_NOMZ
This_DEMO
year_NN
,_,
GSK_NN
is_VPRT [SPAU]
again_TIME
producing_VBG
a_DT
Corporate_JJ
Responsibility_NOMZ
Report_NN
covering_VBG [WZPRES]
Dividends_NN
paid_VBN [WZPAST]
to_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
ADR_NN
holders_NN
are_VPRT
performance_NN
in_PIN
areas_NN
including_VBG [WZPRES]
community_NOMZ
investment_NOMZ
,_,
business_NOMZ
ethics_NN
and_CC
expressed_VBN
as_IN
dividends_NN
per_PIN
GSK_NN
ADS_NN
._.
integrity_NOMZ
,_,
access_NN
to_PIN
medicines_NN
,_,
R&D_NN
and_PHC
environment_NOMZ
health_NN
and_PHC
safety_NN
._.
The_DT
report_NN
will_PRMD
be_VB [PASS]
published_VBN
on_PIN
the_DT
website_NN
at_PIN
the_DT
end_NN
of_PIN
March_NN
._.
DIVIDEND_NN
CALENDAR_NN
Fourth_JJ
quarter_NN
2004_CD
Ex-dividend_NN
date_NN
16_CD
February_NN
2005_CD
Record_NN
date_NN
18_CD
February_NN
2005_CD
Share_NN
price_NN
Payable_JJ
7_CD
April_NN
2005 2004 2003_CD
Share_NN
price_NN
First_JJ
quarter_NN
2005_CD
At_PIN
1_CD
January_NN
12.80_CD
11.92_CD
Ex-dividend_NN
date_NN
11_CD
May_POMD
2005_CD
High_NN
during_PIN
the_DT
year_NN
12.99_CD
13.90_CD
Record_NN
date_NN
13_CD
May_POMD
2005_CD
Low_NN
during_PIN
the_DT
year_NN
10.42_CD
10.00_CD
Payable_JJ
7_CD
July_NN
2005_CD
At_PIN
31_CD
December_NN
12.22_CD
12.80_CD
Decrease_NN
Increase_VB
over_IN
year_NN
5_CD
%_NN
7_CD
%_NN
Second_JJ
quarter_NN
2005_CD
Ex-dividend_NN
date_NN
3_CD
August_NN
2005_CD
The_DT
table_NN
above_PLACE
sets_NN
out_PIN
the_DT
middle_JJ
market_NN
closing_GER
prices_NN
derived_VBN [WZPAST]
from_PIN
the_DT
Record_NN
date_NN
5_CD
August_NN
2005_CD
London_NN
Stock_NN
Exchange_NN
Daily_NN
Ofcial_NN
List_NN
._.
The_DT
Companys_NN
share_NN
price_NN
Payable_JJ
6_CD
October_NN
2005_CD
decreased_VBN
by_PIN
5_CD
%_NN
in_PIN
2004_CD
from_PIN
a_DT
price_NN
of_PIN
12.80_CD
at_PIN
1_CD
January_NN
2004_CD
to_PIN
Third_JJ
quarter_NN
2005_CD
12.22_CD
at_PIN
31_CD
December_NN
2004_CD
._.
This_DEMP
compares_VPRT
with_PIN
an_DT
increase_NN
in_PIN
the_DT
FTSE_NN
100_CD
index_NN
of_PIN
8_CD
%_NN
during_PIN
the_DT
year_NN
._.
Ex-dividend_NN
date_NN
2_CD
November_NN
2005_CD
Record_NN
date_NN
4_CD
November_NN
2005_CD
Payable_JJ
5_CD
January_NN
2006_CD
MARKET_NN
CAPITALISATION_NOMZ
The_DT
market_NN
capitalization_NOMZ
of_PIN
GSK_NN
at_PIN
31_CD
December_NN
2004_CD
was_VBD [BEMA]
72_CD
billion_CD
._.
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
2005_CD
At_PIN
that_DEMO
date_NN
GSK_NN
was_VBD [BEMA]
the_DT
fourth_JJ
largest_JJ
company_NN
by_PIN
market_NN
capitalization_NOMZ
on_PIN
the_DT
FTSE_NN
index_NN
._.
The_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
at_PIN
the_DT
Queen_NN
Elizabeth_NN
II_NN
Conference_NN
Centre_NN
,_,
Broad_NN
Sanctuary_NN
,_,
Westminster_NN
,_,
London_NN
SW1P_NN
3EE_NN
on_PIN
25_CD
May_POMD
2005_CD
._.
28_CD
28_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
GSK_NN
Annual_JJ
Review_NN
2004_CD
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
Internet_NN
Our_FPP1
Reports_NN
ANNUAL_NN
REVIEW_NN
Information_NOMZ
for_PIN
investors_NN
and_CC
about_IN
the_DT
A_NN
review_NN
of_PIN
major_JJ
company_NN
is_VPRT [BEMA]
available_PRED
on_PIN
GSKs_NN
corporate_JJ
communication_NOMZ
website_NN
at_PIN
www_NN
._.
com_NN
themes_NN
for_PIN
2004_CD
and_CC
an_DT
abridged_JJ
version_NN
of_PIN
the_DT
financial_JJ
results_NN
._.
Head_NN
Ofce_NN
and_PHC
Registered_NN
Ofce_NN
GlaxoSmithKline_NN
plc_NN
980_CD
Great_NN
West_NN
Road_NN
Brentford_NN
Middlesex_NN
TW8_NN
9GS_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5000_CD
ANNUAL_NN
REPORT_NN
The_NN
full_JJ
Financial_NN
statements_NOMZ
for_PIN
the_DT
year_NN
United_NN
Kingdom_NN
United_NN
States_NN
of_PIN
America_NN
ended_VBD
31_CD
December_NN
Investor_NN
relations_NOMZ
Investor_NN
relations_NOMZ
2004_CD
._.
980_CD
Great_NN
West_NN
Road_NN
One_CD
Franklin_NN
Plaza_NN
Brentford_NN
PO_NN
Box_NN
7929_CD
Middlesex_NN
TW8_NN
9GS_NN
Philadelphia_NN
PA_NN
19101_CD
Tel_NN
:_:
44_CD
0_CD
20 8047 5557 5558_CD
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Fax_NN
:_:
44_CD
0_CD
20 8047 7807_CD
Tel_NN
:_:
1_CD
215 751 7003_CD
outside_PLACE
the_DT
US_FPP1
Fax_NN
:_:
1_CD
215 751 3233_CD
Registrar_NN
Lloyds_NN
TSB_NN
Registrars_NN
ADR_NN
program_NN
administrator_NN
The_DT
Causeway_NN
The_NN
Bank_NN
of_PIN
New_NN
York_NN
Our_FPP1
Corporate_JJ
Responsibility_NOMZ
Worthing_GER
Shareholder_NN
Relations_NOMZ
Report_NN
may_POMD
be_VB [PASS]
found_VBN [PRIV]
online_NN
at_PIN
West_NN
Sussex_NN
BN99_NN
6DA_NN
PO_NN
Box_NN
11258_CD
www_NN
._.
co._FW
uk_FW
Church_NN
Street_NN
Station_NOMZ
New_NN
York_NN
NY_NN
10286-1258_CD
General_NN
enquiries_NN
,_,
Annual_JJ
Report_NN
orderline_NN
www_NN
._.
com_NN
and_CC
Corporate_JJ
Nominee_NN
service_NN
Tel_NN
:_:
1_CD
877 353 1154_CD
toll_NN
free_JJ
Tel_NN
:_:
0870 600 3991_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
1_CD
610 382 7836_CD
outside_PLACE
the_DT
US_FPP1
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
outside_PLACE
the_DT
UK_NN
Customer_NN
Response_NN
Center_NN
Shareholder_NN
Investment_NOMZ
Plans_NN
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Produced_VBN
by_PIN
Corporate_NN
Communications_NOMZ
,_,
GSK_NN
._.
Dividend_NN
re-investment_NOMZ
enquiries_VPRT
Design_NN
consultancy_NN
by_PIN
salterbaxter_NN
._.
Tel_NN
:_:
0870 241 3018_CD
inside_PLACE
the_DT
UK_NN
Corporate_NN
share_NN
dealing_VBG [WZPRES]
facility_NOMZ
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
Smith_NN
Barney_NN
Printed_NN
in_PIN
the_DT
UK_NN
by_PIN
St._NN
Ives_NN
Direct_NN
Edenbridge_NN
Ltd._NN
outside_PLACE
the_DT
UK_NN
Ordinary_NN
holders_NN
Attention_VB
:_:
GSK_NN
Services_NN
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
the_DT
production_NOMZ
of_PIN
this_DEMO
document_NOMZ
is_VPRT
Tel_NN
:_:
44_CD
0_CD
121 415 7146_CD
53_CD
State_NN
Street_NN
made_VBD
from_PIN
pulps_NN
harvested_VBN [WZPAST]
from_PIN
sustainable_JJ
forests_NN
,_,
also_RB
using_VBG
sawmill_NN
residues_NN
and_PHC
forest_NN
thinnings_GER
._.
It_PIT
is_VPRT
outside_PLACE
the_DT
UK_NN
Employees_NN
39th_NN
Floor_NN
elemental_JJ
chlorine-free_NN
._.
Boston_NN
Monthly_JJ
Savings_GER
Plan_NN
enquiries_VPRT
MA_NN
02109_CD
Brand_NN
names_NN
appearing_VBG [SMP] [WZPRES]
in_PIN
italics_NN
throughout_PIN
this_DEMO
publication_NOMZ
are_VPRT
trademarks_NN
either_CC
owned_VBN
by_PIN
and_CC
or_CC
Tel_NN
:_:
0870 606 0268_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
1_CD
800 347 6179_CD
toll_NN
free_JJ
licensed_VBN
to_PIN
GSK_NN
or_CC
associated_VBN
companies_NN
,_,
with_PIN
the_DT
Tel_NN
:_:
44_CD
0_CD
131 527 3746_CD
outside_PLACE
the_DT
UK_NN
Tel_NN
:_:
1_CD
617 589 3341_CD
outside_PLACE
the_DT
US_FPP1
exception_NOMZ
of_PIN
Boniva_NN
Bonviva_NN
,_,
a_DT
trademark_NN
of_PIN
Roche_NN
,_,
Fax_NN
:_:
1_CD
617 589 3474_CD
and_CC
Entereg_NN
,_,
a_DT
trademark_NN
of_PIN
Adolor_NN
Corporation_NOMZ
,_,
ISA_NN
enquiries_VPRT
Email_NN
:_:
TheTaylorGroup@SmithBarney_NN
._.
com_NN
both_DT
of_PIN
which_WDT [PIRE]
are_VPRT [PASS]
used_VBN
under_IN
licence_NN
by_PIN
the_DT
Group_NN
._.
Tel_NN
:_:
0870 242 4244_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
44_CD
0_CD
190 385 4062_CD
outside_PLACE
the_DT
UK_NN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
corporate_JJ
PEPs_NN
The_DT
Share_NN
Centre_NN
Limited_NN
Oxford_NN
House_NN
Oxford_NN
Road_NN
Aylesbury_NN
Bucks_NN
HP21_NN
8SZ_NN
Tel_NN
:_:
44_CD
0_CD
129 641 4144_CD
Corporate_JJ
share_NN
dealing_VBG [WZPRES]
facility_NOMZ
Smith_NN
Barney_NN
Attention_NOMZ
:_:
GSK_NN
Services_NN
Citigroup_NN
Centre_NN
,_,
Level_NN
20_CD
Canada_NN
Square_NN
,_,
Canary_NN
Wharf_NN
London_NN
E14_NN
5LB_NN
Tel_NN
:_:
44_CD
0_CD
20 7508 1795_CD
Fax_NN
:_:
44_CD
0_CD
20 7890 7281_CD
Email_NN
:_:
TheBalaesGroup@Citigroup_NN
._.
com_NN
New_NN
challenges_NN
,_,
new_JJ
thinking_VBG [PRIV]
GSK_NN
Annual_JJ
Review_NN
2004_CD
29_CD
www_NN
www_NN
._.
